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1. Einleitung und Zielsetzung Chronisch-entzündliche Darmerkrankungen (CED) bestehen hauptsächlich aus den Entitäten M. Crohn (MC) und C. ulcerosa (CU) (Abraham und Cho 2009). Die Pathogenese beinhaltet eine durch Darmbakterien induzierte Dysregulation des intestinalen Immunsystems bei genetisch prädisponierten Individuen (Baumgart und Sandborn 2012; Abraham und Cho 2009; Sartor 2008; Mayer 2010). Bei der Entstehung eines MCs sind Mutationen im NOD2 Gen ein wesentlicher Risikofaktor (Hugot et al. 2001; Ogura et al. 2001; Cuthbert et al. 2002). Bei NOD2 handelt es sich um 
eiŶeŶ iŶtrazelluläreŶ „patterŶ recognition reĐeptor“, ǁelĐher BestaŶdteile des PeptidoglǇkaŶs ;PGNͿ, wie Muramyl Dipeptid (MDP) erkennt und es hierdurch letztendlich zu einer Aktivierung des Transkriptionsfaktors NF-kappa-B kommt (Strober et al. 2006). Mutationen im NOD2 Gen sind bei MC Patienten vor allem assoziiert mit einem jüngeren Alter bei Erstdiagnose, Dünndarmbeteiligung, Ileozökalresektion und einer höheren Rate an postoperativen Rezidiven und Re-Operationen (Büning et al. 2004). Während die CED in der ersten Hälfte des 20. Jahrunderts noch eine seltene Krankheitsgruppe darstellten, kam es in der zweiten Hälfte des 20. Jahrhunderts zu einem dramatischen Anstieg mit in etwa einer Verdopplung der Inzidenz in jeder Dekade (Molodecky et al. 2012). Dieser Aspekt kann nicht allein durch genetische oder immunologische Faktoren erklärt werden, sondern es spielen hier möglicherweise auch Umweltfaktoren eine wichtige Rolle. In den letzten Jahren ist der Einfluss des intestinalen Mikrobioms auf die CED zunehmend in den wissenschaftlichen Focus gerückt. Das Darmmikrobiom – die Gesamtheit aller im Darm lebenden Mikroorganismen – zeigt eine unterschiedliche Zusammensetzung in verschiedenen Teilen des Gastrointestinaltraktes mit der höchsten Anzahl von Mikroorganismen im Kolon von 1011 oder 1012 Zellen/g Darminhalt und einem Gesamtgewicht von ca. 1 kg (Dave et al. 2012; Savage 1977). Verschiedene Studien legen einen Zusammenhang zwischen der intestinalen bakteriellen Komposition und dem Auftreten von CED nahe (Frank et al. 2007; Frank et al. 2011; Willing et al. 2010). In einem NOD2-Knockout Mausmodell zeigte sich, dass NOD2 eine wichtige Rolle für die Zusammensetzung der intestinalen Bakterien spielt (Rehman et al. 2011). Darüber hinaus hat der NOD2 Rezeptor eine bedeutende Rolle in der Sekretion von Defensinen aus Paneth Zellen (Wehkamp et al. 2005). Inwieweit jedoch eine Veränderung der bakteriellen Zusammensetzung ursächlich oder vielmehr Folge einer mukosalen intestinalen Inflammation darstellt, bleibt eine noch offene Frage und ist weiterhin Gegenstand der aktuellen Forschung. Ein Umweltfaktor, welcher im Zusammenhang mit CED steht, ist das Vitamin D. Eine Hypovitaminosis D ist ein häufiges Phänomen bei CED Patienten (Ulitsky et al. 2011; Leslie et al. 2008). Neben seiner Wirkung auf den Calcium- und Phosphatmetabolismus sowie den Knochenstoffwechsel verdichtet sich die Datenlage, dass Vitamin D eine wichtige Rolle als Regulator des angeborenen und erworbenen Immunsystems darstellt (Cantorna und Mahon 2005; Cantorna et al. 2014). Dass es einen Zusammenhang zwischen Vitamin D und NOD2 gibt, konnte in einer Studie gezeigt werden, in der nach 
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Vitamin D Stimulation eine höhere Expression des Vitamin D Rezeptors in humanen Monozyten und Epithelzellen nachgewiesen wurde (Wang et al. 2010). Darüber hinaus wurde in einer kürzlich publizierten genomweiten Assoziationsstudie nachgewiesen, dass Mutationen im Vitamin D Rezeptor mit spezifischen intestinalen mikrobiellen Profilen assoziiert waren (Wang et al. 2016).  Ziel der hier vorgestellten Arbeiten ist es, den Einfluss von NOD2, dem intestinalen Mikrobiom und Vitamin D auf den Verlauf der CED zu untersuchen.   2. Methoden Alle Untersuchungen am Menschen und an Tieren wurden mit Zustimmung der jeweils zuständigen Ethik-Kommissionen, im Einklang mit nationalem Recht sowie gemäß der Deklaration von Helsinki von 1975 (in der aktuellen, überarbeiteten Fassung) durchgeführt. Von allen beteiligten Patienten liegt eine Einverständniserklärung vor.  Über die Durchführung der einzelnen technisch-apparativen Untersuchungen wird ausführlich in den einzelnen Manuskripten eingegangen.   3. Ergebnisse 3.1 Die Stimulation von NOD2 durch ein von S. aureus hergestelltes Peptidoglykan wird durch eine TLR2 Ko-Stimulation mit Lipoproteinen in dendritischen Zellen verstärkt Die wichtigsten Liganden für NOD2 sind das PGN sowie dessen Bestandteil, das MDP. Diese Arbeit fokussierte sich insbesonders auf mehrfach verzweigte, polymere PGN (PGNpol) Fragmente in der Aktivierung des angeborenen Immunsystems (Schäffler et al. 2014). Es wurde der Effekt einer kombinierten NOD2 und TLR2 Stimulation im Vergleich zu einer alleinigen NOD2 Rezeptor-Stimulation untersucht. PGNpol wurde von einem Lipoprotein enthaltenden S. aureus Stamm (PGNpol) sowie von einem Lipoprotein-defizienten S. aureus Stamm (PGNpol∆lgt) isoliert. Während PGNpol sowohl als NOD2 als auch als TLR2 Ligand fungiert, handelt es sich bei PGNpol∆lgt um einen alleinigen NOD2 Liganden. Es kam nach Stimulation mit PGNpol in aus murinem Knochenmark gewonnen dendritischen Zellen (BMDC) zu einer starken Aktivierung und Reifung der dendritischen Zellen im Gegensatz zu PGNpol∆lgt. Eine deutliche Erhöhung pro-inflammatorischer Zytokine nach Stimulation mit PGNpol im Gegensatz zu PGNpol∆lgt konnte in verschiedenen Zellsystemen (BMDC, J774, MonoMac 6) nachgewiesen werden. Zusammenfassend kann festgestellt werden, dass eine kombinierte TLR2 und 
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NOD2 Stimulation zu einer deutlichen Aktivierung des Immunsystems im Gegensatz zu einer Stimulation des jeweils einzelnen Rezeptors allein führt.  Publikation: Schäffler, Holger*; Demircioglu, Dogan Doruk*; Kühner, Daniel; Menz, Sarah; Bender, Annika; Autenrieth, Ingo B. et al. (2014a): NOD2 stimulation by Staphylococcus aureus-derived peptidoglycan is boosted by Toll-like receptor 2 costimulation with lipoproteins in dendritic cells. In: Infection and immunity82 (11), S. 4681–4688. DOI: 10.1128/IAI.02043-14. * contributed equally to the work  3.2 Spezifische klinische Faktoren beeinflussen die Vitamin D Spiegel bei CED-Patienten  Die genauen Auswirkungen einer Hypovitaminosis D auf den Krankheitsverlauf bei CED Patienten sind bisher noch nicht vollständig geklärt, dieser Frage widmet sich die im Folgenden beschriebene Arbeit. In einer retrospektiven Untersuchung wurde die Assoziation von Vitamin D Werten mit klinischen Parametern, wie z.B. medikamentöse, krankheitsgerichtete Therapie, anatomische Situation, Krankheitslokalisation und Krankheitsaktivität untersucht. Es wurden 208 Patienten in die Studie eingeschlossen (123 MC und 85 CU). Ein schwerer Vitamin D Mangel (25-OH-Vitamin D < 27,5 nmol/l) zeigte sich hochprävalent in den Wintermonaten von Januar bis April. Eine Therapie mit einem TNF-alpha hemmenden Wirkprinzip war bei MC Patienten mit signifikant höheren Vitamin D Werten assoziiert, unabhängig von einer möglichen Vitamin D Substitution. Patienten mit MC Befall im Dünndarm bzw. MC Patienten nach Dünndarmresektion zeigten signifikant niedrigere Vitamin D Spiegel. Bei Patienten mit CU war eine höhere Krankheitsaktivität mit niedrigeren Vitamin D Spiegeln assoziiert. Letztendlich kann aus der Arbeit geschlossen werden, dass ein Screening auf eine Hypovitaminosis D insbesondere in den Monaten Januar bis April sinnvoll ist, darüber hinaus bei Patienten mit einem Dünndarmbefall bzw. nach Dünndarmresektion.  Schäffler, Holger; Schmidt, Martin; Huth, Astrid; Reiner, Johannes; Glass, Änne; Lamprecht, Georg (2017c): Clinical factors are associated with vitamin D levels in IBD patients - a retrospective analysis. In: Journal of digestive diseases. DOI: 10.1111/1751-2980.12565.  3.3 Einfluss von krankheitsspezifischen Faktoren auf das Mukosa-assoziierte Darmmikrobiom bei CED Patienten  Während die Untersuchung der intestinalen bakteriellen Komposition mittels Sequenzierung sowohl technisch als auch bioinformatisch aufwendig und kostenintensiv ist, können mittels einer Polymerase Kettenreaktion (PCR) einzelne bakterielle Stämme kostengünstig und zeitnah quantitativ erfasst werden. In dieser Arbeit wurde der Einfluss der Krankheitsentität (MC und UC), von Mutationen im NOD2 Gen, der Therapie mit einem TNF-alpha Blocker sowie dem Vorhandensein einer endoskopisch 
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erkennbaren Inflammation auf die Abundanz von sieben bakteriellen Stämmen (Bacteroides fragilis, Escherichia coli, Prevotella melaninogenica, Clostridium coccoides, Clostridium difficile, Bifidobacterium bifidum und Faecalibacterium prausnitzii) untersucht, welche als wichtige Repräsentanten der jeweiligen Phyla möglicherweise eine Rolle in der Entstehung und im Verlauf von CED haben. Es zeigte sich, dass verschiedene klinische Situationen zu einer veränderten Abundanz von bakteriellen Stämmen führen können. Die Untersuchung einzelner bakterieller Stämme könnte zukünftig eine prädiktive Rolle im Krankheitsverlauf bei CED darstellen, bzw. es könnte hierdurch möglicherweise perspektivisch einen Ansatz einer zielgerichteten Therapie entstehen lassen.    Schäffler, Holger; Kaschitzki, Annika; Alberts, Christian; Bodammer, Peggy; Bannert, Karen; Köller, Thomas et al. (2016): Alterations in the mucosa-associated bacterial composition in Crohn's disease. A pilot study. In: International journal of colorectal disease 31 (5), S. 961–971. DOI: 10.1007/s00384-016-2548-z.  3.4 Mutationen im NOD2 Gen sind assoziiert mit einem distinktiven Krankheitsphänotyp bei MC Patienten In diversen vorherigen Studien konnte bisher für Patienten mit dem Vorliegen einer NOD2 Mutation gezeigt werden, dass diese mit einem spezifischen Krankheitsphänotyp assoziiert sind (s.o.). Wir konnten an unserer MC Kohorte an der Universitätsmedizin Rostock zeigen, dass Patienten, bei denen eine Mutation im NOD2 Gen vorliegt, signifikant häufiger ein Krankheitsbefall im Ileocolon vorhanden war, sowie diese Patienten signifikant häufiger eine Ileocoecalresektion oder einen strikturierenden bzw. perianalen Krankheitsverlauf aufwiesen. Patienten mit einer NOD2 Mutation hatten seltener einen kolonischen MC sowie seltener eine Stoma-Anlage nach einer OP. Patienten mit einer Mutation im SNP13 zeigten häufiger einen perianalen Befall. Im klinischen Alltag wird der Therapieerfolg bzw. das Therapieversagen auf einen TNF-alpha Blocker mittels Durchführung eines therapeutischen Drug Monitorings (TDM) gesteuert. Interessanterweise war das Vorliegen einer NOD2 Mutation assoziiert mit signifikant häufigeren TNF-alpha Spiegeln im subtherapeutischen Bereich und numerisch niedrigeren TNF-alpha Spiegeln im Vergleich zu Patienten ohne das Vorliegen einer NOD2-Mutation. Ein Fazit, welches aus dieser Studie gezogen werden kann, ist, dass Patienten mit dem Vorliegen einer NOD2 Mutation möglicherweise von einem engmaschigeren TDM profitieren könnten, was ein proaktives Vorgehen anstelle eines reaktiven TDM Ansatzes nahelegt.   Schäffler, Holger; Geiss, David; Gittel, Nicole; Rohde, Sarah; Huth, Astrid; Glass, Änne et al. (2018a): Mutations in the NOD2-gene are associated with a specific phenotype and lower anti-TNF trough levels in Crohn's disease. In: Journal of digestive diseases. DOI: 10.1111/1751-2980.12677.  
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3.5 Eine Vitamin D Substitution führt zu einer Veränderung der intestinalen bakteriellen Komposition bei MC Patienten, jedoch nicht bei gesunden Kontrollen   Der Einfluss einer Vitamin D Administration auf die spezifische intestinale bakterielle Komposition bei MC Patienten im Vergleich zu gesunden Kontrollen wurde bisher noch nicht untersucht. In dieser Arbeit führten wir eine prospektive, longitudinale, kontrollierte Interventionsanalyse in Patienten mit MC und gesunden Kontrollen durch, indem wir unter Vitamin D Substitution die intestinale bakterielle Zusammensetzung untersuchten. Darüber hinaus wurde die Krankheitsaktivität sowie als Inflammationsmarker das fäkale Calprotectin miterfasst. Unter Vitamin D Applikation kam es zu keiner signifikanten Änderung der Krankheitsaktivität bzw. des fäkalen Calprotectinwertes. Es zeigte sich jedoch, dass es bei MC Patienten in der frühen Substitutionsphase zu einer spezifischen Veränderung der bakteriellen Zusammensetzung kam, welche im späteren Verlauf wieder revertierte. Bei den gesunden Kontrollen kam es zu keiner Änderung der Zusammensetzung der Darmbakterien. Interessanterweise kam es bei den MC Patienten unter Vitamin D Substitution zu einer Reduktion der 
„operatioŶal taǆoŶoŵiĐ uŶits“ ;OTU’sͿ. Darüber hinaus konnte gezeigt werden, dass bestimmte Bakterienspezies unter Vitamin D Substitution eine höhere Abundanz hatten als in der Kontrollgruppe. Diese Studie legt einen direkten Effekt von Vitamin D auf die Zusammensetzung der intestinalen bakteriellen Zusammensetzung nahe.   Schäffler, Holger; Herlemann, Daniel Pr; Klinitzke, Paul; Berlin, Peggy; Kreikemeyer, Bernd; Jaster, Robert; Lamprecht, Georg (2018a): Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn's Disease patients, but not in healthy controls. In: Journal of digestive diseases. DOI: 10.1111/1751-2980.12591.  3.6 Die mukosa-assoziierte intestinale bakterielle Komposition ist assoziiert mit der Krankheitsaktivität bei MC Patienten CED sind assoziiert mit einer Veränderung der bakteriellen Zusammensetzung, auch genannt Dysbiose. Üblicherweise werden für Mikrobiomstudien Stuhlproben verwendet. In dieser Arbeit an einem Kollektiv von MC Patienten wurden mukosale Biopsate aus routinemäßig durchgeführten Koloskopien bezüglich der intestinalen bakteriellen Komposition untersucht und nach Krankheitsaktivität, Applikation eines TNF-alpha Blockers, lokalem Inflammationsstatus sowie dem Vorhandensein einer NOD2-Mutation stratifiziert. Es konnte gezeigt werden, dass Patienten mit einer höheren 
KraŶkheitsaktiǀität ;geŵesseŶ aŶhaŶd des CDAI, CrohŶ’s Disease AĐtiǀitǇ IŶdeǆͿ eiŶe sigŶifikaŶte Änderung der intestinalen bakteriellen Komposition zeigten. Darüber hinaus konnten einzelne bakterielle Spezies identifiziert werden, welche eine hohe Abundanz bei niedriger, mittlerer und hoher Krankheitsaktivität zeigten. Dies ist die erste Studie, welche einen Zusammenhang zwischen der 
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Krankheitsaktivität bei MC Patienten und einer Veränderung der bakteriellen Zusammensetzung beschreibt.   Schäffler, Holger*; Herlemann, Daniel Pr*; Alberts, Christian; Kaschitzki, Annika; Bodammer, Peggy; Bannert, Karen et al. (2016): Mucosa-attached bacterial community in Crohn's Disease coheres with the Clinical Disease Activity Index. In: Environmental microbiology reports. DOI: 10.1111/1758-2229.12411. * contributed equally to the work  3.7 Das Vorhandensein einer Mutation im NOD2 Gen ist assoziiert mit der Entwicklung eines Darmversagens – unabhängig vom Vorliegen eines M. Crohns Mutationen im NOD2 Gen sind der wichtigste genetische Risikofaktor für das Vorliegen eines MCs. In einer Kohorte von 85 Patienten mit nicht-malignem Darmversagen wurde das Vorhandensein einer Mutation im NOD2-Gen und darüber hinaus im ATG16L1 sowie IL23R Gen untersucht. Es konnte gezeigt werden, dass Patienten mit einem Darmversagen signifikant häufiger eine NOD2 Mutation aufwiesen als die Kontrollgruppe. Bei MC Patienten mit Darmversagen war die NOD2 Mutationsfrequenz zwischen Patienten mit und ohne Darmversagen nicht signifikant verschieden. Das Vorliegen einer NOD2 Mutation war weder mit Faktoren, welche zu einer Darm- oder Multiviszeraltransplantation führen, noch mit einer früheren Indikationsstellung für eine solche Transplantation assoziiert. NOD2 Mutationen scheinen somit die Entstehung von komplikationsträchtigen abdominellen Ereignissen, welche konsekutiv zu einem Darmversagen führen, zu begünstigen oder aber die Adaptation nach einem solchen Eingriff negativ zu beeinflussen.  Schäffler, Holger; Schneider, Nina; Hsieh, Chih-Jen; Reiner, Johannes; Nadalin, Silvio; Witte, Maria et al. (2013): NOD2 mutations are associated with the development of intestinal failure in the absence of Crohn's disease. In: Clinical nutrition (Edinburgh, Scotland) 32 (6), S. 1029–1035. DOI: 10.1016/j.clnu.2013.02.014. * contributed equally to the work  3.8 Zwei Patienten mit einem Darmversagen, Vorliegen einer NOD2-Mutation und einer Lymphknotentuberkulose  In dieser Fallserie werden zwei Patienten mit Darmversagen beschrieben. Beide Patienten bedürfen einer totalen heimparenteralen Ernährung, darüber hinaus liegt bei beiden Patienten eine NOD2 Mutation vor. Es zeigte sich, dass bei beiden Patienten eine Lymphknotentuberkulose diagnostiziert wurde, welche im FDG-PET-CT positiv war. Beide Patienten erhielten eine tuberkulostatische Therapie und zeigten eine klinische Abheilung, die PET positiven Läsionen waren im Verlauf deutlich regredient. Als Schlussfolgerung kann aus dieser Fallserie gezogen werden, dass Patienten mit Darmversagen, 
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welche eine NOD2 Mutation aufweisen, engmaschig auf das Vorliegen einer Lymphknotentuberkulose hin untersucht werden müssen.  Schäffler, Holger; Teufel, Matthias; Fleischer, Sabrina; Hsieh, Chih-Jen; Frick, Julia-Stefanie; Lamprecht, Georg (2014b): Two patients with intestinal failure requiring home parenteral nutrition, a NOD2 mutation and tuberculous lymphadenitis. In: BMC gastroenterology14, S. 43. DOI: 10.1186/1471-230X-14-43.  3.9 M. Crohn Patienten zeigen NOD2- und krankheitsspezifische Genexpressionsprofile in mononukleären Zellen des peripheren Blutes In dieser Arbeit wurden die zwei Hypothesen getestet, dass mononukleäre Zellen aus dem peripheren 
Blut ;PBMC’sͿ eiŶ geeigŶetes Mediuŵ siŶd, uŵ GeŶeǆpressioŶsprofile bei CED Patienten zu untersuchen sowie dass MC Patienten – selbst im Zustand der klinischen Vollremission – eine krankheitsspezifisĐhe GeŶeǆpressioŶ iŶ PBMC’s aufweisen (Schäffler et al. 2018b). Zunächst wurde in Form eines hypothesenfreien Ansatzes mittels Microarray Technologie nach Vitamin D sowie PGN und LPS Stimulation in einem kleinen Kollektiv von 3 MC Patienten und 3 gesunden Probanden 267 Gene identifiziert, welche eine signifikant unterschiedliche krankheitsspezifische Regulation aufwiesen. Eine Eingrenzung dieser Gene und anschließende Verifikation in einem größeren Kollektiv an Patienten und Kontrollen mittels Real-Time PCR zeigte, dass drei Gene krankheitsspezifzisch (CLEC5A, LYZ und TREM1) sowie 6 Gene NOD2-abhängig (CD101, CLEC5A, CXCL5, IL-24, ITGB2, LYZ) reguliert waren. Wir sehen vor allem TREM1 sowie CLEC5A in einem regulatorischen Netzwerk als vielversprechenden Baustein in der Pathophysiologie des MC.  Schäffler, Holger; Rohde, Maria; Rohde, Sarah; Huth, Astrid; Gittel, Nicole; Hollborn, Hannes et al. (2018b): NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn's disease patients. In: World journal of gastroenterology 24 (11), S. 1196–1205. DOI: 10.3748/wjg.v24.i11.1196.          
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4. Diskussion Die genaue Ätiopathogenese der CED ist nach wie vor nicht vollständig geklärt, eine wichtige Rolle in Ihrer Entstehung und im klinischen Verlauf haben einerseits Umweltfaktoren, wie z.B. das intestinale Mikrobiom sowie Vitamin D und andererseits genetische Marker, wie z.B. Mutationen im NOD2-Gen. Die vorliegenden Arbeiten beschäftigen sich einerseits mit dem Wechselspiel dieser Einzelfaktoren untereinander und andererseits mit deren Einfluss auf den Verlauf der CED. Übergeordnetes Ziel der hier durchgeführten Untersuchungen war es, den Krankheitsverlauf ex ante besser einschätzen zu können und somit – anhand der Bestimmung von sogenannten „BioŵarkerŶ“ – ein präziseres Verständnis im Sinne einer personalisieren Medizin für den Patienten zu entwickeln und den Krankheitsverlauf möglicherweise günstig zu beeinflussen.   Der Einfluss einer NOD2 Mutation auf den Verlauf von CED wurde bereits in mehreren Studien intensiv untersucht (Büning et al. 2004). Wir konnten in einer Genotyp-Phänotyp-Assoziationsstudie an MC Patienten in einem norddeutschen CED Zentrum einen Zusammenhang zwischen dem Vorhandensein einer Mutation im NOD2 Gen und bestimmten klinischen Faktoren zeigen, u.a. waren NOD2 Mutationen assoziiert mit ileokolonischem Verlauf sowie strikturierendem und auch penetrierendem Krankheitsverhalten. Insbesondere beim Vorliegen einer Mutation im SNP13 zeigte sich signifikant häufiger ein perianaler Befall. Dass NOD2 auch im klinischen Alltag eine wichtige Rolle spielt, konnten wir dadurch zeigen, dass Patienten mit einer NOD2-Mutation signifikant häufiger subtherapeutische anti-TNF Talspiegel aufwiesen bzw. numerisch signifikant niedrigere anti-TNF Talspiegel hatten. Patienten mit einer NOD2 Mutation könnten somit von einem engmaschigeren TDM profitieren. Möglicherweise ǁäre iŶ dieseŵ „HoĐhrisiko-Kollektiǀ“ auĐh eiŶ VorgeheŶ iŵ SiŶŶe eiŶes proaktiǀeŶ – im Gegensatz zum üblicherweise und auch von den entsprechenden Leitlinien empfohlenen reaktiven TDM – zu diskutieren (Feuerstein et al. 2017). Während Mutationen im NOD2 Gen als wichtigste genetische Risikofaktoren für die Entstehung eines MCs gelten, konnten wir in zwei weiteren Arbeiten zeigen, dass es eine Assoziation von Mutationen im NOD2 Gen und dem Vorliegen eines Kurzdarmsyndromes (KDS) – unabhängig von der zugrundeliegenden Ätiologie – sowie der Entwicklung einer Lymphknotentuberkulose gibt.  Im murinen Modell sowie anhand verschiedener Zellkulturen konnte darüber hinaus nachgewiesen werden, dass eine TLR2 Ko-Stimulation eine wichtige Rolle in der NOD2-abhängigen Aktivierung des angeborenen Immunsystems darstellt.  Ein Vitamin D Mangel ist bei CED hochprävalent und mit einem schlechteren Outcome verknüpft (Gubatan und Moss 2018). Wir konnten zeigen, dass Vitamin D mit einem spezifischen 
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Krankheitsphänotyp bei CED Patienten (Schäffler et al. 2017) assoziiert ist, z.B. haben Patienten mit einem Dünndarmbefall bzw. nach Dünndarmresektionen signifikant niedrigere Vitamin D Spiegel als die entsprechenden Kontrollen. Wir haben gezielt in Form eines interventionellen Ansatzes untersucht, ob die Applikation von Vitamin D auch Auswirkungen auf die intestinale bakterielle Komposition hat. Interessanterweise kam es bei MC Patienten zu einer transienten Veränderung der intestinalen bakteriellen Komposition im Gegensatz zu den gesunden Kontrollen (Schäffler et al. 2018a). Unter Vitamin D Substitution kam es zusätzlich zu einer signifikant erhöhten Abundanz von einzelnen bakteriellen Stämmen, u.a. Alistipes und Parabacteroides. Es bleibt spekulativ und ein Gegenstand von zukünftigen Studien, ob möglicherweise ein Teil dieser Stämme an sich bzw. in Kombination mit Vitamin D einen positiven Einfluss auf die Krankheitsaktivität bei CED Patienten haben könnte.  Mithilfe eines hypothesenfreien Ansatzes mittels Microarray Technologie konnten wir aus 
PBMC’s ǀoŶ MC Patienten nach Vitamin D sowie PGN/LPS Stimulation 267 Gene identifizieren, welche bei MC Patienten krankheitsspezifisch reguliert waren. In einer weiteren Untersuchung in einem größeren Patientenkollektiv wurden verschiedene Gene nachgewiesen, welche krankheitsspezifisch bzw. NOD2-aďhäŶgig eǆpriŵiert ǁurdeŶ. IŶsgesaŵt ďieteŶ PBMC’s eiŶ ǀergleiĐhsǁeise eiŶfaĐh zu generierendes Medium, um Genexpressionsprofile zu untersuchen, welche perspektivisch als Biomarker fungieren könnten. Weitere Genotyp-Phänotyp-Assoziationsstudien der identifizierten Gene in einem größeren Patientenkollektiv sowie funktionelle Studien folgen.     Das intestinale Mikrobiom zeigt einen engen Zusammenhang mit der Entstehung und dem Verlauf von CED. Verschiedene Studien mit  endoskopisch gewonnenen mukosalen Proben bei CED Patienten konnten sowohl mittels RT-PCR als auch über „Next Generation Sequencing“ (NGS) nachweisen, dass bestimmte klinische Konstellationen mit einem spezifischen Darmmikrobiom assoziiert sind (Schäffler et al. 2016; Schäffler et al. 2016). Unter anderem konnten wir nachweisen, dass die Krankheitsaktivität signifikant mit der bakteriellen Zusammensetzung im Darm korreliert. Einzelne Darmbakterien als 
„Markerkeiŵe“ koŶŶteŶ eďeŶfalls identifiziert werden und könnten perspektivisch als Biomarker bei CED Patienten eingesetzt werden. Weitere Studien sind hier notwendig, um das komplexe Zusammenspiel zwischen Darmmikrobiom und dem Krankheitsverlauf bei CED besser zu verstehen.   Wir konnten insgesamt in verschiedenen Studien nachweisen, dass sowohl Vitamin D als auch NOD2 und das intestinale bakterielle Mikrobiom einen spezifischen Einfluss auf den Krankheitsverlauf von CED haben.   
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5. Zusammenfassung Der Krankheitsverlauf bei CED Patienten lässt sich aktuell nur unzureichend vorhersagen, prädiktive Marker stehen nur eingeschränkt zur Verfügung. Die hier vorgestellten Arbeiten beschäftigen sich mit dem Zusammenhang zwischen Darmmikrobiom, Vitamin D und genetischen Risikofaktoren, wie Mutationen im NOD2 Gen bei CED. Aus den hier durchgeführten Untersuchungen resultiert u.a. ein besseres Verständnis darüber, wie sich die einzelnen Faktoren gegenseitig beeinflussen und eine Auswirkung auf den Krankheitsverlauf bei CED haben. Dies alles trägt dazu bei, den Krankheitsverlauf bei CED besser zu verstehen und zukünftig anhand möglicher Biomarker präziser vorherzusagen.                   
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NOD2 Stimulation by Staphylococcus aureus-Derived Peptidoglycan Is
Boosted by Toll-Like Receptor 2 Costimulation with Lipoproteins in
Dendritic Cells
Holger Schäffler,a Dogan Doruk Demircioglu,b Daniel Kühner,b Sarah Menz,c,d Annika Bender,c,d Ingo B. Autenrieth,c,d
Peggy Bodammer,a Georg Lamprecht,a Friedrich Götz,b Julia-Stefanie Frickc,d
Division of Gastroenterology, Department of Medicine II, University of Rostock, Rostock, Germanya; Microbial Genetics, University of Tübingen, Tübingen, Germanyb;
Institute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germanyc; Deutsches Zentrum für Infektionsforschung (DZIF), Partner Side Tübingen,
Tübingen, Germanyd
Mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) play an important role in the patho-
genesis of Crohn’s disease. NOD2 is an intracellular pattern recognition receptor (PRR) that senses bacterial peptidoglycan
(PGN) structures, e.g., muramyl dipeptide (MDP). Here we focused on the effect of more-cross-linked, polymeric PGN frag-
ments (PGNpol) in the activation of the innate immune system. In this study, the effect of combined NOD2 and Toll-like recep-
tor 2 (TLR2) stimulation was examined compared to single stimulation of the NOD2 receptor alone. PGNpol species derived
from a lipoprotein-containing Staphylococcus aureus strain (SA113) and a lipoprotein-deficient strain (SA113 lgt) were iso-
lated. While PGNpol constitutes a combined NOD2 and TLR2 ligand, lipoprotein-deficient PGNpollgt leads to activation of the
immune system only via the NOD2 receptor. Murine bone marrow-derived dendritic cells (BMDCs), J774 cells, andMonoMac 6
(MM6) cells were stimulated with these ligands. Cytokines (interleukin-6 [IL-6], IL-12p40, and tumor necrosis factor alpha
[TNF-]) as well as DC activation andmaturation parameters were measured. Stimulation with PGNpollgt did not lead to en-
hanced cytokine secretion or DC activation andmaturation. However, stimulation with PGNpol led to strong cytokine secretion
and subsequent DCmaturation. These results were confirmed inMM6 and J774 cells. We showed that the NOD2-mediated acti-
vation of DCs with PGNpol was dependent on TLR2 costimulation. Therefore, signaling via both receptors leads to a more po-
tent activation of the immune system than that with stimulation via each receptor alone.
Crohn’s disease is a systemic inflammatory disease, and to-gether with ulcerative colitis, it forms the complex of inflam-
matory bowel diseases (IBD). Mutations within the NOD2 gene,
encoding nucleotide-binding oligomerization domain-contain-
ing protein 2 (NOD2), have been identified as risk factors for the
development of Crohn’s disease (1–3). NOD2 is an intracellular
pattern recognition receptor that senses peptidoglycan (PGN)
fragments, such as muramyl dipeptide (MDP), derived from
Gram-positive bacteria, to activate a cascade of reactions which
consecutively lead to the activation of the transcription factor
NF-B (4).
Dendritic cells (DCs) are important professional antigen-pre-
senting cells (APCs) in the intestine (5, 6) and are crucial for T cell
activation and polarization (7, 8). Depending on the antigen, DCs
can promote either inflammation or tolerance (9). DCs are
thought to contribute to the pathogenesis of Crohn’s disease (10,
11) by inducing T cell activation via antigen presentation. As an
example, colonic CD11cDCs isolated from inflamed parts of the
gut from IBDpatients showed an increased expression of Toll-like
receptor 2 (TLR2), TLR4, and the costimulatory molecule CD40
compared to DCs from noninflamed areas or DCs from healthy
controls (12). Also, the ability of DCs to induce tolerogenic regu-
latory T cells might be lost in Crohn’s disease patients (13).
PGN fragments with a low degree of cross-linking, such as
PGN monomers, have been shown to be natural ligands for the
NOD2 receptor (14). However, the role of more-cross-linked
PGN fragments, so called polymeric PGN (PGNpol), and their
effect in stimulating immune cells are still unclear, as even highly
purified PGNpol might be contaminated with potent immune-
stimulating lipoproteins (15). UsingBacillus anthracis peptidogly-
can, it has been shown that polymeric PGN is a more potent acti-
vator of innate immune cells thanMDP ormonomeric PGN (16).
The importance of PGN in inflammation was recently demon-
strated in mice infected with wild-type (WT) Staphylococcus au-
reus and corresponding O-acetyltransferase A (OatA) mutants. In
S. aureus, PGN is modified by an O-acetyltransferase at the C-6
OH position of N-acetylmuramic acid (17). This modification,
which occurs only in pathogenic staphylococcal strains (18), con-
fers complete resistance of PGN to lysozyme, while mutations of
the oatA gene result in a PGN that is sensitive to lysozyme (17, 19).
In comparing PGNpol from WT S. aureus with PGN from the
oatA-deficient mutant (S. aureus oatA), it turned out that WT
PGNpol strongly suppressed interleukin-1 (IL-1) secretion
and inflammasome activation, while the PGNpol of the S. aureus
oatA strain strongly increased IL-1 secretion and inflam-
masome activation (20). In the absence of oatA, PGN is degraded
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by lysozyme, resulting in a number of PGN breakdown products
which boost inflammation. Thus,modification of PGNbyO-acet-
ylation in S. aureus is an efficient immune escape mechanism.
The interplay between the NOD2 and TLR2 pathways is com-
plex, and interactions between both receptors seem to contribute
to activation or inhibition of the immune system (21). NOD2 was
shown to be part of an inhibitory system which blocks TLR2-
mediated inflammation, resulting in less Th1 cytokine production
after stimulation (22). Additionally, activation of mouse perito-
neal macrophages with the NOD2 ligand MDP resulted in down-
regulation of TLR2/1 signaling-mediated IL-1 expression (23).
However, different studies suggest a synergistic role for NOD2
and TLR2 (24).
Additionally, it is still controversially discussed whether PGN
interacts with TLR2. PGN isolated from either Gram-negative or
Gram-positive bacteria is reported not to be sensed by TLR2 (25).
However, stimulation of primary mouse keratinocytes (MKs)
with PGNpol from S. aureus SA113 resulted in internalization of
the molecule and colocalization with NOD2 and TLR2 receptors
and induced subsequent host immune responses (26). Addition-
ally, lipoproteins of S. aureus have been shown to activate TLR2
(26–29).
To further elucidate the interaction between the NOD2 and
TLR2pathways, we investigated the innate immune sensing of two
different types of naturally occurring S. aureus-derived PGNpoly-
mers. PGNof S. aureus SA113 contains traces of lipoproteins. This
PGN is referred to as the wild-type PGN. The other PGNpol frac-
tion was derived from the S. aureus SA113 lgt mutant, which is
unable to lipidate prolipoproteins and whose PGNpol therefore
does not contain lipoproteins (30).
By studying the effects of PGNpol from the wild type and that
from the lgt mutant (PGNpollgt) on DC maturation and acti-
vation as well as cytokine secretion, we showed that PGNpol is a
potent stimulator of the immune system, through both NOD2
and TLR2, while PGNpollgt, as a selective NOD2 ligand, does
not induce host immune responses. However, the addition of the
synthetic TLR2 ligand Pam3Cys (P3C) to PGNpollgt resulted in
activation of the host immune response. Costimulation with the
NOD2 ligand PGNpollgt and the TLR2 ligand P3C had a syner-
gistic effect on cytokine production, suggesting that NOD2-de-
pendent activation ofDCswith PGN requires TLR2 costimulation
by lipoproteins.
MATERIALS AND METHODS
Animals. C57BL/6 mice were purchased from Charles River (Sulzfeld,
Germany). NOD2/ mice were a kind gift from Tilo Biedermann (De-
partment of Dermatology, Eberhard Karls University, Tübingen, Ger-
many). All mice were housed under specific-pathogen-free conditions at
the animal facilities of the University of Tübingen according to German
law and European guidelines. All experiments were approved by the local
authorities (Regierungspräsidium Tübingen; Anzeigenummer 1.12.11).
Isolation of BMDCs. Bone marrow-derived dendritic cells (BMDCs)
were isolated by flushing the bone marrow from the femurs and tibias of
8- to 14-week-old WT and NOD2/ mice according to a previously
described method (31), with minor modifications.
Cells were harvested at day 8 and used to evaluate the effects of stim-
ulation with different bacterial PGN products on cytokine release and
expression of surface markers, as described below.
Stimulation of BMDCs. DCs were stimulated with different ligands,
e.g., P3C for TLR2, lipopolysaccharide (LPS) for TLR4, or MDP and
PGNpollgt for NOD2, or stimulated with the combined NOD2 and
TLR2 ligand PGNpol, at a dose of 1 g/ml if not otherwise mentioned.
The different PGN types were used at a concentration of 10 g/ml if not
otherwise mentioned. After 24 h, supernatants were harvested and ana-
lyzed for tumor necrosis factor alpha (TNF-), IL-6, and IL-12p40 cyto-
kine concentrations. Additionally, the expression of DC activation and
maturation surface markers major histocompatibility complex class II
(MHC-II) and CD40 was determined by flow cytometry.
Cytokine analysis by ELISA. Concentrations of murine IL-6, IL-8,
IL-12p40, and TNF- in cell culture supernatants were measured by en-
zyme-linked immunosorbent assay (ELISA) according to the manufac-
turer’s protocol (BD Bioscience, Heidelberg, Germany).
Fluorescence-activated cell sorter (FACS) analysis. Immature DCs
were harvested and stimulated for 24 h with different NOD2 or TLR
ligands. Cells were washed with phosphate-buffered saline (PBS) and 1%
fetal calf serum (FCS). Fc-Block was used to prevent nonspecific binding
of antibodies. DCswere incubated for 30min at 4°Cwith a fluorochrome-
conjugated antibody. The following antibodies were used for staining:
allophycocyanin-conjugated anti-mouse CD11c, fluorescein isothiocya-
nate (FITC)-conjugated anti-mouse CD40, CD80, and CD86, phyco-
erythrin (PE)-conjugated anti-mouse TLR2 and TLR4 (all antibodies
from BD Pharmingen), and appropriate isotype controls. After another
washing step (twice), the cells were fixed with 4% paraformaldehyde
(PFA). A total of 5 	 104 cells were analyzed using a FACS LSR Fortessa
flow cytometer (BD Bioscience, Heidelberg, Germany). Data were ana-
lyzed with FlowJo 7.6.4 (TreeStar Inc.).
Culture and stimulation of J774 cells andMM6 cells. J774 cells were
grown in VLE-RPMI 1640 medium with stable glutamine (Biochrom,
Berlin, Germany), 10% FCS, 1% nonessential amino acids, 1% sodium
pyruvate, and 0.5%mercaptoethanol. A total of 1 	 106 cells were seeded
perwell and incubated for 1 h. J774 cells were stimulatedwith Pam3Cys or
PGNpollgt for 48 h. After stimulation, supernatants were collected, and
cytokine (TNF-) concentrations were determined by ELISA (BD Biosci-
ence, Heidelberg, Germany). Mono Mac 6 (MM6) cells were cultured in
VLE-RPMI 1640 medium with stable glutamine (Biochrom, Berlin, Ger-
many), 10% FCS, 1% nonessential amino acids, and 1% penicillin-strep-
tomycin. After stimulation of the Mono Mac 6 cells with Pam3Cys and
PGNpollgt for 48 h, the supernatants were collected, and the concentra-
tion of IL-8 was analyzed by use of an ELISA kit (BD Biosciences) accord-
ing to the manufacturer’s instructions.
Strains and growth conditions. Staphylococcus aureus SA113 (wild
type) and the lgt mutant (no expression of mature lipoproteins) were
grown in tryptic soy broth (Sigma, Steinheim, Germany) at 37°C with
aeration for 16 h. The optical density at 578 nm was 12 (He
ios  spec-
trophotometer; Thermo Scientific).
Isolation of polymeric peptidoglycan (PGNpol). The isolation of ul-
trapure PGN, free ofDNA,RNA, proteins, wall teichoic acids, lipoteichoic
acids, and salts, was done according to the method of de Jonge et al. (32),
with somemodifications. Thesemodifications included the usage of three
different buffers (buffers A to C). The pellet of a 50-ml overnight culture
was boiled in 10 ml buffer A (2.5% SDS in 0.1 M Tris-HCl, pH 6.8) for 20
min at 100°C. The SDS was removed by several washing steps with dou-
ble-distilled water at 4,700 rpm at room temperature. The pellet was re-
suspended with 20 ml 0.1 M Tris-HCl, pH 6.8. Cells were disrupted by
vortexing with glass beads (150 to 212 m). The supernatant was subse-
quently incubated with buffer B for 1 h (10 g/ml DNase and 50 g/ml
RNase in 0.1 M Tris-HCl, pH 6.8), with buffer C overnight (50 g/ml
trypsin in double-distilled water), and, finally, with hydrofluoric acid
(HF) for 4 h.HFwaswashed outwith double-distilledwater, and the PGN
was lyophilized overnight.
Lyophilized PGN (10mg/ml) was digested with 500 Umutanolysin of
Streptomyces globisporus ATCC 21553 (Sigma) in a 12.5 mM phosphate
buffer (pH 5.5) at 37°C for 16 h. The sample was boiled for 3 min and
centrifuged for 5 min at 10,000 rpm. The supernatant was reduced with
sodium borohydride in 0.5 M borate buffer (pH 9) for 20 min at room
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temperature. The pH was subsequently adjusted to 2 with orthophos-
phoric acid. Samples were further processed or stored at 20°C.
The separation and analysis of the peptidoglycan polymer were per-
formed by high-pressure liquid chromatography (HPLC), based on the
method of Glauner (33), using an Agilent 1200 analytical HPLC system. A
250- by 4.6-mm reversed-phase column (Prontosil 120-3-C18 AQ;
Bischoff) guarded by a 20- by 4.6-mm precolumn was used. The samples
were eluted at a flow rate of 0.5 ml/min, using a linear gradient starting
from 100% buffer A (100mMNaH2PO4, 5% [vol/vol] methanol, pH 2.5)
to 100% buffer B (100 mM NaH2PO4, 30% [vol/vol] methanol, pH 2.8)
within 155 min. The column temperature was set to 52°C. The eluted
muropeptides were detected by UV absorption at 205 nm. The corre-
sponding polymer peak (rt  105 to 135 min) (Fig. 1) was collected and
desalted on the same column, using a water-acetonitrile gradient.
LPS contamination was checked using an Endosafe-PTS system
(Charles River, Sulzfeld, Germany). Remaining LPS impurities were re-
moved using an EndoTrapRed endotoxin removal kit (Hyglos). Very low
LPS contents could be detected (0.005 endotoxin unit [EU]/mg).
Statistical analysis. Statistical analysis was performed using Graph-
Pad Prism software (GraphPad, La Jolla, CA). Parameters were analyzed
by a nonparametric one-way analysis of variance (ANOVA) model for
repeated measurements, with the Bonferroni adjustment (*, P  0.05; **,
P  0.01; and ***, P  0.001). P values of 0.05 were considered signif-
icant. Error bars represent standard errors of the means (SEM). If not
otherwise mentioned, figures show means  SEM of values from three
experiments per group. StimulatedDCs fromWTmice were compared to
unstimulated DCs from WT mice, and stimulated DCs from NOD2/
mice were compared to unstimulated DCs from NOD2/ mice.
RESULTS
Purification of polymeric peptidoglycan (PGNpol) from S. au-
reus and its lgt mutant. To address the importance of lipopep-
tide impurities within the PGN fractions in signaling, we isolated
polymeric PGN from two S. aureus SA113 strains. On the one
hand, we isolated PGN fromwild-type SA113, containing residual
mature lipoproteinswithin the polymeric PGNmeshwork.On the
other hand, we isolated PGN from SA113 lgt, which is consid-
ered lipoprotein free because of its inability to produce mature
lipoproteins. A typical pattern for PGN from WT SA113 after
muramidase digestion is shown in Fig. 1. The pattern for PGN
from SA113 lgt was identical to the WT pattern and is therefore
not shown.
Activation and maturation of DCs by PGNpol are due to re-
sidual lipoproteins. In order to elucidate the role of S. aureus-
derived polymeric PGN in the NOD2-mediated activation of
BMDCs, these cells were stimulatedwith PGN isolated fromeither
WT S. aureus SA113 (PGNpol) or SA113 lgt (PGNpollgt).
PGNpol is a ligand of NOD2, but while PGNpollgt is lipoprotein
free, the PGNpol preparation contains lipoproteins of S. aureus,
which are known to be ligands of TLR2 (30).
For control purposes, Pam3Cys (a synthetic triacylated lipo-
peptide), LPS, and MDP were used as specific ligands for TLR2,
TLR4, andNOD2, respectively. Incubation ofDCswith increasing
concentrations of PGNpollgt (up to 100 g/ml) did not stimu-
late secretion of IL-6, as indicated in Fig. 2A. In contrast, PGNpol
(10g/ml) strongly stimulated IL-6 secretion, to a degree that was
comparable with that induced by LPS or Pam3Cys. Furthermore,
incubation with PGNpollgt (up to 100 g/ml) did not induce
secretion of IL-12p40 (Fig. 2B), while PGNpol (10 g/ml)
strongly stimulated IL-12p40 secretion.
In order to find out whether PGNpol and PGNpollgt lead
to DC maturation, DCs were stimulated with PGNpollgt or
PGNpol and afterwards analyzed for MHC-II and CD40
FIG 1 Separation and analysis of polymeric PGN. Separation and analysis of the peptidoglycan polymer were performed using an Agilent 1200 analytical HPLC
system. The corresponding polymer peak (rt  105 to 135 min) was collected and desalted. Remaining LPS impurities were removed. Shown is the pattern for
muramidase-digested PGN from an S. aureus SA113 wild-type overnight culture. The boxed sequence indicates the collected polymeric PGN fragments.
Synergistic Effect of PGN and Lipoproteins on DCs
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surface expression by flow cytometry. DCs stimulated with
PGNpol expressed high levels of MHC-II and CD40, resulting
in highly activated and mature DCs. In contrast, expression of
these surface molecules was nearly unaffected in DCs exposed
to PGNpollgt, suggesting a reduced ability of PGNpollgt to
activate and mature DCs (Fig. 3).
Stimulation with PGNpol leads to increased activation and
maturation of DCs compared to the case with PGNpollgt. To
further elucidate the effect of a bacterial NOD2 ligand and the
potentially costimulatory effect of a TLR2 ligand, DCs from
NOD2/ mice were compared to DCs fromWT mice.
First, secretion of IL-12p40 was tested after stimulation with
PGNpollgt and PGNpol. Consistent with the data shown in Fig.
2A, therewas nodetectable secretion of IL-12p40 after stimulation
with PGNpollgt inDCs from eitherWTmice orNOD2/mice.
In contrast, stimulation with PGNpol induced a significantly
smaller IL-12p40 signal in DCs fromNOD2/ mice than in DCs
from WT mice (Fig. 4). These data strongly suggest that a com-
bined NOD2 and TLR2 signal is necessary to induce a strong se-
cretion of IL-12p40 and that the smaller signal in the DCs from
NOD2/ mice was the result of the sole activation of TLR2. Sim-
ilar results were obtained with IL-6 after stimulation of DCs from
NOD2/ mice with PGNpollgt and PGNpol (data not shown).
To further test the effect of combined TLR2 and NOD2 stimula-
tion onDCactivation andmaturation, we analyzed the expression of
the DC surface markers MHC-II and CD40 by flow cytometry. In
NOD2/ DCs, incubation with PGNpol led to a significantly
smaller proportion of MHC-IIhigh cells than the case in stimulated
WT DCs (Fig. 5A). Furthermore, there was an increased expression
of CD40 in DCs after stimulation with PGNpol compared to
PGNpollgt (Fig. 5B). Taken together, our data strongly suggest
that a combined stimulation of the TLR2 and NOD2 pathways by
PGNpol is important for the activation andmaturation of DCs.
Combined stimulation of DCs with PGNpollgt and
Pam3Cys reveals synergistic effects onTNF- secretionpattern.
TNF- is a key cytokine in IBD and is well known for its role in
mediating innate immune responses (34). To confirm our hy-
pothesis that combined stimulationwith TLR2 andNOD2 ligands
FIG 2 Stimulation with PGNpol, but not PGNpollgt, leads to significant secretion of IL-6 and IL-12p40 in DCs. Incubation of DCs with PGNpol, but not
PGNpollgt, stimulated IL-6 (A) and IL-12p40 (B) secretion, which was comparable to that induced by LPS or Pam3Cys. DCs were stimulated with PGNpollgt
at concentrations of up to 100 g/ml. Stimulation with 10 g/ml PGNpol led to high levels of secretion of IL-6 and IL-12p40. A comparison was made between
unstimulated cells and each stimulant by using a nonparametric one-way ANOVA model for repeated measurements, with the Bonferroni adjustment. ns, not
significant.
FIG 3 Stimulation with PGNpol, but not PGNpollgt, leads to increased MHC-II and CD40 expression in DCs. Immature BMDCs were activated with several
NOD2 or TLR2 ligands. Maturation was quantified by FACS analysis to assess the levels of MHC-II (A) and CD40 (B). The quantification was based on isotype
controls. Stimulation of DCs with PGNpol (10g/ml) led to strongMHC-II and CD40 signals. In contrast, stimulation of DCs with PGNpollgt (10g/ml) did
not lead to increased expression of MHC-II and CD40. A comparison was made between unstimulated cells and each stimulant by using a nonparametric
one-way ANOVA model for repeated measurements, with the Bonferroni adjustment.
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acts synergistically on DC cytokine secretion, we costimulated
DCs with the NOD2 ligand PGNpollgt and the TLR2 ligand
Pam3Cys and determined the secretion of TNF-. In line with our
hypothesis, the costimulation induced a significantly enhanced
expression of TNF- inDCs compared to the case in PGNpollgt-
or P3C-monostimulated DCs (Fig. 6).
To further confirm these findings, the experiments were ex-
tended to additional immune cells, i.e., a murine macrophage cell
line (J774 cells) (Fig. 7) and a human monocyte cell line (MM6
cells) (Fig. 8). In both cell lines, the synergistic costimulation with
PGNpollgt and P3C resulted in an increased expression of pro-
inflammatory cytokines, indicating that the observed effect is not
restricted tomouseDCs but seems to be relevant for the activation
of different types of innate immune cells.
DISCUSSION
NOD2mutations play an important role in Crohn’s disease (1, 2).
However, how exactly these mutations contribute to this specific
disease still remains uncovered. NOD2, as an important intracel-
lular receptor of the innate immune system, senses bacterial cell
wall products, such as MDP, and activates NF-B (35). While
MDPwas the first NOD2 ligand described (36, 37), it later became
clear that polymeric (16, 38) as well as monomeric (14) PGN also
activates NOD2. DCs are the most potent APCs in the intestinal
mucosa and have important functions in the mucosa-associated
immune system (39). Because of their important role in activating
and also regulating the immune system, they also seem to play an
important role in Crohn’s disease (11). Therefore, we studied the
role of NOD2-mediated activation of DCs via natural S. aureus-
derived PGN. In the present study, we focused on the role of poly-
meric PGN, which is an important part of the bacterial cell wall.
Defined isogenic S. aureus mutant strains were used to elucidate
the effect of NOD2 ligand (PGNpollgt) monostimulation or the
synergistic effect of NOD2 and TLR2 ligand (PGNpol) costimu-
lation. While monostimulation with a natural NOD2 ligand
(PGNpollgt) did not lead to activation and maturation of DCs,
costimulation with a NOD2 and TLR2 ligand (PGNpol) led to
strong activation and increased cytokine secretion (IL-6 and IL-
12p40) ofDCs in vivo. This effect was seen not only in isolatedDCs
but also in J774 cells (macrophages) andMM6 cells (monocytes).
In addition to already published work by Müller-Anstett et al.
(26), our data indicate that singular NOD2 activation seems to
FIG 4 Stimulation with PGNpol in DCs is dependent on a NOD2 costimulus. Stimulation with PGNpol led to significantly increased secretion of IL-6 (A) and
IL-12p40 (B) in DCs from WT mice compared to unstimulated controls. In contrast, DCs derived from NOD2/ mice failed to show increased IL-6 and
IL-12p40 secretion upon stimulation with PGNpol. Stimulated DCs from WT mice were compared to unstimulated DCs from WT mice, and stimulated DCs
from NOD2/ mice were compared to unstimulated DCs from NOD2/ mice.
FIG 5 DC stimulation with PGNpol in WTmice leads to increased expression of MHC-II and CD40 compared to that in NOD2/ mice. Stimulation of DCs
fromNOD2/ mice with PGNpol (10g/ml) did not lead to significantlymore expression ofMHC-II (A) or CD40 (B), indicating that the costimulatory effect
of NOD2 and TLR2 is necessary for effective maturation of DCs. Stimulated DCs from WT mice were compared to unstimulated DCs from WT mice, and
unstimulated DCs from NOD2/ mice were compared to stimulated DCs from NOD/ mice. In addition, a comparison between DCs from WT and
NOD2/ mice was made by using a nonparametric one-way ANOVA model for repeated measurements, with the Bonferroni adjustment.
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play aminor role in activating immune cells. However, synergistic
costimulation of the NOD2 and TLR2 pathways results in potent
activation of DCs, macrophages, and monocytes.
In patients withCrohn’s disease, an exaggerated Th1-mediated
immune response may contribute to mucosal inflammation (40).
In vivo, MDP itself is not able to induce a Th1 cytokine profile but
rather invokes a Th2 immune response (41). Additionally, in sup-
port of our results, it has been demonstrated that combined stim-
ulation withMDP plus a TLR2 or TLR4 ligand leads to a synergis-
tic release of IL-6 and IL-12p40 in BMDCs, which is abolished in
NOD2/ DCs (41). While stimulation of the innate immune
system with a sole NOD2 ligand, in our case S. aureus-derived
polymeric PGNpollgt, does not lead to an immune response,
such a response is markedly enhanced after dual stimulation via
the NOD2 and TLR2 pathways. The complex interplay between
NOD2 and TLR2 signaling might have an influence on intestinal
homeostasis.
However, how can these results be translated into the clinical
entity of Crohn’s disease? Activation of NOD2 by MDP protects
mice from experimental colitis (42), thus promoting intestinal
homeostasis. Additionally, PGN from specific lactobacilli features
anti-inflammatory effects and thus seems to be crucial for the
probiotic action of these specific strains (43). These studies further
support the hypothesis that stimulation of NOD2 alone—as op-
FIG 6 Combined stimulation of DCs with NOD2 and TLR2 ligands leads to stronger secretion of IL-12p40 and TNF than stimulation with each of the
stimuli alone. DCs were stimulated with PGNpollgt (10 g/ml), Pam3Cys (1 g/ml), and LPS (1 g/ml). After stimulation with both PGNpollgt and
Pam3Cys, there were significantly higher signals for IL-12p40 (A) and TNF (C) than the case for stimulation with the single components alone. (B) There
was not a significantly higher signal of IL-6 than that for stimulation with the single components. Unstimulated DCs from WT mice were compared to
stimulated DCs from WT mice by using a nonparametric one-way ANOVA model for repeated measurements, with the Bonferroni adjustment.
FIG 7 Combined stimulation of J774 cells with NOD2 and TLR2 ligands
leads to significant TNF- secretion. J774 cells were stimulated with
Pam3Cys (1 ng/ml), PGNpollgt (10 g/ml), PGNpol (10 g/ml), and LPS
(1 g/ml) for 48 h. After stimulation with both PGNpollgt and Pam3Cys,
there was a significant increase of TNF-, which seemed to be higher than
stimulation with the single components. Unstimulated DCs fromWTmice
were compared to stimulated DCs fromWTmice by using a nonparametric
one-way ANOVA model for repeated measurements, with the Bonferroni
adjustment.
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posed to costimulation of NOD2 and TLR2—can possibly lead to
downregulation of inflammatory pathways. A “loss of function”
in the NOD2 gene might therefore be an important part of the
pathogenesis of Crohn’s disease.
In summary, we showed that in DCs, synergistic costimulation
of the NOD2 and TLR2 signaling cascades leads to an increased
activation and maturation of DCs, and also to increased cytokine
secretion, compared to the case with monostimulation. These re-
sults might be important for a better understanding of the com-
plex interplay between these receptors in maintaining homeosta-
sis in the intestinal immune system.
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Clinical factors are associated with vitamin D levels in IBD
patients: A retrospective analysis
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OBJECTIVE: There is growing evidence that vitamin
D deficiency plays a role in the development and the
course of inflammatory bowel disease (IBD). How-
ever, the correlation between vitamin D deficiency
and clinical parameters in IBD is still not completely
understood.
METHODS: A retrospective study of IBD patients
was performed. Vitamin D values were analyzed,
regardless of vitamin D substitution administration,
and correlated with clinical parameters such as medi-
cal therapy, anatomical situation, location of the dis-
ease and disease activity. Level of 25-hydroxyvitamin
D [25(OH)D] <50 nmoL/L was regarded as vitamin
D deficiency and <75 nmoL/L as insufficiency.
RESULTS: In total, 208 IBD patients were analyzed,
including 123 with Crohn’s disease (CD) and 85 with
ulcerative colitis (UC). Therapy with azathioprine did
not affect the vitamin D values of either disease
entity. But CD patients benefited from therapy with
tumor necrosis factor-α inhibitor and exhibited sig-
nificantly higher vitamin D levels than those without.
Furthermore, significantly lower vitamin D levels
were found if CD was located in the small bowel or
if the small bowel had been resected. Moreover, sig-
nificantly lower levels of vitamin D were detectable
for high disease activity (reflected by high simple
clinical colitis activity index values) in patients
with UC.
CONCLUSIONS: Vitamin D deficiency is common
in patients with IBD. However, certain clinical situa-
tions lead to significantly lower vitamin D levels and
may therefore require close monitoring for vitamin D
deficiency.
KEY WORDS: Crohn disease, inflammatory bowel diseases, tumor necrosis factor-alpha, ulcerative colitis,
vitamin D.
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are
chronic intestinal disorders that together form the
complex of inflammatory bowel disease (IBD).1 The
pathogenesis of these diseases involves the inappro-
priate activation of the mucosal immune system,
which is triggered by the intestinal microbiota in
genetically predisposed individuals.1–4 Mutations in
the nucleotide-binding oligomerization domain-
containing protein 2 (NOD2) gene encoding for
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NOD2 have been shown to be a major risk factor in
the development of CD.5–8 In addition, environmen-
tal factors, such as vitamin D deficiency, have been
found to play a role in the pathogenesis of IBD.8,9
Vitamin D is commonly known to be an important
regulator of calcium and phosphate metabolism and
is therefore essential for bone health.10,11 However,
there is mounting evidence that vitamin D also plays
an important role as a regulator of the innate and
adaptive immune system.11–13 In a murine colitis
model the application of calcitriol was associated
with reduced mucosal injury.14 The prevalence of
vitamin D deficiency is high in patients with
IBD.15,16 However, it is still not clear whether vita-
min D substitution has a beneficial effect on the
course of the disease. In a prospective study inflixi-
mab treatment was associated with positive effects on
bone metabolism.17 On the other hand, in a retro-
spective study in patients with CD an inverse associa-
tion between vitamin D levels and intestinal
inflammation was found.18 In another prospective
study the application of vitamin D led to a decrease
in the C-reactive protein (CRP) level in UC patients,
suggesting that vitamin D supplementation has a
beneficial effect on the inflammatory activity of
UC.19 In several other interventional studies vitamin
D substitution appeared to have beneficial effects on
clinical activity in IBD.20–22
The aim of our study was to investigate the preva-
lence of vitamin D deficiency in a single, northern
German IBD cohort and to correlate the vitamin D
levels with different clinical variables (e.g. disease-
specific medication, location of disease, anatomical
situation after surgery and disease activity).
PATIENTS AND METHODS
Patients with UC and CD who were admitted to the
Outpatient Clinic of the Division of Gastroenterol-
ogy, University of Rostock Medical Center (Rostock,
Germany) from January 2011 to September 2014
were retrospectively analyzed. Data were collected
from patients’ medical records, including 25-
hydroxyvitamin D [25(OH)D] levels, 25-OH-vitamin
D substitution, disease activity, disease-specific medi-
cation [azathioprine (AZA), tumor necrosis factor
(TNF)-α inhibitor] and the anatomic situation
(i.e. colectomy). Disease activity was assessed in
patients with CD using the Harvey–Bradshaw index
(HBI),23 and in UC using the simple clinical colitis
activity index (SCCAI)24. It was differentiated among
the ileocecal region (the terminal ileum, defined as
15 cm proximal to the ileocecal valve and cecum)
and small bowel (duodenum, jejunum, ileum other
than terminal ileum).
The patients were divided into two groups, including
one with vitamin D substitution and the other with-
out. Vitamin D substitution was administrated with
colecalciferol 20 000 IE. The vitamin D status of the
patients was assessed based on serum 25(OH)D
levels.10 Vitamin D deficiency was defined as: severe
deficiency, serum 25(OH)D level <27.5 nmoL/L;
deficiency, <50 nmoL/L; insufficiency, <75 nmoL/L.
Normal vitamin D levels are defined as values higher
than or equal to 75 nmoL/L.10,25–28
Statistical analysis
All the data were entered into a Microsoft Access
database and analyzed by using the SPSS 22.0 (IBM,
Armonk, NY, USA). The average of all single vitamin
D measurements per patient represented the individ-
ual level. Continuous variables were expressed as
mean  standard deviation, whereas categorical vari-
ables were expressed as numbers and percentages or
frequencies. To compare the vitamin D level between
the two groups, the t-test was performed in case of
normal distribution; otherwise, the Mann–Whitney
U-test was used for the analysis. Normal distribution
of the variables was assessed by the Kolmogorov–
Smirnov test. P value less than 0.05 was regarded as
statistically significant.
RESULTS
Altogether 208 patients with IBD (123 CD and 85
UC) were included in the study. In total, 1520 25
(OH)D values were analyzed, including 936 values
obtained from the CD group (56.8  32.4 nmol/L,
n = 123), of which 486 were without substitution,
and 584 obtained from the UC group (61.5  33.2
nmol/L), of which 288 were without substitution.
There was no significant difference in the vitamin D
levels between the CD (56.2  20.6 nmoL/L, n= 123)
and UC groups (59.5  22.9 nmoL/L, n = 85).
Vitamin D status
Because vitamin D values vary along the year as a
result of different exposure to the sun, we first ana-
lyzed participants’ vitamin D status during the year.
Vitamin D deficiency in patients with IBD was more
common during the winter months than the summer
months (Fig. 1). Severe vitamin D deficiency was par-
ticularly present from January until April. The highest
number of normal vitamin D values was found in
July and August. Fig. 1 also confirms that the vitamin
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D values in our cohort were obtained throughout the
year. All patients (with and without vitamin D substi-
tution) were included into this graph, since vitamin
D substitution was relatively constant in all groups
over the year.
Vitamin D substitution increased 25(OH)D levels
Vitamin D substitution with colecalciferol was admin-
istrated in patients with vitamin D deficiency. We
compared the vitamin D values in the patients with
and without substitution (Fig. 2). In the CD group,
450 vitamin D values were obtained with substitution
(61.3  21.6 nmol/L, n = 63) and 486 without substi-
tution (42.6  16.7 nmol/L, n = 60). In the UC group
296 vitamin D values were obtained with substitution
(59.9  22.2 nmol/L, n = 46) and 288 without substi-
tution (41.8  19.5 nmol/L, n = 39). In each of the
IBD disease entities (CD and UC), the difference
between vitamin D values with and without substitu-
tion was highly significant (P < 0.001). In addition,
we examined whether higher vitamin D levels might
also correlate inversely with a lower disease activity in
CD or UC. However, the disease activity was not sig-
nificantly different in both groups when comparing
low or high vitamin D levels (data not shown).
Vitamin D values depended on the disease
activity in UC
The average HBI in the CD group was 3.3 and the
average SCCAI in the UC group was 2.9. Because dis-
ease activity may influence vitamin D levels, we strati-
fied patients with CD and UC according to their
disease activity (CD: HBI 0–3 vs >9; UC: SCCAI 0–2 vs
>6; with HBI 0–3 and SCCAI representing disease
remission and HBI >9 and SCCAI >6 for high activity)
and compared the respective vitamin D levels.
We analyzed 439 vitamin D values (56.3  21.2
nmol/L, n = 75) in the HBI 0–3 group in patients
with CD, with 33 vitamin D values (58.3  20.6
nmol/L, n = 9) in the HBI >9 group. No significant
difference of vitamin D values between remission
and highly active disease were detected (Fig. 3a).
Additionally, we compared 199 vitamin D values
(64.3  27.8 nmol/L, n = 40) in the SCCAI 0–2 group
of patients with UC with the SCCAI > 6 group with
55 vitamin D values (44.8  6.9 nmol/L, n = 10). We
found significantly lower vitamin D levels in highly
active disease in the UC group compared with that of
the UC in remission (P = 0.008, Fig. 3b).
Disease-specific medications
To address the association of disease-specific medica-
tion with vitamin D status patients in the CD and
UC groups were stratified according to their disease-
specific medications (AZA or TNF-α inhibitor). TNF-α
inhibitors infliximab and adalimumab were pooled
because of their similar mode of action.
Altogether 39 patients in the CD group received
anti-TNF therapy. UC patients receiving anti-TNF
therapy were not included into the analysis due to
their small sample size (n = 8). AZA was given to
37 patients with CD and 22 with UC. In total
14 patients received both anti-TNF agents and AZA.
Therapy with AZA did not affect the vitamin D values
in patients with either CD (Fig. 4a) or UC (Fig. 4b):
In the CD group 193 vitamin D values (58.3  21.2
nmol/L, n = 37) in patients receiving AZA were com-
pared with 743 vitamin D values from those not
receiving AZA (55.5  21.2 nmol/L, n = 86). In the
UC group 136 vitamin D values from patients receiv-
ing AZA (68.6  32.4 nmol/L, n = 22) were compared
with 448 vitamin D values from patients who were
not receiving AZA (56.9  20.8 nmol/L, n = 63).
In contrast, therapy with TNF-α inhibitor was associ-
ated with significantly higher vitamin D values in the
CD group. In the CD group 287 vitamin D values
(63.2  20.3 nmol/L, n = 39) were obtained under
therapy with TNF-α inhibitor and compared with
649 vitamin D values from patients not receiving
TNF-α inhibitor therapy (54.7  21.3 nmol/L,
n = 84; P = 0.014, Fig. 4c).
Disease location
CD can be localized in all the GI tract, from the
mouth to the perianal region. We compared vitamin
D values in the CD group in terms of the location of
the disease (small bowel, ileocecal region, colon, or
perianal region; Fig. 5).
Figure 1. Vitamin D deficiency in patients with inflamma-
tory bowel disease over the year. ( ) Severe deficiency; ( )
deficiency; ( ) insufficiency; ( ) normal.
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CD patients with disease involvement of the small
bowel yielded 271 vitamin D values (48.5  16.1
nmol/L, n = 31) that were significantly lower than the
665 vitamin D values from those without
(58.8  21.4 nmol/L, n = 92) (P = 0.038, Fig. 5a).
The disease location of other parts of the intestine did
not significantly affect the vitamin D values [terminal
ileum involvement (55.1  18.0 nmol/L, n = 66) vs
no involvement (57.4  23.4 nmol/L, n = 57);
colonic involvement (53.7  19.2 nmol/L, n = 90) vs
no involvement of the colon (62.8  23.2 nmol/L,
n = 33); perianal involvement (60.7  28.0 nmol/L,
n = 26) vs no perianal involvement (54.9  18.8
nmol/L, n = 97) (Fig. 5b–d)].
Vitamin D values after surgical resections
CD often requires surgical resection. Fig. 6 depicts
vitamin D values in CD after surgical resection. The
small bowel was defined as parts of the small bowel
other than terminal ileum and the ileocecal region.
In patients with CD after resection of the small bowel
88 vitamin D values (44.1  13.5 nmol/L, n = 15)
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were compared with 848 vitamin D values from
those without resection of the small bowel
(57.1  20.8 nmol/L, n = 108) with significantly
decreased values (P = 0.023, Fig. 6a). Other resec-
tions do not lead to significant differences in the vita-
min D values [ileocecal resections (55.0  18.3
nmol/L, n = 43) vs no ileocecal resections
(55.8  21.7 nmol/L, n = 80); colonic resection
(51.4  18.1 nmol/L, n = 22) vs no colonic resection
(56.4  20.1 nmol/L, n = 101) (Fig. 6b,c)].
DISCUSSION
Vitamin D deficiency was found to be very prevalent
in the general population29,30 as well as in patients
with IBD15,16. In our retrospective study in a single
northern German IBD cohort we analyzed vitamin D
values in patients with IBD (CD and UC) and corre-
lated them with disease-specific parameters. According
to other studies in patients without IBD, vitamin D
deficiency is more common in the winter months than
the summer months.31 However, even in the summer
months an optimal vitamin D value was achieved
only in the month of July in just about 30% of all
patients with IBD. The reasons for this include the low
ultraviolet B radiation in the high latitude of northern
Germany and low exposure to the sun. Based on our
data, vitamin D deficiency should be tested and trea-
ted more aggressively from January until April. How-
ever, a high incidence of vitamin D deficiency can also
be expected in the summer months.
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Three major results were found in this study. First,
patients under therapy with TNF-α inhibitor had sig-
nificant higher vitamin D levels than those receiving
other therapies. Second, disease activity correlated
with vitamin D levels in patients with UC, but not in
those with CD. Third, patients with CD located in
the small bowel and after small bowel resection
showed significant lower vitamin D levels.
We showed that there was a correlation between the
use of TNF-α inhibitor and high vitamin D levels in
CD. It would be reasonable to argue that patients on
TNF-α inhibitor may have a better disease control
and therefore, higher vitamin D levels (e.g. more
exposure to sunlight, better absorption of vitamin D
and a different diet). However, we could not detect a
correlation between higher disease activity and lower
vitamin D levels in patients with CD. Therefore, the
effect of TNF-α inhibitor on the vitamin D levels
appears to be independent of the disease activity in
CD. The mechanism by which therapy with TNF-α
inhibitor increases vitamin D levels cannot be eluci-
dated from this study. In a recent article Winter et al.
have shown that vitamin D levels may influence the
initial response to TNF-α inhibitor.32 Lower vitamin
D levels prior to treatment were associated with a
higher rate of IBD relapse. This result may be consis-
tent with our study, where the application of TNF-α
inhibitor was associated with high vitamin D levels.
Additionally, we hypothesize that there is a strong
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link between intestinal inflammation, drugs affecting
the intestinal mucosal inflammatory level, the
patient’s vitamin D status and intestinal microbial
composition. In recent years there has been mount-
ing evidence that the gut microbiota play a crucial
role in the pathogenesis of IBD. Interestingly, the use
of TNF-α inhibitors may also result in changes of the
intestinal bacterial composition.33 Previous studies
using murine models show that vitamin D and vita-
min D receptor are important regulators of the intes-
tinal bacterial composition.34–36 In a genome-wide
association study, mutations in the vitamin D recep-
tor gene were associated with different intestinal
microbial profiles.37 While different studies of
patients with IBD have shown an altered microbial
composition, that is, dysbiosis,38–41 one can now
speculate that there are potentially beneficial triggers
in addition to the application of TNF-α inhibitor in
changing the bacterial composition back into a state
of remission, such as the substitution of vitamin
D. However, prospective studies are needed to test
the hypothesis whether vitamin D substitution leads
directly to a change in intestinal bacterial
composition.
Screening for vitamin D deficiency is recommended
by German CD guidelines.42 However, whether vita-
min D substitution has a beneficial effect on the dis-
ease course is still not clear. In a recent prospective
study in patients with UC by Gubatan et al.,43 lower
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Figure 6. Vitamin D values in Crohn’s disease after surgical resections in (a) the small bowel, (b) ileocecum and
(c) colon. 25(OH)D, 25-hydroxyvitamin D.
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vitamin D values were associated with a higher risk
of relapse in the following 12 months. In our study,
patients with a high UC disease activity showed
lower vitamin D levels; however, we did not find
such an association in patients with CD. From these
studies one can hypothesize that vitamin D status is
a surrogate marker of intestinal inflammation in UC.
Different factors could play a role in the pathogenesis
of vitamin D deficiency in patients with IBD. These
include low exposure to sunlight, a different diet,
impaired absorption, impaired conversion of vitamin
D into its active metabolites and an increased metab-
olism of vitamin D.44–46 Vitamin D is fat-soluble and
therefore requires bile acids for its uptake. Changes
in the anatomy after surgical resection of the small
bowel can cause interruptions of the enterohepatic
circulation. This may also play a role in vitamin D
deficiency. In our study a clear correlation was found
between CD with small bowel involvement and low
vitamin D levels. According to this result, resection of
the small bowel also resulted in significantly lower
vitamin D level. Other resections did not lead to sig-
nificant changes in the vitamin D levels, therefore the
small bowel plays an important role in the uptake of
vitamin D, particularly in IBD. As a consequence,
patients with CD located in the small bowel and also
after small bowel resections may benefit from a close
screening for vitamin D deficiency.
In this study, we have demonstrated that certain clin-
ical conditions may have beneficial or adverse effects
on vitamin D levels in patients with IBD. However,
more prospective studies are needed to assess the
consequence of vitamin D deficiency and vitamin D
supplementation on the disease course of patients
with IBD.
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Abstract
Introduction Changes in the intestinal bacterial composition
seem to play a major role in the pathogenesis and in the clin-
ical course of inflammatory bowel diseases (IBD), which con-
sist of Crohn’s disease (CD), and ulcerative colitis (UC).
Mutations in the NOD2 gene are the most important genetic
risk factors for the development of CD. In this study, the
association between mucosal biopsies and the mucosa-
associated bacterial composition from CD and UC patients
regarding their genetic risk factors (mutations in the NOD2
gene), their endoscopic activity, and their medical therapy
(TNF-α blocking therapy) was examined.
Material and methods Seventy biopsies from routine colo-
noscopies from 33 IBD patients (26 CD and 7 UC) were
obtained. Disease activity and clinical characteristics were
assessed. Seven different bacterial strains (Bacteroides
fragilis, Escherichia coli, Prevotella melaninogenica,
Clostridium coccoides, Clostridium difficile, Bifidobacterium
bifidum, and Faecalibacterium prausnitzii) were quantified
using real-time PCR. NOD2 genotyping from patients with
CD was performed.
Results Five of the 24 patients were positive for at least one
mutation in the NOD2 gene. The bacterial composition was
different in CD compared to UC, in macroscopic healthy com-
pared to macroscopic inflamed biopsies, in NOD2 mutated
compared to NOD2 wildtype patients, and in patients receiv-
ing TNF-α blocking therapy compared to patients without this
treatment.
Conclusion This study further characterizes the mucosa-
associated bacteria in IBD patients. Different clinical situa-
tions lead to an altered mucosa-associated bacterial composi-
tion. The analyzed bacteria could be promising targets for
cost-effective surveillance or therapies in IBD patients.
Keywords Crohn’s disease . Ulcerative colitis . IBD .
NOD2 . Mucosa-associated bacteria . RT-PCR
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
intestinal disorders and together form the complex of inflam-
matory bowel diseases (IBD) [1]. Until today the pathogenesis
of these disease entities is not completely understood; howev-
er, it involves an inappropriate activation of the mucosal im-
mune system triggered by the intestinal microbiota in geneti-
cally predisposed individuals [1–4]. This model is supported
by several findings: In IBD inflammation is mainly localized
to areas in the gut with high bacterial quantities. Antibiotics
have a beneficial effect in some patients, e.g., those with fis-
tula or luminal activity [5]. Surgical diversion of the fecal
stream is beneficial in some IBD patients [6, 7]. In several
mouse models of colitis, bacteria are needed for the develop-
ment of inflammatory changes [8]. An association of
adherent-invasive Escherichia coli in ileal samples of patients
with CD has been described [9]. Additionally, there are
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genetic polymorphisms in CD, e.g., mutations in the NOD2
gene, which activate the innate immune system in the process
of bacterial recognition. NOD2 is expressed intracellularly in
antigen presenting cells, e.g., macrophages and dendritic cells,
and to a lesser extent in intestinal epithelial cells and Tcells. A
link between mutations in the NOD2 gene and CD was first
described in 2001 by two groups [10, 11]. Additionally, there
are also clinical associations with mutations in theNOD2 gene
independent of CD, for example graft-versus-host-disease
(GvHD) [12–14], septicemia [15], spontaneous bacterial peri-
tonitis in liver cirrhosis [16], worsened outcome after intesti-
nal transplantation [17], and the development of short bowel
syndrome in the absence of CD [18]. In contrast to this in-
creasing number of clinical conditions which are associated
with mutations in the NOD2 gene, the exact function of
NOD2, and how mutations contribute to the clinical manifes-
tation of CD is still under debate [19, 20]. One aspect is, that
NOD2 as a receptor senses parts of the bacterial cell wall,
which might be an important link between the innate immune
system and the intestinal bacterial composition. Muramyl di-
peptide (MDP) has been described as the classic ligand for the
NOD2 receptor [21, 22]. However, the receptor also senses
peptidoglycan (PGN), which is an important part of the bac-
terial cell wall [23, 24]. The NOD2 receptor has also been
shown to play an important role in the secretion of defensins
from Paneth cells. NOD2−/− mice and patients with certain
mutations in the NOD2 gene display a decreased expression
of α-defensins in the Paneth cells [25, 26]. In another study in
mice, it was shown that there is bilateral interaction of the
NOD2 receptor and the intestinal bacteria, such that NOD2
is also a regulator of the commensal gut microbiota [27].
Furthermore, Rehman et al. provided evidence for a dis-
tinct role for NOD2 in the development of the bacterial com-
position: In NOD2−/− mice, an increased number of commen-
sal microbiota was found. Additionally, the microbial compo-
sition in NOD2−/− mice was already significantly altered at a
very early weaning stage [28].
Nevertheless, it is currently not knownwhether the changes
in the gut microbiota in IBD are due to a disturbed local
environment because of the inflammation or are a primary
cause for the development of these disease entities.
Like in other mammals, the human gut microbiota consists
of different phyla, mainly Firmicutes, Bacteroidetes,
Actinobacteria, and Proteobacteria [29–31]. Most taxa from
the intestinal microbiota belong to the phyla Firmicutes and
Bacteroidetes.
From a clinical point of view, dysbiosis—potentially linked
toNOD2mutations and the resulting alteration in the interplay
with the gut microbiota—may play an important role in the
pathogenesis of CD [32–34]. Also a greater abundance of
Enterobacteriaceae (phylum proteobacteria), mainly E. coli,
was noted [9]. Other strains, like the butyrate-producing
Faecalibacterium prausnitzii, are thought to play a beneficial
role in the intestinal mucosa due to anti-inflammatory capac-
ities [35–37]. Additionally, CD is also linked to a reduced
diversity of the microbiota [38].
To investigate the relationship between the mucosa-
associated bacteria and IBD, biopsy samples from a well-
defined cohort of CD and UC patients were examined in our
study. Real-time PCR technology was used to quantify seven
bacterial strains as important representatives of the four main
bacterial phyla in the human gut. The abundance of these
strains was investigated and the results were correlated to clin-
ical data.
Biopsy samples were investigated from CD and UC pa-
tients from macroscopically healthy and inflamed mucosa of
the colon. Additionally, the CD patients were analyzed regard-
ing mutations in the NOD2 gene and these results were corre-
lated to their clinical course.
Material and methods
Thirty-three IBD patients were recruited from the University
Medical Center Rostock, Germany. Twenty-six patients had
CD and seven patients had UC. The following clinical param-
eters were recorded: age, sex, disease activity, and disease-
specific medication. The disease activity was determined via
Crohn’s Disease Activity Index (CDAI) in CD and via the
Mayo score in UC. Colonoscopy was performed for a clinical
indication and biopsies were taken frommacroscopically non-
inflamed and from inflamed mucosa. Altogether, 70 biopsies
were analyzed. An EDTA blood sample was drawn from the
patients with CD for analysis of mutations in the NOD2 gene.
The study was approved by the ethics board of the
University of Rostock (A 2012–0121). Written informed con-
sent was obtained from each participant prior to enrollment.
DNA extraction
The biopsy specimens were collected in ATL buffer (Qiagen,
Hilden, Germany) and snap frozen at −80 °C immediately.
The DNA isolation was performed with the DNA stool ex-
traction kit (Qiagen, Hilden, Germany). Prior to DNA isola-
tion, tissue samples were homogenized with the tissue
disruptor (Qiagen, Hilden, Germany).
PCR inhibition control
Exclusion of potential inhibitory matrix effects was performed
utilizing real-time PCR targeting human ß-Globin sequences
according to Klaassen et al. with minor modifications [39].
Primers βGlo_up (5′-GGGCAACGTGCTGGTCTG) and
βGLO_down2 (5′-ATACTTGTGGGCCAGGGCAT) were
purchased at TIBMOLBIOL (Berlin, Germany). The reaction
mix consisted of 12.5 μl SYBR Green real-time PCR Master
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Mix (Applied Biosystems, Foster City, CA, USA), 175 nM
βGlo_up, 175 nMβGLO_down2 as well as 2 μl template and
was adjusted to 20 μl per reaction with nuclease free water.
Samples underwent the following PCR-program: one cycle of
95 °C for 10 min and then 40 cycles of 95 °C for 15 s, 60 °C
for 60 s, followed by one cycle of 95° for 15 s, 60° for 20 s and
95 °C for 15 s. Amplified DNAwas detected after each elon-
gation step. Samples with a cycle threshold less than 33 cycles
were classified as Bnon-inhibited.^
PCR analysis
The abundance of seven bacterial strains as representatives of
their corresponding phylum (Table 1) was analyzed (E. coli,
Bacteroides fragilis, Bifidobacterium bifidum, Prevotella
melaninogenica, Clostridium difficile, Clostridium coccoides,
Faecalibacterium prausnitzii). Real-time qPCR was per-
formed using an ABI ViiA 7 (Applied Biosystems,
Waltham, Massachusetts, USA). Primer sequences are shown
in Table 1.
The PCR amplification program was defined as one cycle
at 95 °C for 10 min, 40 cycles at 95 °C for 15 s and 60 °C for
60 s. After each run, a melting point analysis was performed to
control the amplicon specificity. To ensure the functionality of
the primers, bacterial probes from each strain were ordered
from the Leibniz-Institut–Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (DSMZ,
Braunschweig, Germany).
Additionally, primer efficacy was optimized for each prim-
er pair using serial dilutions of bacterial DNA in known con-
centrations. The optimal primer efficacy was confirmed using
the bacterial reference probes from above (Table S1: Primer
efficacies).
To analyze the bacterial composition between different
clinical settings, we used the Delta CT relative quantification
method as described elsewhere [47, 48]. Briefly, CT values of
the specific bacterial strains were normalized to beta-actin
(Delta CT value). Delta CT values from different settings were
directly compared.
NOD2 genotyping
An EDTA blood sample was drawn from the patients with CD
for analysis of mutations in the NOD2 gene. The three major
mutations in theNOD2 gene (SNP 8; R702W, NCBI reference
SNP ID: rs2066844 and SNP 12; G908R, NCBI reference
SNP ID: rs2066845 and SNP 13; 1007 fs, NCBI reference
SNP ID: rs2066847) were detected as described previously
in genomic DNA extracted from whole blood [18]. Briefly,
whole blood was collected in EDTA-anticoagulated tubes and
DNAwas extracted using the QIAamp DNA Blood Mini Kit
according to the manufacturer’s protocol (Qiagen, Hilden,
Germany). The Taqman MGB biallelic discrimination assay
was applied using the two pre-made assays c_ _ 11717468_20
and c_ _11717466_20 for the R702W and the G908R point
mutations in NOD2 as well as a custom developed assay for
Table 1 16S rRNA gene-targeted group and species-specific primers used in this study
Bacteria Phylum Primer name nM Primer sequence (5′–3′) Reference
E. coli Proteobacteria E.coliF395Fw 200 CAT GCC GCG TGTATG AAG AA [40]
E.coliR470Rev 300 CGG GTA ACG TCA ATG AGC AAA [40]
B. fragilis Bacteroidetes Bact-F285 300 GGT TCT GAG AGG AGG TCC C [41]
Univ-R338 200 GCT GCC TCC CGTAGG AGT [41]
Prevotella spp. Bacteroidetes Prevo-F449 300 CAG CAG CCG CGG TAATA [42]
Prevo-R757 300 GGC ATC CAT CGT TTA CCG T [42]
C. coccoides Firmicutes g-Ccocc-F 300 AAATGA CGG TAC CTG ACTAA [43]
g-Ccocc-R 300 CTT TGA GTT TCATTC TTG CGA A [43]
C. difficile Firmicutes Cdifficile-F 300 TTG AGC GAT TTA CTT CGG TAA AGA [44]
Cdifficile-R 200 CCATCC TGTACT GGC TCA CCT [44]
Bifidobacterium bifidum Actinobacteria g-Bifid-F 200 CTC CTG GAA ACG GGT GG [45]
g-Bifid-R 200 GGT GTT CTT CCC GATATC TAC A [45]
Faecalibacterium prausnitzii Firmicutes PrausF480F 300 CAG CAG CCG CGG TAA A [42]
PrausR631R 300 CTA CCT CTG CAC TAC TCA AGA AA [42]
β-Actin ActinF 200 GCT GTG CTG TCC CTG TAT GCC TCT [46]
ActinR 200 CCT CTC AGC TGT GGT GGT GAA GC [46]
β-Globin βGLO_up 175 GGGCAACGTGCTGGTCTG [39]
βGLO_down2 175 ATACTTGTGGGCCAGGGCAT [39]
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the 1007 frame shif t mutat ion (forward pr imer,
GTCCAATAACTGCATCACCTACCT; reverse primer,
CAGACTTCCAGGATGGTGTCATTC and VIC-labeled
probe, CAGGCCCCTTGAAAG; FAM-labeled probe,
CAGGCCCTTGAAAG. Applied Biosystems, Waltham,
MA, USA).
Twenty nanograms of extracted genomic DNA were ap-
plied with 10 μl of TaqManUniversal PCR Master Mix
(Applied Biosystems, Foster City, California, USA) and
0.8 μl of 20 × SNP Genotyping Assay and adjusted to a final
volume of 20 μl. PCR was carried out on an ABI Prism 7000
real-time PCR instrument (Applied Biosystems, Foster City,
CA). The protocol was performed according to the instruc-
tions of the manufacturer and the results were analyzed using
Sequence Detection System (SDS) Software V. 1.2.3.
(Applied Biosystems, Waltham, MA, USA).
Statistical analysis
The mucosal biopsies were compared between CD and UC.
Additionally, comparisons were made between biopsies from
inflamed and non-inflamed mucosa, between NOD2 mutated
and NOD2 wildtype patients and between patients receiving
TNF-α blocking therapy, and patients without this therapy.
Statistical analysis was performed using the GraphPad Prism
4 Software (La Jolla, CA, USA). Parameters were analyzed by
Student’s t test after normal distribution was ensured. p values
<0.05 were considered significant (*p< 0.05; **p< 0.01;
***p<0.001).
Results
Patient characteristics
The patient characteristics of the CD patients are listed in
Table 2. The disease activity in CD patients was measured
via the CDAI [49]. The mean CDAI was 186 (38 –332).
Three patients received a therapy with infliximab/adalimumab
and two patients received a therapy with azathioprine/6-
mercaptopurine.
The patient characteristics of the UC patients are listed in
Table 3. The disease activity in the UC group was measured
via the Mayo score [50]. The mean Mayo score was 4.28 (0–
8). Two patients received therapy with infliximab/
adalimumab.
NOD2 genotyping
Twenty-four of the 26 patients with CD were genotyped for
the three major NOD2 mutations (SNP 8, SNP 12, and SNP
13). Two patients did not give informed consent for genotyp-
ing. Five of 24 patients (20.8 %) were positive for one muta-
tion, which is close to the described percentage in the literature
[51]. The frequency of NOD2mutations was not examined in
UC patients because mutations in the NOD2 gene do not seem
to be associated with the development of UC [52].
Analysis of the abundance of seven different bacterial
strains as representatives of different phyla
In order to assess the role of the above mentioned bacterial
strains as potential representatives of their corresponding phy-
lum (see Table 1), we examined their abundance in different
clinical situations (CD vs. UC, inflamed vs. non-inflamed
mucosa, presence of NOD2 mutations, and use of TNF-
alpha blocking therapy).
Differences of the intestinal bacterial composition in CD
compared to UCwere investigated (Fig. 1). The biopsies were
taken from inflamed and non-inflamed appearing mucosa.
The abundance of seven different bacterial strains was ana-
lyzed quantitatively by real-time PCR. In CD, there was a
significant decrease in the abundance of B. fragilis
(p=0.0089) and B. bifidum (p=0.024) compared to biopsies
from UC patients. There was no significant difference for
E. coli, P. melaninogenica, C. coccoides, C. difficile, and
F. prausnitzii.
Biopsies from macroscopically inflamed and non-inflamed
colonic mucosa were compared in CD patients (Fig. 2). In
biopsies from macroscopically inflamed mucosa of CD pa-
tients, a significant decrease in the abundance of B. fragilis
(p=0.0243) and of C. coccoides (p=0.0013) was observed,
whereas the abundance of E. coli was increased (p=0.0194).
Table 2 Patient characteristics of the CD patients
Number of patients with CD 26
Sex 11 male:15 female
Age mean 41 (22–67)
Patients with AZA/6-MP 2
Patients with IFX/ADA 3
CDAI mean 185.65 (38–332)
Number of patients with NOD2 mutations 5
Table 3 Patient
characteristics of the UC
patients
Number of patients
with UC
7
Sex 4 male:3 female
Age mean 55 (43–75)
Patients with
AZA/6-MP
0
Patients with
IFX/ADA
2
Mayo score mean 4.28 (0–8)
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There was no significant difference for P. melaninogenica,
C. difficile, B. bifidum, and F. prausnitzii. A separate analysis
of UC patients was not performed due to the small number of
patients.
Biopsy samples from inflamed and non-inflamed mucosa
from patients with CDwere compared according to the NOD2
status of the patients (NOD2 mutated vs wildtype, Fig. 3). In
biopsies from NOD2mutated CD patients, there was a signif-
icant increase in E. coli (p = 0.0014) and in C. difficile
(p=0.0007) compared to biopsies from NOD2 wildtype CD
patients. There was no significant difference for B. fragilis,
P. melaninogenica , C. coccoides, B. bifidum , and
F. prausnitzii.
Biopsies from inflamed and non-inflamed mucosa from
CD and UC patients receiving either TNF-α blocking therapy
(infliximab or adalimumab) or not were compared (Fig. 4). In
patients receiving TNF-α blocking therapy, there was a sig-
nificant higher abundance ofF. prausnitzii (p=0.0176) than in
those who did not reiceive TNF-a blocking medication. There
was no significant difference for B. fragilis, E. coli,
P. melaninogenica, C. coccoides, C. difficile, and B. bifidum.
Discussion
The present study addresses the question how inflammation
and the mucosa-associated bacterial composition interact with
each other and how this may be influenced by pharmacolog-
ical intervention.
Fig. 1 Mucosa-associated bacterial composition in biopsies from
patients with CD and UC. Biopsies from patients with CD (n= 26) and
ulcerative colitis (UC) (n = 7) were analyzed for the abundance of seven
different bacterial strains. Delta CT values were compared. In CD, there
was a significant decrease in the abundance of B. fragilis and B. bifidum.
Student’s t test was used for statistical analysis (*p< 0.05)
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In the present study, seven different bacterial strains were
analyzed, because they were regarded as important represen-
tatives of the most important bacterial phyla in the human gut.
B. fragilis andP. melaninogenica for Bacteroidetes,B. bifidum
for Acinetobacteria, C. coccoides for Firmicutes, and E. coli
for Proteobacteriae. C. difficile belongs to the phylum of
Firmicutes but may have a strain specific biology as it may
cause C. difficile associated enteritis. F. prausnitzii also
belongs to the phylum of Firmicutes but appears to have strain
specific role in intestinal health in general and in IBD in par-
ticular. While these tested seven strains quantitatively com-
prise only a small amount of the mucosa-associated bacterial
composition, changes in each strain may reflect changes of the
corresponding phylum. It is possible though that the interac-
tion between host and gut microbiota does not occur at the
level of bacterial phyla but either at specific strains, such as
Fig. 2 Mucosa-associated bacterial composition in macroscopically
inflamed and non-inflamed mucosal biopsies from CD patients.
Biopsies from inflamed and non-inflamed colonic mucosa of patients
with x disease (CD) were obtained and the abundance of seven
different bacterial strains was analyzed. Delta CT values were
compared. In macroscopically inflamed biopsies from CD patients,
there was a significant decrease in B. fragilis, in C. coccoides and an
increase in E. coli compared to non-inflamed biopsies. Student’s t test
was used for statistical analysis (*p < 0.05, **p < 0.01)
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Faecalibacterium prausnitzii or at a more metabolic-
functional level. The potential beneficial or disadvantageous
role of a single strain on the intestinal immune system can
only be uncovered using a distinct mouse model and
metabolic-functional characteristics may be addressed using
metagenomic analysis, both of which are beyond the scope of
this study. On the other hand, it is rather conceivable that the
genetic composition of the host and pharmacologic
intervention of the immune response lead to changes in bac-
terial phyla more than individual bacterial strains or metabol-
ically active bacterial groups.
To address a possible interaction of inflammation and the
local mucosa-associated bacterial composition, inflamed and
non-inflamed mucosa were compared. B. fragilis and
C. coccoides as representatives of Bacteroidetes and
Firmicutes had a reduced relative abundance. Interestingly,
Fig. 3 Mucosa-associated bacterial composition in biopsies from NOD2
mutated and NOD2wildtype CD patients. Biopsy samples from inflamed
and non-inflamed patients with CD were compared according to the
NOD2 genotype (NOD2 mutated vs. NOD2 wildtype). Seven different
bacterial strains were analyzed. Delta CT values were compared. In
biopsies from NOD2 mutated CD patients (n = 5), there was a
significant increase in E. coli and in C. difficile compared to biopsies
from NOD2 wildtype patients (n = 19). Student’s t test was used for
statistical analysis (*p< 0.05; **p < 0.01)
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in biopsies from macroscopically inflamed mucosa, there was
also found a higher prevalence of E. coli, possibly according
to our results in the NOD2 mutated biopsies. We can also
speculate that the reduced number of C. coccoides (phylum
Firmicutes) goes in hand with the study of Sokol et al. [53],
where the C. leptum and C. coccoides groups were also less
represented in active CD. In contrast to these results, we rather
found an increased amount of B. fragilis in healthy compared
to inflamed appearing mucosa.
The intestinal microbial composition apparently plays an
important role in the development and the clinical course of
IBD. Specific changes in the gut microbiota may put individ-
uals at an increased risk of developing IBD [54]. In addition to
the intestinal microbiota, genetic factors also play an impor-
tant role in the pathogenesis of CD, e.g., mutations in the
NOD2 gene [10, 11, 51, 55]. However, whether mutations in
the NOD2 gene and the intestinal microbiota are linked to-
gether in the development of IBD or act independently is still
Fig. 4 Mucosa-associated bacterial composition in colonic mucosa from
patients receiving either TNF-α blocking therapy or not. Biopsy samples
from inflamed and non-inflamed mucosa from CD and UC patients were
stratified into receiving TNF-α blocking therapy (infliximab or
adalimumab) or not. Seven different bacterial strains were analyzed.
Delta CT values were compared. In patients receiving TNF-α blocking
therapy (n= 5), there was a significant increase in F. prausnitzii compared
to patients without TNF-α blocking therapy (n = 28). Student’s t test was
used for statistical analysis (*p< 0.05)
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not completely understood. Rehman et al. demonstrated that
mutations in the NOD2 gene (SNP13) lead to an altered mi-
crobial composition in CD patients, e.g., an increased amount
of Bacteroidetes and Firmicutes in biopsies and fecal samples
[28]. To further study this possible association, the present
study addressed the relation between genetic risk factors and
alterations in the gut microbiota. In biopsy samples from pa-
tients with NOD2 mutations, we found a significant increase
of E. coli compared to biopsies from wildtype patients. These
findings suggest that it may be the host that triggers or allows
an increased abundance of E. coli in CD. In contrast to the
work of Rehman et al., no difference was found in the repre-
sentatives of the phyla of Bacteroidetes and Firmicutes. It
remains elusive if this is due to the fact that in the
abovementioned study the very specific group of patients ho-
mozygous for SNP13 were analyzed. It was shown that
adherent-invasive E. coli (AIEC) are highly present in ileal
mucosa of CD patients [9]. Additionally, in a recently pub-
lished study, it was shown that macrophages from CD patients
cannot control AIEC replication which leads to a disordered
cytokine secretion profile [56]. If the higher abundance of
E. coli in the NOD2 mutated patients in our patient cohort is
associated with these studies could be proven by further stud-
ies utilizing AIEC specific primers.
Maybe the most interesting finding was that a TNF-alpha
blockade was associated with an increased abundance of
F. prausnitzii. F. prausnitzii seems to be an important sensor
and indicator of human health [36]. Different diseases, such as
IBD [33, 57], IBS [58], and colorectal cancer [59] have been
found to be associated with a decreased abundance of
F. prausnitzii. The present study showed that patients receiv-
ing TNF-α blocking therapy had a significantly higher abun-
dance of F. prausnitzii. This might go in hand with a study by
Rajca et al., which showed that CD patients had lower counts
of Firmicutes and F. prausnitzii compared to healthy controls
[60]. Additionally, low rates of F. prausnitziiwere an indepen-
dent predictor of a relapse of CD. An effective medical ther-
apy with a TNF-α blocker might therefore increase the abun-
dance of F. prausnitzii. As the patients enrolled in this study
receiving a TNF-α blocker were evaluated for a secondary
failure, not a primary failure of this drug. One can speculate
that the initial response to this therapy regiment could possibly
alter the abundance of F. prausnitzii, and therefore, the mea-
surement of this specific strain could possibly be a target of
assessing the response of treatment.
Differences were also found in the mucosa between CD
and UC patients: in UC patients there was a significant higher
abundance of B. fragilis and B. bifidum.
There are some limitations within this study. Although the
study group consisted of a substantial number of patients, a
greater number, especially regarding the cohort of UC pa-
tients, would strengthen the conclusions drawn from the re-
sults. The seven investigated strains compromise only a small
proportion of the known mucosa-associated bacterial strains.
However, these strains in general are regarded as important
representatives of their corresponding phylum. Additionally, a
similar approachwas already used in other studies [42, 61]. As
a further limitation, a healthy cohort would have been an op-
timal reference for our IBD patients. But performing a colo-
noscopy in young, age-matched non-IBD probands when the
microbial composition in healthy individuals has already been
extensively studied [62, 63] is ethically debatable. This study
provides insights into the mucosa-associated bacterial compo-
sition in IBD patients in certain clinical situations. The ana-
lyzed bacteria could serve as targets for a directed and cost-
effective surveillance in IBD patients. In future, more precise
analysis might result in a therapeutic approach applying cer-
tain bacterial strains in defined clinical situations.
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Objective: Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene muta-
tions are known to be an important risk factor in the pathogenesis of Crohn’s disease (CD). Spe-
cific disease phenotypes are associated with the presence of NOD2 gene mutation. One
treatment option is to use an anti-tumor necrosis factor (TNF)-α agent. Therapeutic drug moni-
toring (TDM) is usually performed in cases of a loss of response. Our aim was to explore
whether NOD2 gene mutations have an effect on the disease phenotype, vitamin D levels, and
on TDM in CD patients.
Methods: This was a retrospective genotype–phenotype association study on NOD2 gene
mutations in 161 patients with CD.
Results: Altogether 55 (34.2%) patients carried at least one mutant allele of NOD2. NOD2 gene
mutations were associated with ileocecal disease, ileocecal resection, stricturing and perianal
disease, and patients with NOD2 gene mutation had significantly less frequent colonic disease
and received an ostomy less frequently. TDM in patients with NOD2 gene mutation showed
more frequent anti-TNF trough levels in the subtherapeutic range and lower anti-TNF trough
levels than in NOD2 wild-type (WT) patients.
Conclusions: CD patients with NOD2 gene mutation have a specific clinical phenotype and they
may require higher doses of anti-TNF agents to achieve sufficient anti-TNF trough levels. They
may therefore benefit from a proactive TDM than a reactive approach. This could be another
step in the direction of personalized medicine.
KEYWORDS
anti-TNF trough level, Crohn disease, drug monitoring, inflammatory bowel diseases, NOD2
1 | INTRODUCTION
Inflammatory bowel diseases (IBD) are disorders of the alimentary
tract and consist mainly of two entities, Crohn’s disease (CD) and
ulcerative colitis.1 Although the pathogenesis of IBD remains
unknown, studies have shown that genetic and environmental factors
lead to an inappropriate activation of the intestinal immune system.
This process may be triggered by the intestinal microbiota in geneti-
cally predisposed individuals.1,2 Mutations in the nucleotide-binding
oligomerization domain-containing protein 2 (NOD2) gene are associ-
ated with the development and clinical course of CD, e.g., ileal
disease.3–5 NOD2 is an intercellular pattern recognition receptor that
senses muramyl dipeptide,6 a known fragment of peptidoglycan. How-
ever, peptidoglycan on its own may also lead to the activation of
NOD2,7 but this process depends on a toll-like receptor 2 co-
stimulatory signal.8
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confidence interval; CDAI, Crohn’s disease activity index; 25[OH]D, 25-hydro-
xyvitamin D; IBD, inflammatory bowel diseases; IFX, infliximab; OR, odds ratio;
NOD2, nucleotide-binding oligomerization domain-containing protein 2; SNP,
single nucleotide polymorphism; TDM, therapeutic drug monitoring; TNF, tumor
necrosis factor; WT, wild type
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Although tumor necrosis factor (TNF)-α inhibitors (infliximab
[IFX], adalimumab [ADA], golimumab and certolizumab pegol) are a
mainstay in the therapy of IBD, they are not equally effective in all
patients.9,10 On the one hand, a considerable percentage of patients
do not respond to this treatment, on the other hand, secondary loss
of response is frequent.11,12 In patients with loss of response to
anti-TNF agents the analysis of anti-TNF trough levels and anti-drug
antibodies can establish a line of action.13,14 While traditionally,
therapeutic drug monitoring (TDM) is performed reactively in case
of a clinical loss of response (i.e., reactive TDM), proactive TDM is
not associated with remission but with fewer flares than reactive
TDM.15 A recent recommendation proposed by the American Gas-
troenterological Association has suggested reactive TDM but did
not recommend routine proactive therapeutic drug monitoring.16
However, there are no predictive markers for the response rate to
an anti-TNF treatment in IBD, which may be of clinical value for the
treating physician.
Our hypothesis was that the presence of a mutation in the NOD2
gene might have an impact on the clinical outcome in patients with
CD. Therefore, we performed a genotype–phenotype correlation in a
well-characterized patient cohort in a single north German tertiary
center aiming to explore whether mutations in the NOD2 gene have
an effect on the disease phenotype, vitamin D levels, and, in particu-
lar, on TDM in patients with CD.
2 | MATERIALS AND METHODS
2.1 | Patients
From October 2015 until September 2017, 161 patients with CD
from the Department of Gastroenterology of Rostock University
Medical Center (Rostock, Germany) were included in the study. A
diagnosis of CD was made based on the clinical, endoscopic, histologi-
cal and radiological results of the patients. The following data were
collected: clinical characteristics (age both at diagnosis and at the start
of the study, gender, disease location, disease behavior, disease activ-
ity, immunosuppressive or immunomodulatory medications (azathio-
prine [AZA] and TNF-α inhibitor), previous history of surgery
(i.e., colectomy) and 25-hydroxyvitamin D (25[OH]D) levels. To
exclude the potential effect of vitamin D substitution, only vitamin D
values without substitution were included in the study. Disease activ-
ity was assessed using the Crohn’s disease activity index (CDAI)17 and
the Harvey–Bradshaw index (HBI).18 CD was stratified via the Mon-
treal classification.19 All patients with CD under therapy with TNF-α
inhibitor, where TDM was performed from October 2015 until
September 2017, were included in the study. The study was approved
by the Local Ethics Board of the University of Rostock (A-
2015-0042). We obtained written informed consent from all partici-
pants prior to their enrollment.
2.2 | NOD2 genotyping
NOD2 genotyping was performed as previously described.20 Briefly,
we isolated DNA from whole blood using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany). All patients were genotyped for
three major mutations in the NOD2 gene (single nucleotide polymor-
phism [SNP] 8: R702W, NCBI reference SNP ID rs2066844; SNP12:
G908R, NCBI reference SNP ID rs2066845; and SNP13: 1007fs,
NCBI reference SNP ID rs2066847). The specific regions of the NOD2
gene were amplified by polymerase chain reaction (PCR) with Taq
PCR Master Mix Kit (Qiagen); the primers used and the PCR condi-
tions are summarized in the Supporting Information Table S1. After
Sanger sequencing (Seqlab, Göttingen, Germany), all data were ana-
lyzed with Chromas software version 2.6 (Technelysium, Brisbane,
Queensland, Australia).
2.3 | Measurement of drug concentrations and anti-
drug antibodies
We performed reactive TDM, defined as the clinical suspicion of pri-
mary or secondary loss of response and afterwards, confirmation of
this action, in our cohort. The quantification of IFX and ADA was per-
formed with two specific enzyme immunoassays (IDKmonitor Inflixi-
mab and IDKmonitor Adalimumab drug level, ELISA; Immundiagnostik,
Bensheim, Germany) according to the manufacturer’s instructions. In
brief, the therapeutic antibody was bound to the specific monoclonal
anti-IFX or anti-ADA antibodies, which were coated on a plate. After
washing, peroxidase-labeled antibodies were added and the conver-
sion of tetramethylbenzidine was monitored via a photometer. There
was a direct proportion between the intensity of the yellow color and
the IFX or ADA concentration. Furthermore, total IFX and ADA anti-
drug antibodies were detected using the IDKmonitor infliximab or
adalimumab total ADA ELISA (Immundiagnostik). The anti-drug anti-
bodies were separated from the therapeutic antibody during the sam-
ple preparation to minimize interference from therapeutic antibodies
in the serum of the patients. In the assay peroxidase conjugate (perox-
idase-labeled antibody), biotinylated therapeutic antibodies replaced
the unmarked therapeutic antibodies. The marked antibodies formed
a complex with the anti-drug antibody binding via biotin to the
streptavidin-coated plate. The conversion of tetramethylbenzidine
was monitored photometrically. Subtherapeutic trough levels were
defined as <3.0 μg/mL for IFX15 and <4.9 μg/mL for ADA,21
respectively.
2.4 | Statistical analysis
Data were collected and recorded in a Microsoft Access database
(Microsoft, Redmond, WA, USA) and analyzed by using the SPSS Sta-
tistics software version 22.0 (IBM, Armonk, NY, USA). Continuous var-
iables were expressed as mean  standard deviation (SD) or standard
error of mean (SEM), respectively, whereas categorical variables were
expressed as numbers and percentages or frequencies.
To assess whether a mutation in the NOD2 gene (yes vs no) has
an effect on binary clinical characteristics, the Fisher’s exact test was
performed. The analyses of age, disease activity (HBI and CDAI), and
vitamin D level in the mutated vs wild-type (WT) NOD2 groups was
performed with the Student’s t-test in case of normally distributed
variables; if not, we used the Mann–Whitney U test instead. Normal-
ity of the variables was examined with the Kolmogorov–Smirnov test.
The mean vitamin D levels per patient were compared in the NOD2
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mutated and NOD2 WT patients. To exclude an influence of the sea-
sonal differences in vitamin D levels we compared mean vitamin D
levels in winter (from October to March) and summer (from April to
September).
For the statistical analysis of TDM, different TDM (subtherapeutic
vs therapeutic) were compared between the NOD2 groups using the
Fisher’s exact test. The analysis of absolute trough levels was per-
formed with a two-sided t-test or Mann–Whitney U test.
A logistic regression model was applied to assess the associations
between binary NOD2 mutations and several categorical clinical char-
acteristics at the same time. First, odds ratio (OR) and the respective
95% confidence interval (CI) were calculated for univariate models to
select appropriate candidates (with a cut-off value with a P value of
0.20), which were subsequently tested in a multivariate model. The
resulting adjusted OR (ORadj) with their respective P values and CI are
recorded. P value less than 0.05 was regarded as statistically
significant.
3 | RESULTS
In total, 161 patients with CD were included in the study, among them
55 (34.2%) had at least one mutation in the NOD2 gene. The charac-
teristics of the patients are shown in Table 1.
3.1 | Clinical characteristics associated with the
presence of a NOD2 mutation
Mutations in the NOD2 gene were found to be associated with ileoco-
lonic disease (NOD2 mutated vs NOD2 WT: 44 [80.0%] vs 67 [63.2%],
P = 0.032). They appeared to be protective for colonic disease (NOD2
mutated vs NOD2 WT: 4 [7.3%] vs 29 [27.4%], P = 0.003). Stricturing
disease was more common in patients with a NOD2 mutation than in
those with NOD2WT (NOD2 mutated vs NOD2WT: 33 [60.0%] vs 43
[40.6%], P = 0.021). Perianal disease was more frequent in patients
with a NOD2 gene mutation compared with those with NOD2 WT,
although the difference was not statistically significant (19 [34.5%] vs
21 [19.8%], P = 0.054). In addition, patients with a NOD2 mutation
were more likely to undergo ileocecal resection than patients with
WT NOD2 (22 [40.0%] vs 23 [21.7%], P = 0.017). While the SNP was
usually not associated with specific clinical conditions, we found a
high significance for SNP13 and the presence of perianal disease
(NOD2 mutated vs NOD2 WT: 11 vs 29, P = 0.028). Other clinical fac-
tors, such as age, the use of disease-specific drugs, loss of response
and disease activity did not differ between the two groups. In addi-
tion, no significantly different vitamin D levels were found in the two
groups, either in summer or in winter.
To analyze further a possible association between the presence
of a mutation in the NOD2 gene and patient’s different clinical charac-
teristics a logistic regression analysis was performed (Table 2). We
found that the presence of a mutation in the NOD2 gene was associ-
ated with a more than doubled risk for perianal disease (ORadj 2.460,
95% CI 1.120–5.380, P = 0.024) and ileal/ileocecal re-
section (ORadj 2.110, 95% CI 1.040–4.280, P = 0.039), as well as with
a lower risk of receiving an ostomy (ORadj 0.270, 95% CI
TABLE 1 Clinical characteristics of all patients
NOD2
variant
(N = 55)
NOD2
wild-type
(N = 106) P value
Genotype (n)
Heterozygous−/+ 40
SNP8 18
SNP12 8
SNP13 14
Compound
heterozygous+/+
8
Homozygous+/+ 7
Female gender (n, %) 28 (50.9) 66 (62.3) 0.181
Age, years (mean  SD)
At study start
(October 2015)
41.6  15.2 42.3  14.4 0.845
At diagnosis 30.7  13.0 31.1  13.5 0.815
Disease location (n, %)
L1 (ileal) 7 (12.7) 10 (9.4) 0.591
L2 (colonic) 4 (7.3) 29 (27.4) 0.003
L3 (ileocolonic) 44 (80.0) 67 (63.2) 0.032
L4 (isolated upper GI
disease)
7 (12.7) 18 (17.0) 0.647
Disease behavior (n, %)
B1 (non-stricturing/
non-penetrating)
15 (27.3) 45 (42.4) 0.062
B2 (stricturing) 33 (60.0) 43 (40.6) 0.021
B3 (penetrating) 7 (12.7) 18 (17.0) 0.647
P (perianal) 19 (34.5) 21 (19.8) 0.054
Drugs (n, %)
Azathioprine 42 (76.4) 75 (70.8) 0.450
TNF-α inhibitors 33 (60.0) 69 (65.1) 0.605
Vitamin D, nmol/L (mean  SEM)
Summer (April to
September)
56.0  26.5 51.6  25.5 0.685
Winter (October to
March)
54.2  29.4 53.9  25.7 0.959
Surgery (n, %)
Small intestine 19 (34.5) 26 (24.5) 0.181
Ileocecal resection 22 (40.0) 23 (21.7) 0.017
Colonic resection 20 (36.4) 31 (29.2) 0.376
Stoma (n) 5 19 0.165
Ileostoma 2 8
Colostoma 2 8
Combined (Ileostoma/
colostoma)
1 3
Loss of response (n, %) 10 (18.2) 18 (17.0) 0.830
Primary (<6 months) 3 (30.0) 2 (11.1) 0.315
Secondary
(≥6 months)
7 (70.0) 16 (88.9) 0.227
Disease activity (mean  SD)
Crohn’s disease activity
index
103.9  50.4 94.2  43.2 0.959
Harvey–Bradshaw index 5.62  3.0 5.2  2.7 0.101
NOD2, nucleotide-binding oligomerization domain-containing protein 2;
GI, gastrointestinal; SD, standard deviation; SEM, standard error of mean;
SNP, single nucleotide polymorphism; TNF, tumor necrosis factor.
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0.088–0.831, P = 0.022). By using this analysis we combined all
colonic resections that included parts of the ileum as opposed to seg-
mental colonic resections (not including the ileum) to discriminate fur-
ther between these procedures and could not find an association of
colonic resections with NOD2 mutation. Other conditions,
e.g., gender, the use of TNF-α inhibitor, age, vitamin D deficiency and
vitamin D substitution were also not associated with the presence of
NOD2 gene mutation.
3.2 | Trough levels of anti-TNF agents
Altogether 29 patients undergoing TNF-α inhibitor therapy received
55 TDM. Twenty-one (72.4%) of these 29 patients were NOD2 WT,
while the other 8 (27.6%) had at least one mutation in the NOD2 gene
(SNP8 [n = 4], SNP12 [n = 2], SNP13 [n = 4]). We performed 39 TDM
on patients with WT NOD2 (26 treated with IFX and 13 with ADA,
with a mean TDM of 1.9 per patient) and 16 TDM on patients with
mutated NOD2 (6 treated with IFX and 10 with ADA, with a mean
TDM of 2 per patient). Other clinical characteristics of the patients
with TDM are depicted in Table 3. The reason for TDM was primary
loss of response (NOD2 WT vs NOD2 mutated: 4 vs 29), secondary
loss of response (NOD2 WT vs NOD2 mutated: 20 vs 9) or to assess
an action that had been undertaken (NOD2 WT vs NOD2 mutated:
15 vs 5). The reason for the TDM was independent of the presence of
a possible mutation in the NOD2 gene (P = 0.830).
As showed in Table 1, the age between patients with NOD2 WT
and NOD2 mutated was not significantly different, either at the start
of the study or at the diagnosis of the disease. However, TDM in
patients with a mutation in the NOD2 gene was performed at a signifi-
cantly younger age (P < 0.001) and a shorter duration of the disease
than patients with NOD2 WT (P = 0.003). However, when the TDM
of the NOD2 mutated and the NOD2WT groups was compared, other
clinical characteristics (e.g., disease location and disease behavior) did
not show a statistically significant difference.
Patients undergoing TDM with a mutation in the NOD2 gene had
a significantly higher probability of subtherapeutic anti-TNF trough
levels than patients with NOD2 WT (NOD2 WT: TDM subtherapeutic
[n = 17], TDM therapeutic [n = 22]; NOD2 mutated: TDM subthera-
peutic [n = 13], TDM therapeutic [n = 3]; P = 0.016; Figure 1). In
TABLE 2 The potential association of different clinical characteristics with the presence of a mutation in the nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) gene was assessed with logistic regression analysis
Univariate analysis Multivariate analysis
OR (95% CI) P value ORadj (95% CI) P value
Perianal disease (yes vs nota) 2.140 (1.030–4.450) 0.042
2.460 (1.120–5.380)
0.024
Ileal/ileocolonic resection (yes vs nota) 1.930 (0.997–3.750) 0.051
2.110 (1.040–4.280)
0.039
Ostomy (yes vs nota) 0.458 (0.161–1.300) 0.143
0.270 (0.088–0.831)
0.022
Gender (female vs malea) 0.629 (0.325–1.210) 0.167
0.606 (0.302–1.220)
0.158
Colonic resection (yes vs nota) 1.320 (0.664–2.630) 0.427
Anti-TNF-α treatment (yes vs nota) 0.804 (0.411–1.570) 0.525
Age (≥40 years vs <40 yearsa) 0.855 (0.445–1.650) 0.639
Vitamin D deficiency 0.829
Insufficiency vs normala 0.681 (0.255–1.820) 0.442
Deficiency vs normala 0.864 (0.318–2.350) 0.775
Severe deficiency vs normala 1.040 (0.227–0.473) 0.963
Vitamin D substitution (yes vs nota) 1.050 (0.541–2.020) 0.895
Bold text indicates significance.
a Represents reference.
CI, confidence interval; OR, odds ratio; ORadj, odds ratio adjusted; TNF, tumor necrosis factor.
TABLE 3 Clinical characteristics of the patients undergoing
therapeutic drug monitoring (TDM)
NOD2 variant
NOD2
Wild-type P value
Genotype (n) 8 21
Heterozygous−/+ 6
SNP8 4
SNP12 2
SNP13 4
Compound
heterozygous+/+
2
Homozygous+/+ 0
Gender
Female/male 5/3 13/8 1.0
TDM (n) 16 39 NS
With IFX 6 26 NS
With ADA 10 13 NS
Age, years (mean  SD)
At diagnosis 22.6  10.3 25.1  8.9 0.354
At TDM 27.9  11.1 36.2  10.7 <0.001
Disease duration
until TDM
6.5  3.7 12.2  4.7 0.003
Bold text indicates significance. ADA, adalimumab; IFX, infliximab; NOD2,
nucleotide-binding oligomerization domain-containing protein 2; NS, not
significant; SNP, single nucleotide polymorphism.
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addition to the qualitative presence of subtherapeutic anti-TNF
trough levels we further analyzed the numerical anti-TNF trough con-
centration in patients with a mutation in the NOD2 gene. Patients
undergoing TDM with NOD2 gene mutation displayed significantly
lower levels of IFX (NOD2 WT [n = 26] vs NOD2 mutated [n = 6]:
[3.2  2.7] μg/mL vs [1.1  1.3] μg/mL, P = 0.038; Figure 2A) and
ADA (NOD2 WT [n = 13] vs NOD2 mutated [n = 10]: [9.5  4.5] μg/
mL vs [4.5  5.9] μg/mL, P = 0.033; Figure 2B) compared with
patients with NOD2WT undergoing TDM.
3.3 | Anti-drug antibodies
We then investigated whether the lower anti-TNF trough levels were
associated with the presence of anti-drug antibodies and compared
anti-drug antibodies in patients with NOD2 WT and those with NOD2
gene mutation. There was no significant difference in the detection of
anti-drug antibodies between the two groups (NOD2 WT, no anti-
drug antibodies in 27 TDM, positive anti-drug antibodies in 12 TDM;
NOD2 mutated, no anti-drug antibodies in 12 TDM, positive anti-drug
antibodies in four TDM; P = 0.754). In addition, the absolute anti-drug
antibody concentrations were comparable between patients with
NOD2 WT and NOD2 mutated in IFX (NOD2 WT [n = 22] vs NOD2
mutated [n = 6]: [38.1  111.1] μg/mL vs [115.1  179.3] μg/mL,
P = 0.428) and ADA (NOD2 WT [n = 10] vs NOD2 mutated [n = 6]:
[3.9  4.2] μg/mL vs [40.7  71.9] μg/mL, P = 1.000).
3.4 | Effect of AZA on TDM
The SONIC study has shown that the concomitant use of AZA has an
effect on the IFX trough levels.22 Therefore, we examined whether
lower anti-TNF trough levels in patients with NOD2 mutations were
dependent on concomitant therapy with AZA. When TDM from
patients treated with AZA were excluded from the analysis, TDM in
patients with a NOD2 gene mutation had a significantly higher proba-
bility of anti-TNF trough levels in the subtherapeutic range (NOD2
WT: 10 TDM subtherapeutic, 14 TDM therapeutic; NOD2 mutated:
13 TDM subtherapeutic, three TDM therapeutic; P = 0.022). Thus, a
concomitant therapy with AZA had no effect on the TDM levels.
4 | DISCUSSION
The discovery of NOD2 as a genetic risk factor for CD has made a
substantial contribution to our understanding of the pathogenesis of
CD.3,4 In this study we performed a genotype–phenotype correlation
in a single-center north German tertiary IBD center. The present study
demonstrated three major results. First, we found that mutations in
the a mutation in the NOD2 gene were associated with ileocecal dis-
ease, ileocecal resection, stricturing disease behavior, and perianal dis-
ease. Second, patients with NOD2 gene mutations had a significantly
FIGURE 1 Mutation in the nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) gene was associated with lower
infliximab (IFX) and adalimumab (ADA) trough levels. Patients with
NOD2 gene mutation had significantly lower (A) IFX and (B) ADA
levels than those with NOD2 wild-type (WT). Subtherapeutic trough
levels were defined as <3.0 μg/mL for IFX and <4.9 μg/mL for ADA.
FIGURE 2 Mutation in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene was associated with a higher
prevalence of subtherapeutic anti-tumor necrosis factor (TNF) trough levels of (A) infliximab (IFX) and (B) adalimumab (ADA). Subtherapeutic
trough levels were defined as <3.0 μg/mL for IFX and <4.9 μg/mL for ADA. WT, wild type.
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lower probability of colonic CD or a stoma. Third, the presence of a
mutation in the NOD2 gene mutation was associated with a higher
probability of subtherapeutic and numerically lower anti-TNF trough
levels, but not anti-drug antibodies.
In previous studies mutations in the NOD2 gene were associated
with a younger age at diagnosis, ileal involvement and ileocecal
resection,5 the latter of the two was also shown in our study. Muta-
tions in the NOD2 gene were also found to be associated with stric-
turing and perianal disease.23,24 Underscoring these results, in our
cohort the presence of NOD2 gene mutations (SNP8, SNP12, and
SNP13) was also more prevalent in patients with stricturing and peria-
nal disease. Interestingly, the age at disease onset of patients with and
without NOD2 mutation was not significantly different. However, in
terms of the loss of response when TDM was performed, patients
with a mutation in the NOD2 gene were significantly younger than
those with NOD2 WT. The possible association between a loss of
response and the presence of a NOD2 gene mutation should be fur-
ther investigated in larger CD patient cohorts.
The low rate of mutations in the NOD2 gene in patients with
colonic disease has been described previously in Cantó et al.’s study.25
In addition, in our cohort the presence of a NOD2 gene mutation was
significantly associated with a lower risk of a stoma. Since this effect
was found in patients with an ileostoma and in those with a colos-
toma, the lower frequency of colonic CD in patients with NOD2 muta-
tions cannot explain this result. In a previous study we showed that
NOD2 was associated with the development of intestinal failure in the
absence of CD.26 For the authors it remains unclear why patients with
a NOD2 gene mutation have a significantly lower risk of receiving an
ostomy.
The measurement of anti-TNF trough levels can influence the
therapeutic approach, especially in the case of a loss of response.14 In
our study we found that NOD2 gene mutation was associated with a
higher prevalence of subtherapeutic anti-TNF trough levels. In addi-
tion, NOD2 gene mutations were associated with significantly lower
trough levels of IFX and ADA. This effect did not depend on co-
medication with AZA. Moreover, the presence of anti-drug antibodies
was not significantly different between the two groups. The reason
for which TDM was undertaken was not statistically different
between the NOD2 WT and NOD2 mutated cohort. Two hypotheses
can be postulated for this result. First, NOD2 has an effect on the
intestinal barrier function.27,28 A study in patients with severe ulcera-
tive colitis by Brandse et al. showed, that IFX can be lost through the
feces, a mechanism that is associated with a loss of response.29 While
our cohort contained patients with CD, with only a small proportion
of colonic disease localization, especially in patients with a NOD2 gene
mutation, it remains unknown whether anti-TNF agents can also be
lost in the ileocecal region or small bowel in CD; a question that might
be addressed in further studies. However, it may be speculated that a
NOD2-induced barrier dysfunction may also be responsible for lower
anti-TNF trough levels. Second, a NOD2 gene mutation could lead to
higher basal TNF-α levels with consecutively (after treated with an
anti-TNF agent) lower anti-TNF trough levels. In a monocytic cell line,
an overexpression of NOD2 reduced the effects of anti-TNF agents.30
In agreement with our results, a study by Juanola et al. showed that a
mutation in the NOD2 gene was associated with a loss of response to
the treatment with anti-TNF agents.31 On the other hand, in different
studies the presence of a mutation in the NOD2 gene did not have an
effect on response to treatment with an anti-TNF agent.32,33 How-
ever, based on our data we cannot elucidate the mechanisms by
which the presence of a NOD2 gene mutation may lead to lower anti-
TNF trough levels.
A limitation of our study was that the number of TDM performed
was relatively low. However, our data suggested that there was a
strong association between the presence of NOD2 gene mutation and
lower anti-TNF trough levels, since there was a noticeable difference
between the anti-TNF trough levels in IFX and ADA between patients
with NOD2 WT and NOD2 mutated. This effect is of specific clinical
relevance, since the presence of a NOD2 gene mutation may not only
predispose patients to ileocolonic disease, ileocecal resection and
perianal disease, but also to lower anti-TNF trough levels. Patients
with a mutation in the NOD2 gene may therefore require higher doses
of anti-TNF agents in order to obtain sufficient levels of these drugs,
or a more intense TDM strategy. Therefore, one can argue that
patients with a mutation in the NOD2 gene might particularly benefit
from proactive therapeutic drug monitoring rather than reactive TDM.
This would be another important step in the direction of personalized
medicine in IBD and the results should be further investigated in a
larger, prospective, controlled clinical trial.
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Vitamin D administration leads to a shift of the intestinal
bacterial composition in Crohn’s disease patients, but not in
healthy controls
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OBJECTIVE: Dysbiosis is a common feature in the
pathogenesis of inflammatory bowel diseases (IBD).
Environmental factors, such as vitamin D deficiency,
seem to play a role in the intestinal inflammation of
IBD. The aim of this study was to investigate whether
vitamin D administration has an impact on the bac-
terial composition in Crohn’s disease (CD) compared
to healthy controls (HC).
METHODS: A prospective, longitudinal, controlled
interventional analysis was conducted in seven
patients with CD in clinical remission and 10 HC to
investigate the effect of orally administrated vitamin
D on the intestinal bacterial composition using 16S
ribosomal RNA gene amplicon sequencing. Clinical
parameters were assessed.
RESULTS: In contrast to HC, microbial communi-
ties of CD patients changed significantly during early
vitamin D administration. However, a further
increase in vitamin D level was associated with a
reversal of this effect and additionally with a decrease
in the bacterial richness in the CD microbiome. Spe-
cific species with a high abundancy were found dur-
ing vitamin D administration in CD, but not in HC;
the abundancy of Alistipes, Barnesiella, unclassified
Porphyromonadaceae (both Actinobacteria), Rose-
buria, Anaerotruncus, Subdoligranulum and an unclassi-
fied Ruminococaceae (all Firmicutes) increased
significantly after 1-week vitamin D administra-
tion in CD.
CONCLUSIONS: Vitamin D has a specific influence
on the bacterial communities in CD, but not in
HC. Administration of vitamin D may have a positive
effect in CD by modulating the intestinal bacterial
composition and also by increasing the abundance of
potential beneficial bacterial strains.
KEY WORDS: Crohn disease, inflammatory bowel diseases, microbiota, vitamin D.
INTRODUCTION
Inflammatory bowel diseases (IBD) consist of
Crohn’s disease (CD) and ulcerative colitis
(UC) which are chronic inflammatory diseases of the
alimentary tract.1 While the pathogenesis is still not
completely understood, an important part of the dis-
ease is known to be inappropriate activation of the
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mucosal immune system caused by intestinal micro-
biota in patients with a genetical risk profile.1–4
Mutations in the nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) gene, encod-
ing for the NOD2 receptor, are major risk factors for
the development of CD.5–8 In addition, environmen-
tal factors, such as vitamin D deficiency, seem to play
a role in the pathogenesis of IBD as well.8,9 Vitamin
D is commonly known as an important regulator of
calcium and phosphate metabolism and is therefore
essential for bone health.10,11 However, there is
increasing evidence that vitamin D also plays an
important role as a regulator of the innate and adap-
tive immune system.11–13 In a murine colitis model,
the application of 1,25-dihydroxyvitamin D3 (1,25
[OH]2D3) was associated with reduced mucosal
injury.14 Vitamin D deficiency is highly prevalent in
IBD patients.15,16 Interestingly, stimulation with vita-
min D increased the expression of the NOD2 recep-
tor in primary monocytic and epithelial cells, linking
the innate immune system with vitamin D.17 Vitamin
D was shown to have an effect on the dendritic and
monocyte-derived macrophages cell function.19–21
From a clinical point of view, the administration of
tumor necrosis factor (TNF)-alpha inhibitor is associ-
ated with higher vitamin D levels in IBD.18 On the
other hand, in CD patients where infliximab was ini-
tiated, lower vitamin D levels were associated with a
higher rate of clinical remission at week 14.22
Even now, it is still not clear whether vitamin D admin-
istration has a beneficial effect on the disease course in
IBD. In a prospective study, infliximab treatment had a
positive effect on bone metabolism.23 Along the same
line in different studies in CD patients, an inverse asso-
ciation between vitamin D levels and intestinal inflam-
mation was found.24,25 In several interventional
studies, vitamin D administration appeared to have
beneficial effects on the clinical disease activity and C-
reactive protein (CRP) values in IBD patients.26–29
However, whether vitamin D also has an influence
on the intestinal bacterial composition is still not
known. In murine models, vitamin D and the vita-
min D receptor (VDR) are important regulators of
intestinal bacterial composition.30–32 In a recent
genome-wide association study (GWAS), mutations
in the VDR gene were associated with different intes-
tinal microbial profiles.33
To address the hypothesis, whether administration of
vitamin D has an effect on the intestinal microbial
communities in CD, we performed a controlled
prospective and longitudinal analysis in CD patients
in clinical remission and healthy controls (HC).
MATERIAL AND METHODS
Study design
The study was approved by the Institutional Review
Board of the University Medical Center Rostock
(A 2016-0109). The study was registered in the Ger-
man Clinical Trials Register (Registration number
DRKS00013485). Written informed consent was
obtained from each participant prior to their
enrollment.
Seven patients with ileocolonic CD (Montreal classifi-
cation34: L3) and vitamin D deficiency (25[OH]D <75
nmol/L) were recruited from the Outpatient Clinic of
Rostock University Medical Center (Rostock, Ger-
many). The patients were in clinical remission and did
not have a change of their CD-specific therapy during
the previous 6 months before they were enrolled in
this study. HC with vitamin D deficiency and no his-
tory of IBD were recruited from the Rostock Medical
School. In both groups, oral vitamin D administration
was given with cholecalciferol (MIBE GmbH Arznei-
mittel, Brehna, Germany) 20 000 IU daily from day
1 until day 3, then every other day for a total of
4 weeks. In this study, a target vitamin D level was set
to be between 100 and 150 nmol/L. Serum 25-hydro-
xyvitamin D (25[OH]D) levels were measured weekly
(before administration = week 0). In both groups,
300 000 IU vitamin D were administered per patient
over the course of the study. In CD patients, calprotec-
tin levels were measured at week 0 and week 4. Fresh
stool samples were collected weekly (weeks 0, 1, 2, 3
and 4) for analysis of the intestinal bacterial micro-
biota. The disease activity in CD patients was assessed
using the Crohn’s disease activity index (CDAI);35
other clinical parameters, including the localization of
the disease, medical therapy, duration of the disease,
were recorded. Clinical characteristics of all the partici-
pants are shown in Table 1.
DNA extraction
DNA was isolated from whole blood with the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Ger-
many) according to the instructions of the
manufacturer.
NOD2 genotyping
Regarding the NOD2 genotyping we focused on the
three major mutations of the NOD2 gene (SNP
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8, R702W, National Center for Biotechnology Infor-
mation [NCBI] reference single nucleotide polymor-
phism [SNP] ID: rs2066844; SNP 12, G908R, NCBI
reference SNP ID: rs2066845; and SNP 13, 1007 fs,
NCBI reference SNP ID: rs2066847). For the amplifi-
cation of the regions of the NOD2 gene, the Taq PCR
Master Mix Kit (Qiagen) and primers/polymerase
chain reaction (PCR) conditions as specified in
Table S1 were employed. Additionally, the PCR prod-
ucts were subjected to Sanger sequencing (Seqlab,
Göttingen, Germany). The resulting data were ana-
lyzed using with the Chromas 2.6 (Technelysium Pty.
Ltd., Brisbance, Australia).
Preparation of 16S rRNA gene sequencing libraries,
sequencing run and data analysis
The isolated DNA was amplified with the bacterial
16S ribosomal RNA (rRNA) gene primers Bakt_341F
(CCTACGGGNGGCWGCAG) and Bakt_805R
(GACTACHVGGGTATCTAATCC).36 The amplicon
PCR, the index PCR, a quantity and a quality control
and the sequencing of the individual libraries as a
pool in one Illumina MiSeq run was performed as
described in a previous study.37 The raw sequences of
the study were deposited at the Short Sequence
Archive (SRA) under the accession number
‘PRJEB21819’. For our data analysis, the resulting
sequences were assembled using the program QIIME
1.9.138 with the ‘joins paired-end Illumina reads’
function with default settings to merge forward and
reverse sequences with an overlap of at least 30 bp.
We discharged sequences without overlap. After con-
verting ‘fastq’ to ‘fasta’ using the ‘convert_fastaqual_-
fastq’ function, we used the SILVA NGS pipeline for
the resulting sequences, using default settings.39 This
pipeline aligns the reads to a database with the SINA
aligner.40 With this program, problematic reads such
as PCR artefacts (including potential chimeras) and
non-ribosomal reads are filtered out and consecu-
tively discarded. The reads are then quality filtered
using the following settings: reads less than
50 aligned nucleotides and reads with more than 2%
of ambiguities, 2% of homopolymers or low align-
ment quality, defined by a 40 alignment score
reported by SINA. After the alignment, the sequences
were dereplicated by clustering by a 98% sequence
identity to each other using CD-HIT.41 The longest
read in each cluster was Basic Local Alignment Search
Tool (BLAST) searched against SILVA SSU Ref 128 to
classify the sequences. The resulting classification of
the reference sequence of each cluster was mapped to
all the members of the cluster as well as their repli-
cates. The sequences which have an average BLAST
alignment coverage and alignment identity of less
than 93% were considered as unclassified and we
defined them as the virtual taxonomical group ‘No
Relative’.
Statistical analysis
Continuous variables were expressed as mean  stan-
dard deviation or medians and interquartiles,
whereas categorical variables were expressed as num-
bers and percentages. The disease activity, measured
by CDAI and the calprotectin value in the CD cohort
from week 0 and week 4, was compared using a
paired t-test.
Operational taxonomic unit (OTU) counts based on
genus level were rarefied to 3500 reads per sample
using the single_rarefraction.py script implemented
in QIIME. To compare the dominant taxa in the dif-
ferent time points (week 0 until week 4) during vita-
min D administration, the occurrence of the 22 most
abundant OTUs was visualized in a heatmap using
Explicet.42 This program was also used in a
rarefaction-based analysis, here with bootstrapping
for richness. We visualized the differences in the bac-
terial community composition through non-metric
Table 1. Clinical characteristics of the Crohn’s disease
(CD) patients and health controls (HC)
Characteristics
CD group
(N = 7)
HC group
(N = 10)
Age, years (mean  SD) 44.9  12.4 24.8  3.1
Sex (M/F), n 4/3 7/3
Localization of CD
(Montreal classification)
L3 -
NOD2 mutations (CD),
n
2 -
(SNP8
heterozygous)
CD treated with TNF-α
inhibitor (infliximab/
adalimumab), n
5 -
Total vitamin D
administrated (IU)
300 000 -
CDAI (mean  SD)
Week 0 81.6  43.0
-
Week 4 57.3  36.2 -
Stool calprotectin, mg/kg
(mean  SD)
Week 0 297.8  613.0 -
Week 4 178.6  305.6 -
CDAI, Crohn’s disease activity index; F, female; M, male; NOD2,
nucleotide-binding oligomerization domain-containing protein 2;
SD, standard deviation; SNP, single nucleotide polymorphism;
TNF, tumor necrosis factor.
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multidimensional scaling (NMDS) plots using Bray–
Curtis dissimilarity indices based on a genus rank
classification. We used the software package PAST43
for non-parametric multivariate analysis of variance
(PERMANOVA) to analyze the differences between
OTU compositions and a Tukey’s pairwise test to cal-
culate significant differences between the number of
OTUs between the patient samples. A linear discrimi-
nant analysis (LDA) effect size (LEfSe) analysis44 was
performed to determine bacterial groups which are
significantly different between the samples using the
‘one against all’ strategy for multi-class analysis. The
program LEfSe uses a non-parametric test that cou-
ples standard tests for statistical significance with
additional tests encoding biological consistency and
effect relevance. P < 0.05 was regarded as statistical
significance.
RESULTS
Effect of vitamin D administration on clinical
parameters in CD and HC
Vitamin D administration led to a significant increase
in 25(OH)D levels in CD and HC (CD: week
0 [39.7  23.0 nmol/L] vs week 4 [121.4  43.2
nmol/L], P < 0.001; HC: week 0 [29.6  6.3 nmol/L]
vs week 4 [143.0  25.2 nmol/L], P < 0.001; Fig. 1).
The vitamin D levels was not significantly different
between CD and HC at each time point from week
0 to week 4. We identified two of the seven patients
as having a mutation in the NOD2 gene (SNP 8, het-
erozygous; Table 1) but these did not show a specific
response to the vitamin D treatment (data not
shown).
In CD, vitamin D administration was associated with
a non-significant decline of the CDAI and the calpro-
tectin levels between week 0 and week 4 (CDAI: week
0 [81.6  43] vs week 4 [57.3  36.2], Fig. 2a; cal-
protectin: week 0 [297.8  613.0 mg/kg] vs week
4 [178.6  305.6 mg/kg], Fig. 2b). One patient
showed a strong decline of the calprotectin level
under vitamin D administration (week
0 [1685 mg/kg] vs week 4 [793 mg/kg]) while staying
in clinical remission for the whole study period.
Vitamin D administration was associated with a
temporal shift of the intestinal microbiota in CD,
but not in HC
Bacteroidetes and Clostridia were among the most
abundant phyla/classes in the bacterial community
analysis (Fig. S1). This could be observed at all time
points (week 0 to week 4) in CD as well as in
HC. However, to assess the effect of vitamin D
administration on different microbial communities,
we visualized changes in the bacterial composition
on the bacterial genus levels using NMDS in HC
(Fig. 3a) and CD (Fig. 3b). In the HC group, there
was no significant difference between week 0 and
week 4 as well as between the different time points
of vitamin D administration. In the CD group, we
observed a shift of the bacterial composition from
week 0 to week 1, which reversed in weeks 2, 3 and
4 (Table S2). The shift from week 0 to week 1 was
not significant, which might be attributed to the fact
that the bacterial composition of two patients at week
0 clustered within the bacterial communities of week
1. The bacterial community at week 1 differed signifi-
cantly from those at week 2, week 3 and week 4 in all
patients during vitamin D administration (week 1 vs
week 2, P = 0.007; week 1 vs week 3, P = 0.01; week
1 vs week 4, P = 0.011). In contrast, the bacterial com-
munity at week 0 did not differ significantly from those
at weeks 2, 3 and 4 (all P > 0.05). The use of TNF-α
inhibitor, the disease activity (CDAI) and the presence
of a mutation of the NOD2 gene did not have a
Figure 1. The level of 25-hydroxyvitamin D (25[OH]D)
in Crohn’s disease (CD) patients and healthy controls
(HC) from week 0 (w0) to week 4 (w4). The administra-
tion of vitamin D increases the 25(OH)D levels in CD and
HC significantly. However, the increase in 25(OH)D levels
does not differ between CD and HC at different time points
from week 0 to week 4. Values are expressed as medians
and interquartile ranges. The largest data points is <1.5
times the box height (“upper-inner fence”) as shown with
short horizontal lines and similarly for that below the box.
****P < 0.001 by Turky’s pairwise test.
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significant effect on the bacterial communities during
vitamin D administration.
Vitamin D administration was associated with
specific abundant bacteria in CD, but not in HC
To further assess if vitamin D has an impact on the
abundance of specific strains in CD and HC, we char-
acterized alterations in the bacterial genera using
LEfSe.44 While in CD different specific abundant bac-
teria before and at different time points during vita-
min D administration were found, the analysis of the
HC cohort did not detect any abundant strains. The
results of the CD group are shown in a heatmap
(Fig. 4). The bacteria were stratified into five groups
to differentiate the response to the vitamin D admin-
istration (highest abundance at weeks 0 to 4). Before
vitamin D administration (week 0) the typical bacte-
ria (significantly more abundant based on LEfSe anal-
ysis) were Sutterella (Betaproteobacteria), next to
Bifidobacterium (Actinobacteria) and an unclassified
lineage of the Lachnospiracea. After 1 week of vitamin
D administration (week 1), the typical bacteria
shifted toward an Alistipes (Bacteroidetes)-dominated
bacterial community. Barnesiella and unclassified Por-
phyromonadaceae (both Actinobacteria), as well as
Roseburia, Anaerotruncus, Subdoligranulum and an
unclassified Ruminococaceae (all Firmicutes) were
also highly prevalent at this time point. After 2 weeks
of vitamin D administration (week 2), the Bacteroi-
detes became less prominent and Firmicutes, espe-
cially Faecalibacterium, Veillonella, and Blautia,
Fusicatenibacter and Intestinibacter became the typical
part of the bacterial community composition. In the
third week of vitamin D administration, Parabacter-
oides (Bacteroides) were mainly abundant throughout
the study but were significantly less abundant in
weeks 1–2. Other indicator OTUs were Lachnospira
(Firmicutes), Coprobacter (Bacteroides) and Parasutter-
ella (Betaproteobacteria). At week 4, Lactobacillus and
Megasphera (both Firmicutes) were significantly
enriched. However, both had numerically a relatively
low abundance.
Vitamin D administration was associated with a
decrease in the bacterial taxa in CD, but not in HC
In previous studies, a reduction of the bacterial diver-
sity was found in CD.45,46 To address the question if
vitamin D administration also has an effect on the
diversity in CD and HC, we analyzed the number of
bacterial taxa at the different time points (week
0 until week 4). There was no significant difference
between CD and HC in the number of bacterial taxa
before vitamin D administration (P > 0.05, Tukey’s
test). While the number of bacterial taxa in HC did
not change significantly (HC: week 0 vs week
4, P > 0.05; Tukey’s test), the bacterial taxa in CD
decreased significantly during vitamin D administra-
tion (CD: week 0 vs week 4, P = 0.001; Tukey’s test).
Additionally, the number of bacterial taxa was signifi-
cantly lower in CD compared to HC at weeks 3 and
4 of vitamin D administration (CD vs HC, week 3:
P = 0.007, week 4: P = 0.0001; Tukey’s test; Fig. 5).
DISCUSSION
Dysbiosis is an important feature in the pathogenesis
of IBD.45–48 Environmental factors such as vitamin D
deficiency also seem to play a role in the develop-
ment and the clinical disease course of IBD. Here we
have investigated whether there is an interaction of
vitamin D and intestinal microbiota in CD because
vitamin D has been shown to have an influence on
intestinal inflammation and therefore possibly on
microbial communities as well. Vitamin D has been
Figure 2. Crohn’s disease activity index (CDAI) and calprotectin during vitamin D administration in Crohn’s disease
patients. Vitamin D administration leads to a non-significant decrease in (a) the CDAI and (b) the calprotectin level. One
patient shows a strong decline of the CDAI and the calprotectin level. Logarithmic scale in (b).
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shown to ameliorate intestinal inflammation, but it
is not clear whether this is a direct effect on the
inflammatory response and the intestinal microbiota
is only secondarily altered or whether this is a direct
effect on the intestinal microbiota. Therefore, vitamin
D was given to HC and CD patients who were in
clinical remission to analyze the microbial composi-
tion in both groups. Vitamin D administration was
associated with a significant shift of the intestinal
bacterial communities in CD patients at week
1. While the bacterial composition in HC was not
significantly affected by vitamin D administration,
we observed temporal changes in the bacterial com-
munities during vitamin D administration in CD
patients (Fig. 3). Vitamin D has therefore a strong
effect on the microbial composition in CD, but not
in HC, suggesting an important role in the pathogen-
esis of IBD. The strongest effect was observed at week
1 of vitamin D administration. However, the increase
in 25(OH)D levels over three additional weeks
caused again a shift in the bacterial community that
was more similar to the initial bacterial community
at week 0. There may be alternative explanations for
the temporal nature of the effect of vitamin D. First,
the effect of vitamin D on the bacterial communities
is in itself only temporal and the microbiota revert
after 2 weeks. Second, there may be an optimal 25
(OH)D level (‘vitamin D window’) which resembles
the vitamin D levels at week 1 (64.6  29.8 nmol/L)
and a further increase in vitamin D levels might
therefore cause reversal of effect on the bacterial
composition.
Another important finding of our study is the change
in the bacterial diversity during vitamin D adminis-
tration (Fig. 5). Studies found a lower bacterial spe-
cies diversity in CD patients compared to HC.49,50
However, in our study, the number of bacterial taxa
was not significantly different between HC and CD
before the administration of vitamin D. This might
be attributed to the fact that our patients were in sta-
ble clinical remission. After 2 weeks of vitamin D
administration, the number of bacterial taxa declined
in CD patients but did not change in HC. In general,
a higher diversity is thought to be associated with
beneficial effects for the host. Our results suggest that
an increased vitamin D concentration causes a loss of
OTUs that are potentially beneficial and supports the
‘vitamin D window’ hypothesis. However, it can be
speculated that week 4 is too early to see a long-term
effect of vitamin D administration on the composi-
tion of the bacterial communities. Further, prospec-
tive studies are needed to test the presence of an
optimal vitamin D range in IBD.
The mechanisms of how vitamin D administration
leads to a shift of the bacterial communities in CD
remains speculative. Several studies have shown a
correlation between vitamin D status, the mucosal
immune system and the microbiota in IBD.51,52
Mutations in VDR are risk factors for the develop-
ment of IBD8 and vitamin D can activate the NOD2
pathway.17 A recent study by Wang et al. showed that
Figure 3. Vitamin D administration leads to a temporal
shift of the bacterial communities in Crohn’s diseae (CD),
but not in healthy controls (HC). Non-metric multidimen-
sional scaling plot (NMDS) based on Bray–Curtis dissimilar-
ity of the bacterial communities from (a) HC and (b) CD at
different time points during vitamin D administration
(NMDS 0.092) without CD patient no. 6 on week 4 and CD
patient no. 1 on week 3. While there is a shift of the bacterial
composition in the CD group from week 0 to week 1, no
such effect is found in HC. (●) Week 0, (▪) Week
1, (+) Week 2, (□) Week 3, (○) Week 4.
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variations in VDR had an influence on gut
microbiota.33
For the treatment of IBD, the role of probiotics
remains controversial. While in UC probiotics may
have a positive effect in specific, well-defined clinical
situations, the efficacy of probiotics in CD remains
uncertain.53,54 In the present analysis we have identi-
fied specific bacterial species which show an
increased abundance during vitamin D administra-
tion. In addition to many other abundant strains, we
observed a prominent change in the abundancy of
Alistipes and Parabacteroides during vitamin D admin-
istration in CD but not in HC. Both species appear to
be of special importance in the pathogenesis of IBD.
In contrast to the increased abundance of Alistipes,
Parabacteroides showed a decreased abundance during
vitamin D administration in the first and second
week of the study but an increase at week 3 and week
4. In murine dextran sulphate sodium (DSS)-induced
colitis, Alistipes finegoldii was protective against coli-
tis.55 Additionally, in a study using VDR-knockout
mice, Alistipes was depleted in cecal stool.31 Other
studies have proposed an important role for Parabac-
teroides in the pathogenesis of intestinal inflamma-
tion and found a decrease in Parabacteroides at
inflamed compared to non-inflamed sites of the
intestine.56,57 Additionally, oral administration of
Parabacteroides distasonis led to decreased severity in a
murine model of DSS colitis.58 Interestingly, in our
analysis the abundance of Parabacteroides decreased
in the first 2 weeks. As a consequence, Alistipes and
Parabacteroides might therefore have beneficial effects
on the host and vitamin D administration may possi-
bly induce the growth of these species. In addition to
these highly abundant species, several other OTUs
were found to be significantly increased during vita-
min D administration in the first week. These
Figure 4. Heatmap of the bacterial communities during vitamin D administration in the Crohn’s disease (CD) cohort.
Group A shows the bacteria with a high abundance in week 0 (w0), group B in week 1 (w1), group C in week 2 (w2), group
D in week 3 (w3) and group E in week 4 (w4). This figure shows the abundant species in the CD group.
Figure 5. Number of bacterial taxa during vitamin D
administration for 4 weeks in patients with Crohn’s disease
(CD) and healthy controls (HC). While the number of bac-
terial taxa, shown in operational taxonomic units (OTUs)
at week 0 (w0) is not different between CD and HC, it
decreases significantly in CD compared to HC during vita-
min D administration at week 3 (w3) and week 4 (w4).
Values are expressed as medians and interquartile ranges.
The largest data points is <1.5 times the box height
(“upper-inner fence”) as shown with short horizontal lines
and similarly for that below the box. NS, not significant.
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included Roseburia, of which a decrease of Roseburia
hominis has been associated with a higher disease
activity in UC.59 Absence of Roseburia before colect-
omy in UC was associated with a higher risk of pou-
chitis in UC.60 Faecalibacterium prausnitzii, which
showed high abundance from week 1 to week 3, is a
well-known butyrate-producing strain which is
thought to have anti-inflammatory properties.61–63 A
specific microbial community containing Barnesiella,
also showing a high abundance at week 1, had bene-
ficial effects on the intestinal microbial composi-
tion.64 We hypothesize from our data that the
appearance of several beneficial bacterial strains dur-
ing vitamin D administration has a protective effect
on the disease course in CD. Vitamin D might there-
fore enhance the probiotic capacity of these strains
via an increased abundance. In line with that, vita-
min D was required for a positive probiotic effect in
a murine colitis model.65 A combination of probio-
tics and vitamin D may have a synergistic effect on
the disease activity in CD. Further studies will be
needed to test this hypothesis.
One aspect of criticism in this study is that the con-
trol group was significantly younger than the CD
group due to technical reasons, which might also
have an effect on the intestinal microbial composi-
tion. Although we found a highly significant change
of the bacterial communities in CD but not in HC,
this effect could also be influenced by the age of the
participants in this study. In further studies, age-
matched control groups might clarify this aspect.
As a conclusion, the administration of vitamin D has
a specific impact on the bacterial profile in CD,
shown by the shift of the bacterial composition, the
different highly abundant and potentially beneficial
bacterial strains and the reduced diversity during vita-
min D administration. In contrast to CD, in the HC
group, no specific effects of vitamin D administration
have been detected. This is the first controlled pro-
spective interventional analysis which shows a spe-
cific effect of vitamin D administration on the
microbial communities in CD, but not in
HC. Therefore, vitamin D administration may be an
important additional therapeutic intervention in the
management of CD.
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Summary
In inflammatory bowel diseases (IBD), microbial com-
munities often become imbalanced suggesting abnor-
mal microbial-gut interactions. In this study, we
analysed the mucosa-attached gut microbiota from 26
Crohn’s disease (CD) patients using 16S rRNA gene
amplicon sequencing. The samples were stratified
according to their disease activity (Crohn’s disease
activity index, CDAI). The different disease activity cat-
egories had a comparable bacterial richness. Bacterial
communities of patients in remission and intermediate
CDAI (0–220) were relatively similar and dominated by
the genus Bacteroides (>40%). The bacterial composi-
tion of patients assigned to a high CDAI category was
dominated by Pelomonas (25%) and Flavobacterium
(13%) but had a low relative abundance of Bacteroi-
detes (4%). This indicates the presence of specific
abundant bacterial taxa at different CDAI levels. In
addition, bacterial communities were also significantly
influenced when a tumour necrosis factor (TNF)-a
inhibitor was applied or by the local mucosal inflam-
mation level. As a consequence, a shift of the micro-
bial composition may also indicate a change of the
disease activity in CD patients.
Importance
The intestinal microbiota plays a major role in the devel-
opment and the clinical course of IBD. The microbial
composition of IBD patients in contrast to healthy con-
trols has already been extensively studied. Here, we
show for the first time that there is a clear coherence
between changes in the mucosa-attached bacterial com-
munity in CD and the disease activity (measured in
CDAI). Additionally, we were able to demonstrate that
there is coherence of the bacterial community with the
use of a TNF-a inhibitor and the local mucosal inflam-
mation status. These results lead to a better under-
standing of the mucosa-attached microbial communities
in CD and could potentially result in the development of
novel therapeutic strategies.
Introduction
Inflammatory bowel diseases (IBD) mainly consist of
Crohn’s disease (CD) and ulcerative colitis (UC). The
etiology of these disease entities is still not completely
understood. However, chronic activation of the intestinal
immune system caused by the microbiota in a geneti-
cally predisposed host might play an important role (Sar-
tor, 2008; Abraham and Cho, 2009; Frank et al., 2011).
Different studies reported alterations in the intestinal
microbiota of IBD patients compared to healthy controls
(Frank et al., 2007; 2011; Willing et al., 2010). The intes-
tinal microbiota therefore might play a role in the patho-
genesis of IBD (Manichanh et al., 2012). For example, it
was shown that patients with CD have a decreased pro-
portion of so-called beneficial bacteria, like Bifidobacte-
ria and Lactobacilli and an increased proportion of
potentially pathogenic bacteria like Escherichia coli (Fav-
ier et al., 1997; Darfeuille-Michaud et al., 1998; Ott
et al., 2004; Backhed et al., 2005; Frank et al., 2007;
Sartor, 2008; Neish, 2009; Willing et al., 2009; Arumu-
gam et al., 2011; Chassaing and Darfeuille-Michaud,
2011; Martinez-Medina and Garcia-Gil, 2014). However,
in another study an increased proportion of Bifidobacte-
rium and the Lactobacillus group was found in IBD
patients compared to healthy controls (Wang et al.,
2014). In active IBD patients Faecalibacterium prausnit-
zii is significantly decreased compared to healthy con-
trols (Swidsinski et al., 2008; Sokol et al., 2009).
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Another study showed a decrease in Clostridium family
in active UC and both active and inactive CD as well as
an increase of Bacteroides in CD (Andoh et al., 2011).
IBD patients have a depletion of commensal bacteria
(Frank et al., 2007) and their microbial community is
less diverse (Ott et al., 2004; Dicksved et al., 2008;
Nishikawa et al., 2009).
Mutations in the nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) gene are a risk fac-
tor for the development of CD (Hampe et al., 2001;
Hugot et al., 2001; Ogura et al., 2001). NOD2 was
shown to be important for the regulation of commensal
microbiota in the murine intestine (Petnicki-Ocwieja
et al., 2009). NOD2-mediated microbial imbalance also
increases the risk of colitis and colitis-associated carci-
nogenesis in a murine model (Couturier-Maillard et al.,
2013). Different studies have also linked certain CD
associated mutations in the NOD2 gene with decreased
expression of antimicrobial peptides from Paneth cells in
patients with ileal CD (Zasloff, 2002; Wehkamp et al.,
2005). However, whether these changes in the microbial
community are cause or consequence for the develop-
ment of IBD is still under debate.
To further improve our understanding of how the gut
microbiome contributes to the development of CD, we
analysed the mucosa-attached intestinal microbiota from
biopsies obtained during routine colonoscopies of CD
patients using high resolution 16S rRNA gene amplicon
sequencing. In contrast to previous studies, we analysed
the samples with respect to the disease activity, as
assessed by the Crohn’s disease activity index (CDAI) in
CD (Best et al., 1976). Our results show coherence of
the bacterial community with the different CDAI catego-
ries, the use of a tumour necrosis factor (TNF)-a inhibi-
tor and the local mucosal inflammation.
Impact of the disease activity in CD to the bacterial
community
Colonoscopy of 26 CD patients was performed for a clin-
ical indication and biopsies were taken from macroscopi-
cally healthy and if present also from inflamed mucosa
(Table 1 and Table S1). A total of 54 biopsy samples
were PCR amplified and sequenced using Illumina
MiSeq that resulted in 17.5 million reads (80% of the
sequences and index reads with a Q-score 30). The
sequences were assembled using QIIME (Caporaso
et al., 2011) and investigated by the SILVA NGS pipeline
(Quast et al., 2013). SILVA_NGS quality control and
clustering resulted in 5 101 365 assembled sequences
that were assigned to 558 operational taxonomic units
(OTUs) on the bacterial genera level and used for the
further analysis.
We characterized the disease activity of our cohort
using the CDAI (Best et al., 1976) and made a stratifica-
tion into mildly active (CDAI 0–150), moderately active
(CDAI 151–220) and severely active disease (CDAI
221–450). In our cohort, we found no significant differ-
ence in the number of bacterial taxa in the different dis-
ease activity categories (Kruskal–Wallis test p>0.05)
(Fig. 1). Previous studies found a lower microbial diver-
sity in IBD patients compared to healthy controls (Ott
et al., 2004; Manichanh et al., 2006; Frank et al., 2007;
Willing et al., 2010; Tong et al., 2013). However, these
studies compared healthy mucosal biopsies to inflamed,
whereas our study rather focused on the impact of the
microbial composition in different clinical situations.
The dominant bacterial phyla in the samples covering
almost half of the bacterial population samples were
Bacteroidetes (46%) followed by Firmicutes (15%) and
the classes Betaproteobacteria (18%) and Gammapro-
teobacteria (14%) (Fig. 2). Verrucomicrobia, Actinobac-
teria and Deinococcus-Thermus were only present in
single samples.
In contrast to previous studies (Eckburg et al., 2005;
Frank et al., 2007), we found Bacteroidetes to be
Table 1. Patient characteristics.
Crohn’s disease (CD)
Number of patients 26
Sex 11 male: 15 female
Age mean 41 (22–67)
Patients with AZA/6-MP 2
Patients with IFX/ADA 3
CDAI 0–150 n518
CDAI 151–220 n518
CDAI 221–450 n518
CDAI mean 185.6 (38–332)
Number of biopsies 54
Number of biopsies from macroscopically
inflamed mucosa
17
Number of biopsies from macroscopically
healthy mucosa
37
Number of patients with NOD2 mutations 4
26 CD patients were recruited from the University Medical Center
Rostock, Germany and in total 54 biopsies analysed. Additionally,
an ethylenediaminetetraacetic acid blood sample was drawn for
analysis of mutations in the NOD2 gene. The disease activity was
assessed using the CDAI (Best et al., 1976) and stratified into three
categories: remission (CDAI< 150); moderate (CDAI 150–220) and
highly active disease (CDAI 220–450). Three patients were treated
with a TNF-a inhibitor (Infliximab, IFX/Adalimumab, ADA). Twenty-
four of twenty-six patients were genotyped for the three major
NOD2 mutations (SNP 8, SNP 12 and SNP 13). Two patients did
not give informed consent for genotyping. Four of twenty-four
patients (16.7%) were positive for at least one mutation in the
NOD2 gene. The study was approved by the ethic board of the Uni-
versity of Rostock (A 2012-0121). Written informed consent was
obtained from each participant prior to enrollment.
AZA, Azathioprine; 6-MP, 6-mercaptopurine; IFX, infliximab; ADA,
adalimumab; CDAI, Crohn’s disease activity index; NOD2,
nucleotide-binding oligomerization domain-containing protein 2.
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dominant over Firmicutes. However, the study of Frank
et al. (2007) in IBD also showed a reduction of Firmi-
cutes and an expansion of Proteobacteria in line with
our findings. Moreover, DNA extraction can bias the
recovery of Bacteroidetes strongly (Momozawa et al.,
2011). For example, the DNA stool kit, which was also
used in this study, leads to a lower yield of Firmicutes
compared to other extraction methods (Wu et al., 2010).
The samples between the CDAI categories 0–150 and
151–220 were relatively similar. However, a major differ-
ence was found between the mucosa-attached microbial
communities of the CDAI group 221–450 compared to
the other CDAI groups. An exception was patient P10 in
the CDAI category 221–450. The mucosa-attached bac-
terial community of this specific patient was similar to
the CDAI category 0–150. Interestingly, this patient
received a TNF blocker. Other exceptions were patients
P6, P19 (both category 0–150) and P21 (category
151–220). Their bacterial communities were more simi-
lar to the CDAI category 221–450.
To assess the differences in the microbial commun-
ities according to the disease activity, we visualized the
dissimilarities of the bacterial composition on bacterial
genus levels using non-metric multidimensional scaling
(NMDS) (Fig. 3). Bacterial communities clearly sepa-
rated on the first coordinate, depending on whether they
were obtained from patients with a low or high CDAI. In
addition we tested the differences of the mucosa-
attached bacterial communities in the different CDAI
categories, in a one-way PERMANOVA test using
Bray–Curtis dissimilarity index. The bacterial community
composition between the disease activity (CDAI) catego-
ries was significantly different (p< 0.01). This result
suggests coherence between the bacterial composition
and the disease activity, indicating that the bacterial com-
position in a state of remission differs significantly com-
pared to the bacterial composition in highly active CD.
Specific abundant bacteria in the different disease
activity groups
From a clinical point of view it would be of major interest
to identify specific bacterial strains which are representa-
tives of a certain disease activity group. In order to eluci-
date this question, we further characterized alterations
in the bacterial communities using LEfSe (Segata et al.,
2011). Since the separation between CDAI categories
was highly significant (Table S2), we arranged the data
according to the CDAI categories. LEfSe first compares
the data using a non-parametric test (Kruskal–Wallis
with alpha5 0.05). The results are then compared
between the categories with a Wilcoxon rank test
(alpha50.05). Subsequently, significant different fea-
tures are compared with linear discriminant analysis
(logarithmic score 2.0) to assign OTUs with significant
higher abundance in a CDAI category.
Among the high abundant bacteria (> 0.1% in aver-
age) identified in the biopsies from patients in clinical
remission were Anaerostipes (Clostridia) and an uncul-
tured Coriobacteriaceae (Actinobacteria). Bifidobacteria
were also significantly enriched but low in abundance. In
the category CDAI 151–220, we detected a relatively
high number of Lachnospiraceae (Firmicutes) among
which were Roseburia, Blautia, Pseudobutyrivibrio and
other ‘uncultured Lachnospiraceae’. In addition, we
found other Firmicutes (Megasphera, Flavonifractor, Veil-
lonella, ‘uncultured Erysipelotrichaeae’) and Haemophi-
lus (Gammaproteobacteria). However, the most
abundant bacterium in this group was assigned to the
genus Bacteroides (Bacteroidetes) which had very high
abundances in some samples. The highest CDAI cate-
gory was dominated by Burkholderiales (Betaproteobac-
teria) belonging to the genera Pelobacter, Paucibacter,
Aquabacterium, Acitovorax and Ralstonia. Among the
highly abundant bacteria were also Flavobacterium, Bre-
vundimonas and Sphingomonas. Among the Lachnospir-
aceae we detected only Coprococcus.
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Fig. 1. Boxplots showing the number of bacterial taxa in Crohn’s dis-
ease in the different disease activity categories.The biopsy speci-
mens were collected in ATL buffer (Qiagen, Hilden, Germany) and
frozen at 2808C immediately. Tissue samples were homogenized
with the Tissue Disruptor (Qiagen, Hilden, Germany) and DNA isola-
tion was performed with the DNA stool extraction kit (Qiagen, Hilden,
Germany). Samples were PCR amplified and processed according
to the Illumina protocol using a 500 cycle V2 chemistry kit on an Illu-
mina MiSeq machine. We used the QIIME (Caporaso et al., 2011)
‘joins paired-end Illumina reads’ function with default settings to
merge forward and reverse sequence with an overlap of at least 20
bp whereas sequences without overlap were discharged. The result-
ing assembled sequences were analysed using Silva_NGS (SILVA
release version 115) with default settings (ambiguity and homopoly-
mers 2%, OTU clustering 98%, min seq. quality 30%, min length
150 bp, min align. Identity 50%). For richness estimations, we used
Explicet (Robertson et al., 2013), which performed a rarefaction-
based analysis through bootstrapping.
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Since IBD can be in remission and also flare, the bac-
teria in the highest CDAI category could potentially
serve as predictors for a more severe disease course
and therefore serve as bacterial markers for upcoming
disease flares or may even be pathophysiologically
related to the disease activity. As a consequence, one
can hypothesize that restoring the microbial community
in highly active IBD patients back to a ‘non-inflamed’
microbial community could also lead to a reduction of
the disease activity. However, it is still not completely
understood if the changes in the microbial community
lead to the inflammation in IBD or if the mucosal
inflammation triggers the changes in the microbial
composition.
In our cohort, the abundance of F. prausnitzii (Firmi-
cutes) did not change significantly in the different CDAI
categories. A diminished abundance of F. prausnitzii has
been associated with IBD (Swidsinski et al., 2002; Sokol
et al., 2008; 2009). F. prausnitzii seems to have anti-
inflammatory capacities in vitro as well as and in vivo
(Sokol et al., 2008). In our study the bacterial genera,
Blautia and Roseburia, had a high abundance in the
mildly active CD cohort (CDAI 151–220). Both, Rosebu-
ria hominis and F. prausnitzii are butyrate-producing
strains (Machiels et al., 2014), which might play an
important role in the regulation of Treg cell homeostasis
in the colon (Smith et al., 2013). In a study with UC
patients (Machiels et al., 2014), a decrease of R. hominis
P3_H
P4_H
P5_H
P10_I*
P11_I*
P12_HB*
P8_I*
P9_H*
P6_IB
P7_HB
P13_H
P14_H
P16_H*
P17_H*
P18_H*
P1_H
P2_H
P15_H
P19_HB
P20_HB
P28_HB
P29_HB
P30_H
P31_I
P24_H
P25_H
P32_I
P33_H
P34_H
P35_I
P36_I
P26_H
P27_I
P21_H
P22_H
P23_H
P45_H
P46_I
P47_I
P39_I
P40_H
P50_H
P51_I
P48_H
P49_H
P43_IB
P44_HB
P37_H*
P38_H*
P52_H
P53_I
P54_I
P41_H
P42_I
0 10 20 30 40 50 60 70 80 90
Bacteroidetes/Bacteroides
Betaproteobacteria/Pelomonas
Bacteroidetes/Flavobacterium
Gammaproteobacteria/Escherichia
Firmicutes/Lachnospiraceae/uncultured
Betaproteobacteria/Sutterella
Gammaproteobacteria/Pseudomonas
Bacteroidetes/Prevotella
Firmicutes/Faecalibacterium
Bacteroidetes/Parabacteroides
Bacteroidetes/Pedobacter
Firmicutes/Lachnospiraceae/uncultured
Gammaproteobacteria/Stenotrophomonas
Bacteroidetes/Barnesiella
Firmicutes/Clostridium
Firmicutes/Enterococcus
Firmicutes/Ruminococcaceae/uncultured
Firmicutes/Roseburia
Alphaproteobacteria/Brevundimonas
Bacteroidetes/Alistipes
C
D
A
I 
0
 -
 1
5
0
C
D
A
I 
1
5
1
 -
 2
2
0
C
D
A
I 
2
2
1
 -
 2
8
4
Fig. 2. Bacterial composition in patients with CD. The disease activity was assessed via CDAI. H5 healthy; I5 inflamed; B5Application of a
tumour necrosis factor -a (TNF-a blocker; * Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene mutation.
CDAI with the bacterial community 617
VC 2016 Society for Applied Microbiology and JohnWiley & Sons Ltd, Environmental Microbiology Reports, 8, 614–621
and F. prausnitzii was inversely correlated with the dis-
ease activity. Willing et al. (2010) found a decrease of
Roseburia in ileal CD compared to healthy controls. Fur-
ther, another study described an association of a dimin-
ished abundance of Blautia and Roseburia in patients
with UC before colectomy with an increased risk of pou-
chitis after ileal pouch-anal pouch anastomosis (Machiels
et al., 2015). It remains speculative if these bacteria have
anti-inflammatory capacities and are therefore more prev-
alent in the mildly active CD group because of the inflam-
mation and potentially could also be beneficial in patients
with a highly active disease. A murine model would be
needed in order to test this hypothesis.
Coherence between different clinical characteristics
and the mucosa-attached bacterial communities
In addition to the disease activity (CDAI), we measured
a possible coherence between the mucosa-attached
microbial communities and the use of a TNF-a inhibitor,
the inflammation status of the biopsy and the presence
of a mutation in the NOD2 gene. Again, the differences
of the mucosa-attached bacterial communities compared
to the above mentioned parameters were tested using a
one-way PERMANOVA.
Tumour necrosis factor-a
The parallel direction and length of the vectors for the
CDAI and the use of a TNF-a inhibitor to the first coordi-
nate indicate a strong opposing impact of these factors
to the separation of the bacterial communities. In a pro-
spective study, dysbiosis, defined as a reduction in Bac-
teroides, F. prausnitzii and Clostridium coccoides, was
associated with relapse after discontinuation of inflixi-
mab therapy (Rajca et al., 2014). In other studies with
CD and UC patients in remission and subsequent exac-
erbations of their disease, the use of thiopurines was
associated with a specific microbial composition and
diversity of the fecal samples (Wills et al., 2014). In our
study, patients with CD showed a significantly different
bacterial community composition when TNF-a inhibitors
were applied (p5 0.02). Moreover, the opposite direction
of the disease activity (CDAI) and the use of a TNF-a
inhibitor in the NMDS plot (Fig. 3) suggest a positive
effect of this treatment on the bacterial community com-
position. One can hypothesize that this specific therapy
could reverse the microbiota to the typical composition
of remission. However, the low sample size in the group
of patients treated with a TNF-a inhibitor makes it diffi-
cult to draw firm conclusions.
Inflammation status
The natural course of IBD includes poorly predictable
phases of activity and remission (Baumgart, 2009;
Cosnes et al., 2011). If the composition of the gut micro-
biota is associated with intestinal inflammation, a better
understanding of the imbalanced microbiota in the
inflamed lesions and the macroscopically healthy parts
of the gut could also result in better surveillance meth-
ods or even new therapeutic approaches, e.g. a specific
probiotic therapy. In our cohort, the bacterial commun-
ities detected in macroscopically healthy and macro-
scopically inflamed mucosa were small but significant
(p5 0.03). Our results therefore suggest that the impact
of the disease activity (CDAI) on the mucosa-attached
bacterial community is stronger than the local inflamma-
tion status.
NOD2 gene
A study by Rehman et al. (2011) showed that NOD2
plays an important role in the intestinal microbial compo-
sition and that certain mutations are associated with a
distinct intestinal microbial profile suggesting that the
genetic composition of the host modifies its microbiome.
In our study, there was a non-significant trend between
the presence of mutations in the NOD2 gene and the
bacterial composition (p5 0.12). There are different
potential explanations for this result. In contrast to the
study of Rehman et al. (2011), which had a very distinct
group of patients homozygous for SNP13, our analysis
also included patients with SNP8 and SNP12, which
potentially do not have the same clinical impact on the
CDAI
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Fig. 3. NMDS-based on Bray–Curtis dissimilarity of the mucosa-
attached bacterial community from CD patients (NMDS stress
0.11).The plot covers a total of 54 probes from CD patients
whereas () represent biopsies from patients with a CDAI of 0–
150, () represent biopsies with a CDAI of 151–220 and (1) repre-
sent biopsies with a CDAI 221–450. The vectors for CDAI and
TNF-a inhibitor were added post hoc and represent the correlation
coefficients between these factors and the NMDS scores. Variations
in the bacterial community structure were characterized using
NMDS with Bray–Curtis dissimilarity using the PAST software pack-
age version 3.08 (Hammer et al., 2001).
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pathogenesis of CD compared to SNP13 (Hampe et al.,
2001; Hugot et al., 2001). Another potential explanation
for this result is that the NOD2 receptor seems to play a
more pronounced role in the ileum of patients with CD
(Wehkamp et al., 2004; 2005) whereas we used only
biopsies from colonic mucosa. Additionally, this non-
significant trend may also be attributed to the small
absolute number of NOD2 mutated patients in our
cohort and their uneven distribution to the different cate-
gories. To further elucidate the impact of NOD2 on the
inflammation and the bacterial community, a higher num-
ber of patients with NOD2 mutations may be needed
and also non-IBD patients with NOD2 mutations should
be screened towards their bacterial composition. How-
ever, such a study cohort will be difficult to obtain.
This is the first study which describes a clear coher-
ence between changes in the bacterial community in CD
and the disease activity (CDAI). In summary, we find a
correlation of the mucosa-attached bacterial community
with the disease activity. In future, these results might
also be used as a diagnostic tool in defining the dis-
ease’s course and could also serve as targets in evolv-
ing new treatment strategies in IBD.
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Background & aims: Short bowel syndrome (SBS) and intestinal failure (IF) are multi-factorial conditions
which in adults result from extensive intestinal resection. NOD2 is an intracellular pattern recognition
receptor associated with CD. An unexpected high frequency of NOD2 mutations has been found in
patients undergoing intestinal transplantation (35%). The role of NOD2 in a cohort with SBS/IF not
specifically requiring intestinal transplantation has not been studied yet.
Methods: The course of 85 patients with non-malignant SBS/IF was characterized. The major NOD2
mutations, as well as ATG16L1 and IL23R were determined. The allele frequencies were compared to the
published frequencies of CD patients and controls.
Results: In non-CD patients (72%) allele frequencies of NOD2 mutations were statistically more frequent
than in controls (14% vs 6%, p¼ 0.006). In CD patients (28%) allele frequencies were not different between
SBS and controls (29% vs 22%, p ¼ 0.23). NOD2 mutations were neither associated with parameters
potentially heralding the need for transplantation nor with an earlier time to the indication for intestinal
transplantation.
Conclusions: NOD2 mutations are associated with the development of SBS/IF in the absence of CD, but not
with specific complications. NOD2 mutations may increase the risk for more extensive intestinal
resection or may impair intestinal adaptation.
 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
1. Introduction
Short bowel syndrome is a chronic condition secondary to
extensive resection of small intestine. The most frequent underly-
ing non-malignant diseases in adults are Crohn’s disease, mesen-
teric ischemia, ileus or (post) surgical complications, trauma and
desmoid tumors of themesentery. Treatment consists of either long
term special diet plus medical treatment including high dose
anti-motility agents, bile acid binders and electrolyte as well as
micronutrient substitutions or home parenteral nutrition (HPN).
Intestinal transplantation becomes a treatment option, if HPN fails
because of intestinal failure associated liver disease (IFALD),
thrombosis of central veins used for catheter insertion or frequent
line related sepsis.1,2
Nucleotide-binding oligomerization domain-containing protein
2 (NOD2) is an intracellular pattern recognition receptor that
senses muramyl dipeptide and peptidoglykan from bacterial cell
walls and subsequently activates NFkB.3 Mutations in the NOD2
gene have been identified as risk factors for the development of
Crohn’s disease (CD).4e6 In a healthy British/German cohort the
allele frequency of the NOD2 mutations, R702W, G908R and
3020insC, also known as SNP8, SNP 12 and SNP 13, were 3.5, 0.6 and
2.1%,7 conferring an increased risk for Crohn’s disease of 2e4 fold in
the heterozygous state and of up to 17 fold in the homozygous or
compound heterozygous state.8 Besides NOD2, other risk alleles for
Crohn’s disease are described in the literature, for example
autophagy-related protein 16 L1 (ATG16L1) or mutations in the
Interleukin-23 receptor (IL-23R).9,10
Abbreviations: SBS, short bowel syndrome; IF, intestinal failure; IFALD, intestinal
failure associated liver disease; CD, Crohn’s disease; HPN, home parenteral
nutrition.
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Acute cellular rejection after intestinal transplantation shares
some histological and more so macroscopic-endoscopic features
with acute Crohn’s disease. This has led Fishbein to study the fre-
quency of NOD2 mutations in intestinal and multivisceral trans-
plant recipients.11 12 of 34 intestinal failure patients undergoing
transplantation carried at least one such mutation. Interestingly
only three of these patients had CD, two of which had a NOD2
mutation. In their study, which addressed the post-transplantation
outcome, NOD2mutations were a risk factor for rejection and were
accompanied by decreased secretion of defensins, which are
stimulated by NOD2 signaling. These findings were not replicated
in the study by Janse, who found no difference in NOD2 mutations
between intestinal transplant recipients and donors.12 On the other
hand, the study by Ningappa, which was focused but not limited to
children, detected a strong association of the frame shift mutation
(3020insC/SNP13) with combined liver and intestinal failure
requiring combined transplantation.13
Both Fishbein and Ningappa have pointed out, that their cohorts
represent intestinal failure patients with the need for trans-
plantation, and that a study in patients without or prior to the need
for transplantation would shed light on why NOD2 mutations
appear to be related to complicated intestinal failure and a prob-
lematic posttransplant course.11,13 Thereforewe have studied NOD2
mutations and the clinical course of 85 adult patients in our in-
testinal failure program, which includes long term conservative
management (oral and parenteral nutrition), rehabilitative surgery
and both intestinal and combined transplantation. Here we report,
that in non-CD patients NOD2 mutations are associated with the
development of IF but not specifically with the need for intestinal
or multivisceral transplantation. Pathophysiologically, NOD2 mu-
tations may impair the physical and/or immunological intestinal
barrier function and thereby increase the risk for perioperative
complications leading to more extensive resection and/or
compromise intestinal adaptation.
2. Materials and methods
The study was approved by the Ethics committee of the uni-
versity hospital of the University of Tübingen (022/2011BO2). All
patients gave written informed consent (separately for the study
and for the genotyping).
2.1. Patient cohort
All patients were Caucasian adults of northern European
ancestry and fulfilled the definition of short bowel syndrome or
intestinal failure.14 16 patients had never been on long term (>4
weeks) HPN, but required intensive dietary measures to maintain
oral compensation (special diet, >5 meals per day, high dose
antidiarrheal medication); these patients are referred to as short
bowel syndrome (SBS). All other patients (69 of 85) fulfilled the
definition of intestinal failure requiring HPN.14 Of these 9 were
weaned from HPN. The beginning of SBS/IF was defined as the time
point when specific nutritional intervention became necessary for
the first time. Index surgery was defined as the surgical interven-
tion, which led to the need for specific nutritional intervention. 2
patients had intestinal failure that occurred at childhood (age 0e
10). 2 patients had an underlying malignancy that had lead to in-
testinal failure. They did not receive antineoplastic therapy but
were only treated to maintain their nutritional status. Both died
1673 and 460 days after intestinal failure had ensued. None of the
patients received or had received growth hormone, epidermal
growth factor, teduglutide, somatostatin/octreotide or a
dipeptidylpeptidase-IV-inhibitor. Data were analyzed as of May
31st 2011.
2.2. Definition of HPN related complications and the need for
intestinal or multivisceral transplantation
Central vein thrombosis was detected by Doppler, contrast
enhanced CT scan or contrast enhanced MRI, which were initiated
upon clinical suspicion or prior to insertion of a new central cath-
eter. All other data were extracted from clinical files and from
personal interview.
The indication for intestinal transplantation was defined as the
failure of HPN because of impending loss of venous access
(thrombosis of 2 or more central veins) or the development of
IFALD as judged by a persistently elevated bilirubin of >2 mg/dl
despite attempts to optimize the composition of the parenteral
nutrition. Need for multivisceral transplantation including the liver
was defined, if the bilirubin was persistently elevated above 4 mg/
dl. Recurrent sepsis per se was not defined as an indication.
2.3. Mutation detection
The three CD-associated mutations in the NOD2 gene (SNP 8;
R702W,NCBI reference SNP ID: rs2066844 and SNP 12; G908R, NCBI
reference SNP ID: rs2066845 and 3020insC, SNP 13; 1007fs, NCBI
reference SNP ID: rs2066847) were detected in genomic DNA
extracted from whole blood as described by Fishbein et al. with
minor modifications.11 Briefly DNAwas extracted fromwhole blood
collected in EDTA-anticoagulated tubes using the QIAampDNAMini
kit according to the manufacturer’s protocol (Qiagen, Hilden, Ger-
many). The Taqman MGB biallelic discrimination assay was applied
using the two pre-made assays c_ _ 11717468_20 and c_
_11717466_20 for the R702W and the G908R point mutations in
NOD2 as well as a custom developed assay for the 1007 frame shift
mutation (forward primer, GTCCAATAACTGCATCACCTACCT; reverse
primer, CAGACTTCCAGGATGGTGTCATTC and VIC-labeled probe,
CAGGCCCCTTGAAAG; FAM-labeled probe, CAGGCCCTTGAAAG).
The ATG16L1 SNP (rs 2241880) and IL23R SNP (rs1004189) were
detected using the two pre-made biallelic discrimination assays c_
_9095577_20 for ATG16L1 and c_ _1272321_10 for IL23R (Applied
Biosystems).
Briefly, 50 ng of genomic DNA was mixed with 10 ml of
2  TaqMan Universal PCR Master Mix No AmpErase UNG and 1 ml
of 20  SNP Genotyping Assay in a final volume of 20 ml, and PCR
was carried out on an ABI Prism 7000 Real Time PCR instrument
(Applied Biosystems, Foster City, CA). Thermal cycling conditions
were: 95 C/10 min followed by 40 cycles of 92 C/15 s and 60 C/
60 s. Detection of fluorescent signal was performed according to the
recommended protocols for the ABI Prism 7000 Real Time PCR
machine (Applied Biosystems, Foster City, California, USA), and the
results were analyzed by the associated Sequence Detection System
(SDS) Software V. 1.2.3. (Applied Biosystems).
2.4. Statistical analysis
Statistical analysis was performed using JMP 9 (SAS, Cary, NC).
Allele frequencies of NOD2 mutations were calculated by dividing
the sum of mutated alleles by the sum of chromosomes analyzed.
Differences in the proportions were tested using the chi-squared
test. Continuous data such as the rate of both line related sepsis
and thrombosis of central veins were compared using the unpaired
two-sided t test. Residual intestinal length and duration of HPN
were positively skew; they were therefore log-transformed prior to
using the t-test. These data are presented as geometric means and
95% lower and upper confidence intervals. Survival rates were
estimated by the KaplaneMeier method, and the log rank test was
used to test the difference between survival curves. Frequencies of
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line related sepsis and thrombosis of central veins were compared
using the student’s t-test.
3. Results
3.1. Study cohort
Figure 1 summarizes the cohort of 85 patients. Given the
known association of CD with NOD2 mutations and given the fact
that in the adult population CD is among the most frequent causes
of SBS and IF,1,2 patients with a history of CD were analyzed
separately. The median follow up since the diagnosis of SBS/IF was
1354 days (95% CI 2012e3421 days) with no significant difference
between CD and non-CD patients. Figure 1A shows the current
status of CD and non-CD patients. 15 patients never received long
term HPN and are therefore referred to as orally compensated SBS.
9 patients were weaned from PN after a median of 471 days (range
183e1197 days). Among the transplanted patients twowith CD lost
their graft. Patients suffering from CD were significantly younger at
their diagnosis of CD than those with another etiology (22.8  10.9
vs. 47.1  20.6 years; p < 0.0001). In CD patients it took 19.9  12.4
years after their initial diagnosis of CD until they developed SBS/IF;
this reflects recurrent resection(s). None of the CD patients had a
gastroenterostomy and none had a bypassed segment. In com-
parison, non-CD patients were not only significantly older at
diagnosis but also their SBS/IF was mostly established in one
operation and thus it took only 2.3  5.7 years after their initial
diagnosis to develop IF (Fig. 1B). Residual small intestinal length
was significantly shorter in non-CD patients than in CD patients
(Fig. 1C). In addition in the non-CD group ultra short bowel with
less than 20 cm small intestine was more frequent (13 of 49 non-
CD vs. 1 of 23 CD patients with known residual small intestinal
length, p < 0.001). The duration of parenteral support was 895.5
days, not significantly different between CD and non-CD patients
(Fig. 1D).
3.2. Survival and need for transplantation in CD and non-CD
patients receiving PN
Figure 2 shows overall survival (panel A) and survival without
transplantation (panel B) of CD and non-CD patients with IF. The
analysis was limited to the 69 patients receiving PN (20 CD and 49
non-CD) because they had IF and were thus theoretical candidates
for intestinal transplantation if their PN would have failed. Patients
who only transiently received PN were included because death
(due to PN related complications) occurred in some patients during
the time period when others, who were eventually weaned, still
received PN.
Death was limited to the non-CD group and mostly occurred
during the first 3 years of PN (p¼ 0.03 compared to the CD group by
Log-rank test, Fig. 2A). 5 patients were transplanted in the CD group
and 4 in the non-CD group. A trend towards an early (up to about
1500 days of HPN) worse prognosis of IF in non-CD patients became
also evident, when these transplantations, which were intended to
prevent death, were included in the survival analysis (Fig. 2B).f
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Fig. 1. Patient cohort. Patients with CD as the underlying etiology of SBS/IF are compared to other etiologies (non-CD). A: Current status (two CD patients who lost their graft and
went back to PN are included in the Tx group, see text for details). B: Age at diagnosis and time to development of SBS/IF. C: Residual small intestinal length. D: Duration of
parenteral support (included are all patients with parenteral support, see text for details).
f The two patients who lost their grafts and went back to PN (see Table 2) are
depicted as transplanted in Fig. 2B. This trend is not reflected in the statistical
analysis because the statistical analysis addressed the entire time frame of up to
6500 and 8300 days respectively.
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Taken together the data of Fig. 2 confirm the better early (up to
about 5 years) outcome of CD patients on HPN compared to non-CD
patients,15 but they also indicate that the need for intestinal or
multivisceral transplantation does occur in some CD patients with
IF and long standing HPN.
3.3. NOD2 mutations are unusually frequent in intestinal failure
Because of the association of three NOD2 mutations (R702W,
G908R and 3020insC) with CD as well as with IF requiring trans-
plantation11,13 we tested our cohort of SBS/IF for the allele fre-
quency of these mutations. 70 of 85 patients were genotyped (24
CD and 46 non-CD). 3 patients died before genotyping was initiated
and thus no DNA and no approval for typing could be obtained. 12
patients did not give informed consent for genotyping. Taking into
account the comparably small numbers there were no discernable
differences in the clinical course between patients that were gen-
otyped and those who were not. Allele frequencies of NOD2 mu-
tations of the CD patients with SBS/IF were compared to published
frequencies of Caucasian CD patients of north European ancestry
and allele frequencies of NOD2 mutations of the non-CD patients
were compared to the published frequencies of healthy Caucasian
controls7 (Table 1). In non-CD patients with SBS/IF the allele fre-
quency of NOD2mutations was significantly higher than in healthy
controls (14% vs. 6%, p ¼ 0.006). In CD patients with SBS/IF the
NOD2 allele frequency was somewhat higher than in the CD control
cohort, but the difference was not significant (29% vs. 22%,
p ¼ 0.23). It was not possible to formally stratify the CD patients
into ileal, ileocolonic and colonic disease, because many of these
patients had been operated before that classification became
widely used or operations were performed for secondary compli-
cations not attributable to either of these disease manifestations.
But given that all the CD patients had undergone significant
resection of their small intestine it can be assumed that they all had
either ileal or ileocolonic disease. In this subgroup of CD the allele
frequency of NOD2 mutations is higher than in the entire CD
population (19.7% and 26.9%,7). Thus there is probably no or only a
minor difference between CD patients with or without SBS/IF with
regard to NOD2mutations. All together 22 of 70 genotyped patients
(31%) carried al least one NOD2 mutation.
Table 2 summarizes the etiology of SBS/IF of the non-CD patients
and their NOD2 mutational status in order to correlate NOD2 mu-
tations to a specific etiology. There was a non-significant trend for a
higher allele frequency in the ischemia group compared to the
other non-CD etiologies (20% vs 8.3%, p ¼ 0.095).
3.4. NOD2 mutations in patients with an indication for intestinal
transplantation
Table 3 summarizes the 16 of 69 patients with IF and an indi-
cation for intestinal, combined or multivisceral transplantation
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Fig. 2. Survival and transplantation of CD and non-CD patients. A: Overall survival. B: Survival without transplantation, i.e. combination of spontaneous survival and transplantation
(to prevent death) as undesirable outcomes of if. n ¼ 69.
Table 1
Allele frequencies NOD2 mutations in SBS/IF patients 70 of 85 SBS/IF patients were
genotyped (24 CD and 46 non-CD). Frequencies of NOD2 mutations of the CD pa-
tients with SBS/IF were compared by X2 test to published frequencies of Caucasian
CD patients of north European ancestry and allele frequencies of NOD2 mutations of
the non-CD patients were compared to the published allele frequencies of healthy
Caucasian controls.6 31% of all genotyped patients carried at least one NOD2 mu-
tation (50% of CD and 22% of non-CD patients).
Etiology Allele frequencies of NOD2
mutations (wt/hetero/homo or
compound-hetero)
p
SBS/IF Control
CD
(24 of 24 genotyped)
29% (12/10/2) 22% (442/191/55) p ¼ 0.006 by X2 test
Non-CD
(46 of 61 genotyped)
14% (36/7/3) 6% (256/34/0) P ¼ 0.23 by X2 test
Table 2
Etiologies of short bowel syndrome/intestinal failure in the study cohort and NOD2
mutational status. In the non-CD patients with ischemia as the underlying etiology
the NOD2 allele frequency appears to be higher than in the other etiologies of non-
CD patients, but the difference is not statistically significant (p ¼ 0.095).
Etiology n NOD2 wt NOD-2 mutation
(hetero/homo or compound)
Unknown
CD 24 12 12 (10/2) 0
Non-CD 61 36 10 (7/3) 15
Ischemia 29 15 7 5/2 7
Surgical complication 10 8 1 1/0 1
Ileus 6 4 0 2
Trauma 4 3 0 1
Other 12 6 2 1/1 4
All 85 48 22 (17/5) 15
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based on HPN failure. Overall IFALD was the most frequent indi-
cation, followed by central vein thrombosis (2 central veins) and
recurrent sepsis. Of the 9 transplantations performed 5 were for
IFALD. 2 patients died on the waiting list as a result of IFALD, both
early after the start of the transplantation program in 2006. The
NOD2 mutational status was available in 13 of these 16 patients. 5
of the 13 patients (38%) carried at least one NOD2 mutation. This
number remarkably resembles the 31% patients with at least one
NOD2 mutation in the entire cohort. Also, the time until individual
patients developed an indication for intestinal or multivisceral
transplantation was not different whether they carried a NOD2
mutation or not (NOD2 wild type 1188 days, 95% CI 245e4869 days
and NOD2mutation 1025, 95% CI 744e10409 days; p¼ 0.34 by Log-
rank test).
Because of the low absolute number of transplanted patients in
our cohort we tested whether clinical parameters that may herald
the need for transplantation were associated with the carriage of
NOD2 mutations. To this end persistently elevated levels of bili-
rubin (>1 mg/dl), the frequency of central line related sepsis and
the frequency of thrombosis of central veins were analyzed, but no
such association became evident (Table 4).
3.5. SNPs in ATG16L1 and IL23R are not associated with SBS/IF
In order to test whether the association of NOD2mutations with
SBS/IF was specific, we tested single nucleotide polymorphisms
(SNPs) of two other CD susceptibility genes, ATG16L1 (rs 2241880)
and IL23R (rs1004189). The association of ATG16L1 and NOD2 is
still controversial,9,16 while IL23R and NOD2 are thought to act
independently in the pathophysiology of CD. There was a non-
significant trend in the ATG16L1 rs2241880 SNP towards higher
risk allele frequencies in the CD and non-CD SBS/IF cohorts (SBS/IF
CD 70.4% vs CD control 58.1%, p ¼ 0.21 and SBS/IF non-CD 53.8% vs
healthy control 51.3%, p ¼ 0.70). The risk allele frequencies of the
IL23R SNP (rs1004189) did not differ from those reported in the
literature for CD patients and non-CD healthy controls (SBS/IF CD
38.6% vs CD control 38.1%, p ¼ 0.99 and SBS/IF non-CD 21.2% vs
healthy control 29.6%, p ¼ 0.27).9,10
4. Discussion
Two groups have reported unexpected high frequencies of
NOD2 mutations (about 30%) in IF patients who undergo intestinal
or multivisceral transplantation because of failing HPN.11,13 The
question of the current study was, whether NOD2 mutations are
associated with SBS/IF in general or specifically with a complicated
course requiring transplantation. The data indicate that NOD2
mutations are associated with the development of intestinal failure
in the absence of Crohn’s disease but not specifically with the
development for the need for transplantation.
Prior to transplantation NOD2 mutations may in principle affect
the clinical course in three ways: (a) they may put the individual at
an increased risk in the context of the index surgery leading to an
increased loss of intestinal surface, (b) they may inhibit adaptation
of the residual bowel or (c) theymay be related to the development
of specific complications resulting in the need for transplantation.
In order to address these different potential mechanisms we gen-
otyped our SBS and IF patients and characterized their clinical
course.
Several aspects indicate that the current study addressed a valid
patient cohort: (a) A long enough observational period was covered
to include a subset of patients who develop or have developed the
need for transplantation. In a recent European prospective survey
28.6% of adult HPN patients with IF had died or had been trans-
planted after 5 years.2 In our cohort it was 23% (16/69) of patients
after a median follow up of 2.45 years (895.5 days). (b) 9 patients
were weaned of parenteral support mostly as a result of recon-
structive surgery putting unused intestinal segments in continuity.
These patients were included in the IF group because they were at
risk, although for a shorter period of time, to develop IF or HPN
related complications. Again these data match the 12.8% patients
weaned in the European survey.2 (c) The need for transplantation
was clearly defined as failure of HPN even if contraindications
existed that precluded transplantation, i.e. candidacy for trans-
plantation.17 Recurrent sepsis per se was not defined as an indica-
tion for transplantation because in our experience this can usually
be managed by medical treatment and change of the central line if
indicated.18 This approach to transplantation has also been
Table 3
Transplantation status of patients with if all 70 patients with HPN (61 permanent and 9 weaned) were analyzed for the need for intestinal or combined transplantation.
Status for Tx N CD/non-CD n Indication of Tx Type of Tx Outcome
Transplanted 9 CD 5 3 IFALD 1 Multivisceral 1 combined liver
and intestine 1 isolated intestine
3 Full oral autonomy
1 Central vein thrombosis 1 Isolated intestine Initially, full oral autonomy chronic
graft failure after 3.5 y graft enterectomy,
back on HPN by catheter in VCI
1 Recurrent sepsis 1 Isolated intestine plus kidney Acute rejection graft enterectomy
after 3 months, back on HPN, multiple
complications
Non-CD 4 2 IFALD 2 Multivisceral 2 Full oral autonomy
2 Central vein thrombosis 2 Isolated intestine 2 Full oral autonomy
Waiting list 2 CD 1 1 Central vein thrombosis
Non-CD 1 1 Central vein thrombosis
Died on waiting list 2 CD 0
Non-CD 2 2 IFALD
Candidacy
but contraindication
3 CD 2 1 Central vein thrombosis1 IFALD
Non-CD 1 1 IFALD 1 Dead secondary to IFALD
Table 4
Markers potentially heralding the need for intestinal transplantation A persistently
elevated bilirubin (>1 mg/dl), the frequency of line related sepsis and the frequency
of thrombosis of central veins (each per 1000 catheter days) were taken as pa-
rameters potentially heralding the need for transplantation.
NOD2
wild type
NOD2
mutated
Test p
Persistently elevated
bilirubin (>1 mg/dl) [n]
5 of 37 3 of 19 Fisher’s exact test 1.00
Line related sepsis/1000
catheter days
1.62 1.66 Student’s t-test 0.96
Thrombosis of central
veins/1000 catheter days
0.37 0.27 Student’s t-test 0.65
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validated in the European survey.2 (d) The cohort was stratified for
CD and non-CD as the underlying etiology because of the known
increased frequency of NOD2 mutations in CD patients.7 For the
non-CD patients it included a variety of different and typical un-
derlying etiologies.1 Thus, given the unknown association of NOD2
mutations with specific diseases other than CD, there was no bias
towards specific etiologies.
With regard to the role of NOD2 mutations our cohort includes
29% CD patients who in most series of adult intestinal failure
comprise about one third of patients requiring parenteral support2
but who are more rarely transplanted1 and who made up only a
small minority in the three studies addressing the role of NOD2
mutations in patients requiring intestinal or multivisceral trans-
plantation.11e13
In non-CD patients with IF we found a statistically significant
increased allele frequency of NOD2 mutations compared to
healthy controls of European ancestry. Furthermore in the limited
number of patients with an indication for transplantation (both CD
and non-CD) the rate of NOD2 mutations (5 of 13 patients with a
known NOD2 mutational status; 38%) appeared similar to the
entire cohort (22 of 70 patients with a known NOD2 mutational
status; 31%). Taken together these data suggest that NOD2 muta-
tions are associated with the development of SBS/IF after
abdominal surgery in non-CD patients, but not specifically with
the development of an indication for intestinal or combined/
multivisceral transplantation. This is further supported by the lack
of an association of the NOD2 mutational status with the time
until the development for an indication of transplantation or with
clinical markers potentially heralding the need for. While this
study was under review similar findings were reported from an
independent cohort.19
While NOD2 mutations apparently favor the development of
SBS/IF in non-CD patients, two other CD-related polymorphisms in
ATG16L1, which is part of the autophagy pathway, and in IL23R,
which is part of the adaptive immune system, were not associated
with the development of SBS/IF. This could be due to several rea-
sons: a) The risk allele frequency of ATG16L1 is much higher than
that of the NOD2 mutations. Thus, while there was a trend for a
higher than expected allele frequency, a true association of the
ATG16L1 polymorphism with the development of SBS/IF may have
remained undetected in the presence of this high background. b)
Along the autophagy pathway ATG16L1 acts down-stream of
NOD2.20,21 Thus any NOD2 related pathway may diverge from the
CD pathway without the involvement of ATG16L1. c) In the path-
ogenesis of CD, the IL23R polymorphism is thought to act inde-
pendent of NOD2. Thus the finding that the IL23R polymorphism
was unrelated to the development of SBS/IF indirectly supports the
specificity of the NOD2 association.
Our data confirm the notion, that NOD2 mutations affect the
pretransplant course of intestinal failure11,13 but extend this
finding to indicate that they are not associated with the specific
development for the need for transplantation. Thus NOD2 muta-
tions may affect the development of SBS/IF at two steps: They may
either pose the individual at an increased risk for complications in
the context of abdominal surgery or they may negatively affect the
process of adaptation. NOD2 is mainly expressed in Paneth cells in
the small intestine and in antigen presenting cells (monocytes,
macrophages and dendritic cells). It is a cytosolic pattern recog-
nition receptor for muramyl dipeptide (MDP) and peptidoglykan
(PGN), which are components of gram-positive and gram-negative
bacteria.3 The exact physiological role of NOD2 and the patho-
physiology resulting from its characteristic mutations are still
incompletely understood. At least five different hypotheses are
currently debated: 1) NOD2 is part of an inhibitory system, which
blocks the activation of NF-kappa-B after stimulation of TLR2. As a
consequence, NOD2 mutations lead to an exaggerated immune
response.22 2) An intact NOD2 signal leads to a polarization of the
adaptive immune response towards a Th2 type response, while a
defective NOD2 signal leads to an excessive Th1 response.23 3)
NOD2 mutations lead to a defective production of alpha-defensins
in Paneth cells24 thus favoring a change in the luminal microbiota
in the ileum. 4) Mutant NOD2 inhibits the expression of the anti-
inflammatory cytokine interleukin 10 (IL-10) by suppressing the
activity of heterogenous nuclear ribonucleoprotein A1.25 5) NOD2
mutations lead to a defect in the autophagy pathway resulting in
impaired bacterial handling and antigen presentation in dendritic
cells.20,21 In humans, NOD2 mutations are also linked to an
increased mortality in the setting of sepsis, bone marrow trans-
plantation and spontaneous bacterial peritonitis, suggesting a
critical impairment of the intestinal barrier function and the
handling of subsequent translocation of bacteria or components of
the bacterial wall.26e28 Thus patients carrying a NOD2 mutation in
these cohorts and IF patients without CD in our cohort may share
with CD patients a defect in their innate immunity and their
intestinalv barrier function with a higher risk for bacterial
translocation.
Adaptation after extensive intestinal resection is a multifactorial
but incompletely understood process29 and at present there is no
defined role for NOD2 or NOD2 mutations in it. Nevertheless
physical barrier function is a prerequisite for vectorial transport.30
To our knowledge the effect of NOD2 mutations on the physical
intestinal barrier function has not been addressed experimentally
but some evidence points to a possible role. IL-10 is required for
stabilization of the deranged intestinal barrier function in the
setting of total parenteral nutrition.31,32 Furthermore IL-10 pro-
duction depends on an intact NOD2 function at least under some
experimental conditions.25,33 Thus NOD2 mutations may lead to a
reduced IL-10 production and thus to a reduced epithelial barrier
function, which in turn short circuits transport and inhibits func-
tional adaptation.
In summary we present direct evidence that NOD2 mutations
are associated with the development of SBS/IF after intestinal
resection. Furthermore indirect evidence suggests that this is
linked to reduced physical and/or immune mediated intestinal
barrier function resulting in more extensive resection and/or
impaired capacity for intestinal adaptation of nutrient, electrolyte
and water absorption. If a much larger and very well characterized
cohort would be available to study there might be an approach to
relate the clinical course to the NOD2 mutational status and draw
conclusions regarding the role of NOD2 in the pathophysiology of
SBS/IF. Unfortunately neither such a cohort nor a scientific con-
sortium is available at present. Thus, elucidation of the role of NOD2
mutations in the pathophysiology of SBS/IF will require an animal
study.
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CASE REPORT Open Access
Two patients with intestinal failure requiring
home parenteral nutrition, a NOD2 mutation and
tuberculous lymphadenitis
Holger Schäffler1, Matthias Teufel2, Sabrina Fleischer2, Chih-Jen Hsieh3, Julia-Stefanie Frick4 and Georg Lamprecht1*
Abstract
Background: Mutations in the NOD2 gene are a significant risk factor to acquire intestinal failure requiring home
parenteral nutrition. Tuberculous lymphadenitis is the main manifestation of extrapulmonary tuberculosis. Defects
in the innate immunity, including NOD2 mutations, may increase the risk for acquiring infections caused by
M. tuberculosis. An association of intestinal failure, mutations in the NOD2 gene and tuberculous lymphadenitis
has not been described before.
Case presentation: We report of two patients with intestinal failure secondary to mesenteric ischemia. Both
patients presented with fever and weight loss while receiving long term home parenteral nutrition. Both of them
were found to have mutations in the NOD2 gene. Catheter related infections were ruled out. FDG-PET-CT scans
initially obtained in search for another infectious focus that would explain the symptoms unexpectedly showed
high FDG uptake in mediastinal lymph nodes. Direct or indirect evidence proved or was highly suggestive for
tuberculous lymphadenitis. Intravenous tuberculostatic therapy was started and led to a reversal of symptoms and
to resolution of the lesions by FDG-PET-CT.
Conclusion: Mutations in the NOD2 gene may put patients both at an increased risk for acquiring M. tuberculosis
infections as well as at an increased risk of intestinal failure after extensive intestinal resection. Thus we suggest to
specifically include reactivated and opportunistic infections in the differential diagnosis of suspected catheter
related infection in patients with intestinal failure who carry mutations in their NOD2 gene.
Keywords: NOD2, Intestinal failure, Tuberculous lymphadenitis, Catheter related blood stream infection
Background
Tuberculous lymphadenitis is the most frequent site of
extrapulmonary tuberculosis. About 20% of all TBC cases
in the US are extrapulmonary. From this group, about
40% are tuberculous lymphadentis [1]. Detection of M. tu-
berculosis is mainly via the innate immune system by
extracellular or intracellular pattern recognition receptors
(PRR) such as toll-like receptors (TLR) and nucleotide-
binding oligomerization domain receptors (NOD) [2-4].
Mutations in specific TLR genes were found to be associ-
ated with susceptibility to TBC [5,6].
Clinical relevance of mutations in the NOD2 gene
arises from their association with Crohn’s disease [7-10].
In 2001, a link between mutations in the NOD2 gene
and Crohn’s disease was first established independently
by two different groups [11,12]. However, the exact func-
tion of NOD2 is still under debate [13]. Besides Crohn’s
disease, other disease entities seem to be related to mu-
tations in the NOD2 gene like GvHD [14-16], acute
septicemia [17], spontaneous bacterial peritonitis in liver
cirrhosis [18,19] and worsened outcome after intestinal
transplantation [20]. Mutations in the NOD2 gene and
an increased susceptibility for infectious diseases have
been reported in the literature [21]. NOD2 is also
thought to be an important receptor in recognizing M.
tuberculosis, because on the one hand both the receptor
and the pathogen are intracellular and on the other hand
the cell wall of M. tuberculosis contains peptidoglycan,
which is one of the ligands of NOD2 [22]. However, the
role of NOD2 in tuberculous lymphadenitis has not been
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studied yet. To this end a recent study has described a
new SNP in the NOD2 gene as a possible risk factor for
pulmonary tuberculosis in the Chinese Han population
[23]. In another study it was reported that genes in the
NOD2 signaling pathway are associated with susceptibility
to infections withMycobacterium leprae in China [24].
Short bowel syndrome (SBS) and intestinal failure re-
quiring long term home parenteral nutrition (HPN) are
rare heterogeneous clinical conditions in which extensive
parts of the intestine have been removed surgically. The
main causes of short bowel syndrome in adults are
Crohn’s disease, intestinal ischemia, volvulus, ileus, des-
moid tumors and trauma [25]. Recently we have de-
scribed an increased frequency of NOD2 mutations in
SBS patients without underlying Crohn’s disease [26]. In-
fections associated with intestinal failure requiring home
parenteral nutrition are mainly catheter-related [27,28].
Here we describe two individuals with short bowel
syndrome, mutations in the NOD2 gene and tuberculous
lymphadenitis. This is a clinically important finding be-
cause in a HPN patient intermittent fever, the key symp-
tom of tuberculous lymphadenitis, usually indicates
catheter related blood stream infection. To our best
knowledge, this is the first case report linking these clin-
ical entities together.
Materials and methods
Genotyping of patients was performed as part of a larger
study in a cohort of short bowel patients, which was
approved by the Ethics Committee of the University of
Tuebingen (022/2011BO2). The patients gave written in-
formed consent. The three major mutations in the NOD2
gene (SNP 8; R702W, NCBI reference SNP ID: rs2066844
and SNP 12; G908R, NCBI reference SNP ID: rs2066845
and 3020insC, SNP 13; 1007 fs, NCBI reference SNP ID:
rs2066847) were detected in genomic DNA extracted from
whole blood as described previously [26].
Direct Nucleic Acid Amplification Test (NAAT) to de-
tect M. tuberculosis complex DNA was performed using
the ProbeTec ET DTB (DTB) (Becton-Dickinson). For
identification of Mycobacterium tuberculosis complex
species GenoType® MTBC (Hain) was used according to
manufacturer’s instructions. As gold standard culture
techniques using 2 solid and BACTEC™ MGIT™ 960 liquid
broth were applied. For direct susceptibility testing we used
the BACTEC™ MGIT™ 960. As interferon-gamma-release
assay we used the QuantiFERON-TB® Gold In-Tube test
(Cellestis) according to manufacturer’s instructions.
Case presentation
Patient 1
Patient 1 is a 44 year-old Caucasian woman with intes-
tinal failure. In 2008, she required surgical resection of
most of her small intestine (except for 70 cm of prox-
imal jejunum) and the right colon resulting in a duo-
denotransversostomy due to acute occlusion of her
superior mesenteric artery. Total parenteral nutrition
was initiated at the University of Tübingen intestinal
failure outpatient clinic. The initial clinical course was
dominated by numerous infectious complications, e.g.
recurrent line infections (05/2009, 04/2010, 02/2012), a
liver abscess and an episode of acute cholecystitis in the
absence of cholelithiasis, which was interpreted as an-
other ischemic episode in the splanchnic circulation
(Figure 1).
Despite an extensive workup (including ultrasound and
CT-scan) the etiology of the ischemic events could not be
determined. The diagnosis of Takayasu Arteriitis was enter-
tained because of diminished/absent peripheral pulses but
vasculitis was neither found by histology in the resected
specimens nor by PET-CT in the large vessels. Workup for
a coagulation disorder revealed a heterozygous prothrom-
bin mutation (G20210A). An antiphospholipid syndrome
was ruled out and the JAK2-mutation was also not de-
tected. A HIV test was negative.
Because of the severity of two acute episodes of arter-
ial occlusion the patient was maintained on low dose
steroids (Prednisolone 5 mg) and received long term
anticoagulation with enoxaparin (Clexane) and later fon-
daparinux (Arixtra). Under this regimen, the patient did
not develop another episode of intestinal or systemic ar-
terial ischemia.
Genetically she was found to be heterozygous for the
1007 fs NOD2 mutation. In 2010, after two years of suc-
cessful parenteral nutrition without any infectious com-
plications the patient started to lose weight and had
intermittent episodes of fever. The laboratory values
showed an increased CRP value (30.5 mg/dl) and anemia
(6.7 g/dl). A catheter-related infection was excluded by re-
peated blood cultures. Another FDG-PET-CT was ob-
tained addressing again the question of a large vessel
vasculitis. Unexpectedly it showed for the first time an in-
tensive uptake of the FDG tracer in three lymph nodes in
the mediastinum. An interferon-γ-release assay was posi-
tive (Quantiferon®). A transbronchial biopsy of one of the
lymph nodes revealed necrotic material and a granuloma
by histology, highly suggestive for tuberculous lympha-
denitis. M. tuberculosis-DNA was detected by PCR and
cultures obtained from the lymph node also grew M. tu-
berculosis. Intravenous tuberculostatic therapy with Eth-
ambutol, Isoniazid and Rifampicin was given for 4 months
followed by Isoniazid and Rifampicin for another
8 months. The follow-up FDG-PET-CT after 7 months of
therapy showed a significant size reduction and decreased
FDG uptake of the lymph nodes in the mediastinum. The
patient stayed on prophylactic therapy with Isoniazid until
today, because she continued low dose steroids.
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Patient 2
Patient 2 is a 77 year-old Caucasian woman who had an
infarction of the small intestine and right colon due to
atherosclerotic occlusion of the superior mesenteric artery
in November 2003. She required extensive resection of
her small bowel, which resulted in a jejunotransversost-
omy with 20 cm of proximal jejunum. Total parenteral nu-
trition was started and was managed at the University of
Tübingen intestinal failure outpatient clinic. In 2010 she
developed fever, weight loss and night sweats. An elevated
ESR and LDH were found. Repeated attempts to verify
catheter related blood stream infection including numer-
ous blood cultures, several rounds of empiric antibiotic
therapy and an empiric exchange of the catheter had no
sustained effect on these symptoms. A FDG-PET-CT scan
was performed addressing a potential infectious focus
other than the catheter. Unexpectedly it revealed PET-
positive lymphadenopathy in the cervical region and in
the mediastinum. An interferon-γ-release assay was nega-
tive (Quantiferon®). A bronchoscopic biopsy of the suspi-
cious lymph node revealed granulomatous necrotizing
lymphadenitis, but acid fast bacilli could not be stained. A
specific pathogen could not be cultured and eubacter-
ial PCR as well as PCR for M. tuberculosis were nega-
tive. The family history revealed that several relatives
had suffered from tuberculosis. Based on the sum of
indirect evidence the diagnosis of tuberculous lymph-
adenitis was made. Tuberculostatic therapy (Isoniazid,
Rifampicin, Ethambutol and Levofloxacin) was applied
intravenously for 6 months. The patient soon felt bet-
ter and gained weight. Fever and anemia resolved, and
the LDH and the ESR returned to normal values.
Regression of the enlarged and hypermetabolic lymph
nodes was verified by another PET-CT-scan obtained
7 months after the initiation of specific therapy. One
remaining small mediastinal lymph node was regarded
as non-specific, (Figure 2).
Figure 1 Patient 1. Upper row - before tuberculostatic therapy: High FDG uptake in an infracarinal lymph node (left panel: fusion images of PET/
CT) correlating with central necrosis in the contrast enhanced CT (middle panel). Coronal MIP with high FDG uptake in several mediastinal lymph
nodes (right panel). Lower row - 8 month follow up: No FDG uptake (left panel: PET/CT) and significant size reduction of the visualized lymph
nodes (middle panel: ceCT). No pathological FDG uptake in the mediastinal lymph nodes on coronal MIP of PET (right panel).
Figure 2 Patient 2. Upper row - before tuberculostatic therapy:
high FDG uptake in several mediastinal and one right axillary (arrow)
lymph nodes. Additionally, further lymph nodes with high FDG uptake,
especially in the left paraaortal (arrow head) region. Lower row - 7 month
follow up after initiation of tuberculostatic therapy: No FDG uptake in the
right axillary lymph nodes and significant regression of FDG uptake of
the paraaortal lymph nodes after therapy. All PET positive lymph nodes
had a morphological correlate and showed a significant size reduction
after therapy in contrast enhanced CT (not shown).
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The patient was found to be heterozygous for the
R702W mutation in the NOD2 gene.
Conclusion
In patients with intestinal failure on HPN the occur-
rence of low grade fewer, night sweats, declining per-
formance status, low albumin and sometimes increased
bilirubin usually prompts the diagnosis of a line related
infection. This is because about 30% of line related infec-
tions in this cohort do not present with typical symp-
toms of high grade fever and rigors upon start of a new
infusion but rather with those atypical symptoms [28].
In addition line related infections are the most frequent
complication in HPN patients occurring with a fre-
quency between two episodes per year and one episode
every three years [28]. Nevertheless the diagnosis of line
related infection could not be firmly established in either
of these patients and empiric therapy was not successful.
Instead tuberculous lymphadenitis was diagnosed and
successfully treated. Predisposition for acquiring or re-
activating tuberculosis may have been facilitated by the
fact that patients with SBS receiving long term HPN
have an impaired immune response [29]. Furthermore
patient 1 was receiving steroids over a prolonged period
of time system. It must also be noted that patient 2 may
have had an atypical mycobacterial infection. On the
other hand, tuberculosis, especially tuberculous lymph-
adenitis, has not been recognized as a specific problem
in intestinal failure patients on HPN yet. So how may
these conditions be related other than by chance?
Both patients carried a mutation in the NOD2 gene
(patient 1: 1007 fs, patient 2: R702W). NOD2 is an intra-
cellular pattern recognition receptor which recognizes
muramyl dipeptide (MDP) as part of peptidoglycan of
the bacterial cell wall [30,31]. The cumulative incidence
(homozygous, heterozygous and compound heterozy-
gous) of mutations in the 3 major NOD2 SNPs (R702W,
G908R and 1007 fs) is 13.6% in a cohort of healthy con-
trols [7]. Recently we and others have reported an in-
creased frequency of NOD2 mutations in SBS patients
[26,32]. At present it is not clear, whether a defect in
NOD2 signaling leads to an altered response to operative
stress ultimately resulting in a SBS or whether intestinal
adaptation to the SBS situation is diminished resulting
in long term HPN [26].
M. tuberculosis is mainly recognized via PRR like TLRs
and NOD2. Certain mutations in the TLR genes, e.g. TLR1
and TLR6 are associated with an increased risk of acquir-
ing M. tuberculosis [5,6]. In one study, host cells after ex-
posure to M. tuberculosis were sensing the microbe-
associated molecular pattern (MAMP) using independent
PRRs like NOD2 and TLR. The study showed, that these
receptors were non-redundant and interacted with each
other synergistically [33]. In addition monocytes from
patients homozygous for the 1007 fs mutation (3020insC)
show diminished TNF and IL-10 cytokine response after
stimulation with M. tuberculosis compared to heterozy-
gous or homozygous wild-type controls. A cohort study in
377 African Americans with tuberculosis found that cer-
tain SNPs in the NOD2 gene were associated with either
resistance or susceptibility to tuberculosis [34]. Neverthe-
less NOD2 mutations have not been firmly established as a
risk factor for tuberculosis and several studies argue
against such a correlation [35,36].
Thus, NOD2 mutations may be the common risk fac-
tor for both patients to develop intestinal failure requir-
ing HPN and to acquire or reactivate tuberculosis, in
these two cases tuberculous lymphadenitis. From a clin-
ical point of view these two cases highlight the import-
ance to search for alternative infectious complications
other than line related blood stream infection in patients
with SBS on HPN, including tuberculosis.
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Abstract
AIM
To investigate disease-specific gene expression profiles 
of peripheral blood mononuclear cells (PBMCs) from 
Crohn’s disease (CD) patients in clinical remission.1196 March 21, 2018|Volume 24|Issue 11|WJG|www.wjgnet.com
ORIGINAL ARTICLENOD2 - and disease-specific gene expression profiles of 
peripheral blood mononuclear cells from Crohn’s disease patientsBasic Study
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METHODS
Patients with CD in clinical remission or with very low 
disease activity according to the Crohn’s disease 
activity index were genotyped regarding nucleotide-
binding oligomerization domain 2 (NOD2 ), and PBMCs 
from wild-type (WT)-NOD2  patients, patients with 
homozygous or heterozygous NOD2  mutations and 
healthy donors were isolated for further analysis. The 
cells were cultured with vitamin D, peptidoglycan (PGN) 
and lipopolysaccharide (LPS) for defined periods of time 
before RNA was isolated and subjected to microarray 
analysis using Clariom S assays and quantitative real-
time PCR. NOD2 - and disease-specific gene expression 
profiles were evaluated with repeated measure ANOVA 
by a general linear model.
RESULTS
Employing microarray assays, a total of 267 genes 
were identified that were significantly up- or downregul-
ated in PBMCs of WT-NOD2  patients, compared to 
healthy donors after challenge with vitamin D and/or 
a combination of LPS and PGN (P  < 0.05; threshold: 
≥ 2-fold change). For further analysis by real-time 
PCR, genes with known impact on inflammation 
and immunity were selected that fulfilled predefined 
expression criteria. In a larger cohort of patients and 
controls, a disease-associated expression pattern, 
with higher transcript levels in vitamin D-treated 
PBMCs from patients, was observed for three of 
these genes, CLEC5A  (P  < 0.030), lysozyme  (LYZ ; P  < 0.047) and TREM1  (P  < 0.023). Six genes were 
found to be expressed in a NOD2 -dependent manner 
(CD101 , P  < 0.002; CLEC5A , P  < 0.020; CXCL5 , P  < 
0.009; IL-24 , P  < 0.044; ITGB2 , P  < 0.041; LYZ , P  
< 0.042). Interestingly, the highest transcript levels 
were observed in patients with heterozygous NOD2  
mutations.
CONCLUSION
Our data identify CLEC5A  and LYZ  as CD- and NOD2 -
associated genes of PBMCs and encourage further 
studies on their pathomechanistic roles.Key words: Peripheral blood mononuclear cells; Gene 
expression; NOD2 ; Lysozyme ; Crohn’s disease; CLEC5A
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.Core tip: Peripheral blood mononuclear cells (PBMCs) 
are a useful tool to study peculiarities of the immune 
response in the context of Crohn’s disease (CD). Here, 
we investigated whether PBMCs from patients with 
CD, even at the stage of clinical remission, exhibit 
altered gene expression profiles after challenge with 
pathogen-associated molecular patterns and vitamin D. For TREM1 , lysozyme  and CLEC5A , disease-associated 
expression patterns, with higher transcript levels in 
patient-derived PBMCs, were observed. The two latter 
genes, along with four other transcripts, also showed NOD2 -dependent expression profiles. TREM1  and 
CLEC5A  may act with NOD2  in a regulatory network 
with a pathophysiological role in CD.
Schäffler H, Rohde M, Rohde S, Huth A, Gittel N, Hollborn H, Koczan D, Glass Ä, Lamprecht G, Jaster R. NOD2- and disease-
specific gene expression profiles of peripheral blood mononuclear cells from Crohns disease patients. World J Gastroenterol 2018; 24(11): 1196-1205  Available from: URL: http://www.wjgnet.com/1007-9327/full/v24/i11/1196.htm  DOI: http://dx.doi.org/10.3748/wjg.v24.i11.1196INTRODUCTION
Inflammatory bowel diseases (IBD) are chronic intestinal 
disorders and mainly consist of the two entities Crohn’s 
disease (CD) and ulcerative colitis (UC)[1,2]. The clinical 
course of IBD is characterized by intermittent periods 
of relapses and remission, which are unpredictable 
in clinical practice. The pathogenesis of IBD is multifa­
ctorial, including genetic and environmental factors, 
and involves an inappropriate activation of the mucosal 
immune system, which is triggered by the intestinal 
microbiota in genetically predisposed individuals[1­5]. In 
Caucasian populations, nucleotide­binding oligomerization 
domain 2 (NOD2) has emerged as one of the main 
susceptibility genes for CD[6­8]. NOD2 is an intracellular 
pattern recognition receptor sensing muramyl dipeptide 
(MDP)[9,10], a fragment of peptidoglycan (PGN), but also 
PGN by itself[11,12] and, upon ligand binding, induces 
activation of the transcription factor NF­κB[13]. However, 
NOD2 activation via PGN is dependent on a TLR2 co­
stimulatory signal[14]. 
In addition, the environment, e.g., vitamin D de­
ficiency, also affects the development and clinical course 
of IBD[15­17]. Vitamin D deficiency has a high prevalence 
in IBD patients[17,18]. We have recently shown that 
clinical factors, e.g., the use of tumor necrosis factor 
(TNF)­α inhibitor, are associated with significant changes 
in vitamin D levels[19]. Vitamin D was originally mainly 
implicated in bone health, regulating calcium and pho­
sphate metabolism[20,21], but recent evidence has shown 
that vitamin D also profoundly impacts the innate 
and adaptive immune system[22­24]. Underscoring its 
role in the pathogenesis of CD, vitamin D was shown 
to be an inductor of NOD2 gene expression[25]. Using 
peripheral blood mononuclear cells (PBMCs) and 
dendritic cells, Dionne et al[26] showed that 1, 25­vitamin 
D acts as a modulator of the innate immune system. 
However, little is known about the effects of vitamin 
D and the presence of NOD2 mutations on different 
gene expression levels in CD. The aim of our study 
was therefore to further characterize different gene 
expression profiles in CD patients and healthy controls 
correlating to NOD2 mutation status and vitamin D 
pretreatment. We identified different genes associated 
with the presence of CD and mutations in the NOD2 1197 March 21, 2018|Volume 24|Issue 11|WJG|www.wjgnet.com
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gene. Follow­up studies on these genes may provide 
novel insights into the pathogenesis of CD and could 
contribute to the establishment of biomarkers to better 
predict the clinical course of the disease.MATERIALS AND METHODSPatients and controls
Sixteen patients with CD were recruited from the 
Rostock University Medical Center. The disease activity 
was determined via the Crohn’s disease activity index 
(CDAI)[27]. Furthermore, all patients were classified 
according to the Montreal classification[28], and age, 
gender and disease­specific medication were recorded. 
Six healthy volunteers without immune­mediated 
gastrointestinal or other autoimmune disorders served 
as controls. EDTA blood samples were drawn from 
all participants for genotyping studies and isolation 
of PBMCs. Plasma levels of vitamin D and C­reactive 
protein (CRP) were determined using routine laboratory 
methods.
The study was approved by the ethics board of the 
University of Rostock (A­2015­0042). Written informed 
consent was obtained from each participant prior to 
enrollment.Isolation, culture and treatment of PBMCs
PBMCs were isolated from EDTA venous blood using 
density­gradient centrifugation over Pancoll (PAN­Biotech, 
Aidenbach, Germany). Immediately after isolation, 
PBMCs were resuspended in cryopreservation medium 
[fetal calf serum (FCS) supplemented with 10% 
dimethyl sulfoxide (DMSO)] and stored at ­150 ℃ 
until required. After thawing, the cells were cultured 
in RPMI­1640 medium supplemented with 10% FCS 
and 1% penicillin/streptomycin (all reagents from 
Biochrom/Merck, Berlin, Germany), and exposed to 
1α,25­dihydroxyvitamin D3 (Santa Cruz Biotechnology, 
Dallas, TX, United States) at 40 nmol/L as indicated. 
After an incubation period of 20 h at 37 ℃ in a 5% 
CO2 humidified atmosphere, lipopolysaccharide (LPS; 
1 µg/mL; Sigma­Aldrich, Deisenhofen, Germany) 
and peptidoglycan (PGN; 10 µg/mL; Sigma­Aldrich) 
were added to the cells as indicated, and incubation 
continued for another 6 h (Figure 1). Subsequently, the 
cells were lysed in RTL Plus buffer, which was included 
in the RNeasy Plus Kit (Qiagen, Hilden, Germany), and 
subjected to RNA isolation (see below).NOD2 genotyping
DNA was isolated from whole blood using a QIAamp 
DNA Blood Mini Kit (Qiagen) according to the man­
ufacturer’s protocol. All patients and controls were 
genotyped with respect to the three major mutations 
in the NOD2 gene (SNP 8; R702W, NCBI reference SNP 
ID: rs2066844, SNP 12; G908R, NCBI reference SNP 
ID: rs2066845 and SNP 13; 1007fs, NCBI reference 
SNP ID: rs2066847). The corresponding regions of 
the NOD2 gene were amplified by PCR using a Taq 
PCR Master Mix Kit (Qiagen) and primers as specified 
in Table 1. The following PCR conditions were used: 
5 min, 94 ℃; 1 min, 94/60/72 ℃ (45 cycles); 7 
min, 72 ℃; 4 ℃. After Sanger sequencing (Seqlab, 
Göttingen, Germany), the data were analyzed using the 
software Chromas, version 2.6. Individuals with no SNP 
mutations were considered wild­type (WT) for NOD2.
Microarray analysis of RNA expression profiles
RNA was extracted employing an RNeasy Plus Kit 
according to the manufacturer’s protocol. Total RNA 
samples were quantified with a spectrophotometer 
(NanoDrop 1000, Thermo Fisher Scientific, Waltham, 
MA, United States), and their integrity was confirmed 
using the Agilent Bioanalyzer 2100 with an RNA Nano 
chip kit (both from Agilent Technologies, Waldbronn, 
Germany).
Expression profiling was performed using 200 ng 
RNA and the Affymetrix Human Clariom S Assay 
(Affymetrix/Thermo Fisher Scientific), which interrogates 
over 20000 well­annotated genes. Therefore, the so­
called Whole Transcriptome protocol was employed. T7 
promoter tags were introduced into all RNA molecules 
by using N6 3′­ends for DNA strand synthesis, before 
RNA strand replacement according to Eberwine[29] was 
conducted. Non­labeled aRNA was produced by in vitro transcription. All RNA molecules were amplified 
in a linear manner, avoiding a 3′ bias. Using purified 
aRNA as a template, a new strand­identical single­
strand DNA was produced by adding random primers 
and dNTPs (including dUTP, which replaced a limited 1198 March 21, 2018|Volume 24|Issue 11|WJG|www.wjgnet.com
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0 h                                                      16 h                              22 h
PBMC culture
-150 ℃Figure 1  Protocol of peripheral blood mononuclear cells treatment. 
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in PBMCs were expressed as 2­(∆Ct) values.Statistical analysis
Real­time PCR data were analyzed with repeated­
measures ANOVA. Mean group differences were 
compared for “disease” (patients with CD vs controls) 
and “NOD2­status” (WT, heterozygote, homozygote), 
as well as for (within­subject factors) “vitamin D 
application” (yes vs no) and “stimulation” (LPS, PGN, 
LPS + PGN, controls), employing a general linear model 
for repeated measurements. Age was considered 
a covariate in the disease model because disease 
groups were not balanced by age, and NOD2 groups 
were tested post hoc by LSD. Normal distribution of 
measurements was assessed using the Kolmogorov­
Smirnov test. P < 0.05 was considered statistically 
significant. All data were processed using IBM® SPSS® 
Advanced Statistics 22.0.RESULTS
PBMCs provide an easily accessible tool to investigate 
disease­associated peculiarities of the antipathogenic 
immune response of patients with CD. To study tran­
scripts in an unbiased manner, we initially chose a 
microarray approach. Therefore, PBMCs from healthy 
individuals and patients with CD in remission (n = 3 
each; all of them NOD2­WT) were pretreated with 
vitamin D3 for 20 h before they were challenged 
simultaneously with LPS and PGN for 6 h. Subsequen­
tly, global gene expression was analyzed employing 
Clariom S assays, and data were compared with those 
of untreated controls. Table 2 gives an overview of the 
significant differences between patients with CD and 
controls under identical conditions of PBMC treatment.
Under basal conditions and any treatment regimen, 
genes upregulated in patients with CD exceeded 
downregulated genes both in number and maximum 
change. Complete lists of the 267 genes are presented 
as Supplementary Table 1.
Many of the differentially expressed genes are well­
known modulators of immune cell functions in the context 
of innate and adaptive immunity, and unsurprisingly, 
some of them have previously been implicated in the 
pathogenesis of CD, including several immune cell 
receptors, cytokines/chemokines and their cognate 
receptors and the antimicrobial peptide lysozyme[30­36]. 
The latter transcript was found to be upregulated in 
PBMCs of patients with CD in response to LPS/PGN 
treatment, independent of the presence or absence of 
vitamin D3. Intriguingly, expression of various genes 
was synchronously up­ or downregulated under different 
conditions, suggesting a robustness of the expression 
profile against external perturbations. 
For in­depth analysis, we selected a panel of 11 
genes from the list of candidates shown in Table 2 
that fulfilled the following criteria: (1) differential ex­
pression in PBMCs from patients with CD and controls 
under basal conditions and/or under at least two 
amount of dTTP). After digestion with RNase H, 
endpoint fragmentation was performed with uracil­DNA­
glycosylase in combination with apurinic/apyrimidinic 
endonuclease 1, and biotinylated dNTPs were added 
to the 3′­ends of the single­stranded DNA fragments 
with deoxynucleotidyl transferase. Subsequently, 
hybridization of the microarrays was performed at 45 ℃ 
in a GeneChip® Hybridization Oven 645 (Affymetrix/
Thermo Fisher Scientific). After overnight incubation, 
the microarrays were scanned using the GeneChip 
Scanner 3000 (Affymetrix/Thermo Fisher Scientific) at 
0.7 µm resolution.
Primary data analysis was performed with the 
Affymetrix Transcriptome Analysis Console software 
version 3.1.0.5 including the Robust Multiarray Average 
module for normalization. Gene expression data were 
log­transformed. A change was considered significant 
when the ANOVA P­value met the criterion P < 0.05 
at fold changes >|2|, i.e., expression increments or 
declines larger than two. Along with the publication of 
the manuscript, our complete microarray data will be 
available in the Gene Expression Omnibus database 
(GEO accession number: GSE110186).Quantitative reverse transcriptase-PCR using real-time TaqManTM technology
Unless indicated otherwise, reagents from Thermo 
Fisher Scientific were used in all subsequent steps. 
Cellular RNA prepared as described above was treated 
with a DNA­free kit to remove traces of genomic DNA, 
and 250 ng of RNA per sample was reverse transcri­
bed into cDNA using TaqManTM Reverse Transcription 
Reagents and random priming. Using a ViiA 7 se­
quence detection system (Thermo Fisher Scientific), 
target cDNA levels were quantified by real­time PCR. 
Therefore, qPCR MasterMix (Eurogentec, Seraing, Liège, 
Belgium) and the following human­specific TaqManTM 
gene expression assays with fluorescently labeled 
MGB probes were used: Hs00355476_m1 (CCL20), 
Hs00188627_m1 (CD101), Hs00370621_m1 (CLEC12A), 
Hs04398399_m1 (CLEC5A), Hs01902549_s1 (CLEC7A), 
Hs01099660_g1 (CXCL5), Hs01114274_m1 (IL24), 
Hs00167304_m1 (ITGAM), Hs00164957_m1 (ITGB2), 
Hs00426232_m1 (LYZ), Hs00234007_m1 (MSR1), 
Hs01065279_m1 (PECAM1), Hs00218624_m1 (TREM1), 
and Hs99999905_m1 (GAPDH). PCR conditions were as 
follows: 95 ℃ for 10 min, followed by 40 cycles of 15 s at 
95 ℃/ 1 min at 60 ℃. Relative amounts of target mRNA 
Table 1  Primer for NOD2 -genotypingSNP Primer8 Forward: 5CCTCTTCAATTGTGGCAGGC-3Reverse: 5-CTCCTGCATCTCGTACAGGC-312 Forward: 5-ATGGAGGCAGGTCCACTTTG-3Reverse: 5-TTACCTGAGCCACCTCAAGC-313 Forward: 5-GATGGTACTGAGCCTTTGTTGA-3Reverse: 5-CAGACTTCCAGGATGGTGTCAT -3
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treatment regimens (vitamin D3, LPS+PGN and their 
combination, respectively) and (2) an established or 
potential role in inflammation and/or regulation of the 
immune response. Table 3 shows details regarding all 
selected genes as well as a twelfth gene, TREM1, that 
was included as a control as an established vitamin 
D­responsive gene with immunomodulatory function[37]. 
Interestingly, three pro­inflammatory mediators, CCL20, CXCL5 and IL-24, displayed lower expression levels 
in patients with CD, which might be a consequence of 
their disease­specific medication (see below).
The expression profiles of the selected genes were 
subsequently studied by real­time PCR. In addition 
to WT­NOD2 patients and healthy controls (n = 6 
each, including the samples previously analyzed by 
microarray technology), we also included patients with 
heterozygous and homozygous mutations of NOD2 (n = 
5 each). Furthermore, we refined the protocol of PBMC 
treatment using LPS and PGN both in combination and 
as individual factors (Supplementary Table 2).
The clinical characteristics, laboratory findings and 
the medication of all 16 patients are shown in Table 4. 
Except for one person with a slightly increased CDAI 
of 166, all patients presented with a CDAI of < 150, 
indicating disease remission[27]. The CRP­values of 13 
patients were in the normal range (below 5 mg/L). In 
the remaining three patients, modestly elevated CRP­
values (all below 14 mg/L) were detected. Disease 
activity in all patients could still be considered low. 
All but two patients presented with vitamin D levels 
below 75 nmol/L, suggesting an insufficiency or even 
deficiency (levels below 50 nmol/L). This finding was 
not unexpected, as all of the samples were collected 
during the European winter season. As a consequence, 
a vitamin D substitution therapy was initiated, if app­
ropriate. Three of the patients were on steroids (> 10 mg 
prednisolone/d) at the time of the study, 7 received 
azathioprine, and 12 were treated with anti­TFN­α 
antibodies. Healthy controls consisted of 3 males and 3 
females with an age range from 25 to 53 years.
For statistical data analysis, a general linear model 
repeated measure was chosen to assess mean differ­
Table 2  Numbers and maximum changes of up- and downregulated genes in peripheral blood mononuclear cells from Crohns disease patient vs  identically treated controls Treatment of PBMCs Upregulated genes Downregulated genesUntreated   85 (59-fold)   39 (39-fold)Vitamin D3   25 (21-fold) 12 (9-fold)LPS/PGN 54 (6-fold) 15 (5-fold)Vitamin D3 + LPS/PGN   29 (15-fold)   8 (5-fold)P < 0.05; Threshold: ≥ 2-fold change. PBMCs: Peripheral blood mononuclear cells; LPS: Lipopolysaccharide; PGN: Peptidoglycan.Table 3  Genes selected for real-time PCR studiesTranscript Fold changes: patients vs  controls Details on function/ reasons to studyBasal +D, -L/P -D, +L/P +D, +L/PMSR1 9.56 13.19 14.72 macrophage scavenger receptor[49]; differentially expressed in 3 of 4 groupsCD101 2.66 expressed on various immune cells; inhibits expansion of colitogenic T cells[30]CLEC5A 2.82 3.11 C-type lectin member 5A, pattern recognition receptor; involved in antibacterial/antiviral defense[43]CLEC7A 4.53 3.94 C-type lectin member 7A, pattern recognition receptor; control of fungal infections[50]CLEC12A 6.04 4.52 C-type lectin member 12A, pattern recognition receptor, inhibits cell death-
induced inflammation[51]ITGAM 2.18 CD11b; integrin αM; expressed by many immune cells; polymorphisms linked to autoimmunity[52]LYZ 3.51 2.03 antimicrobial enzyme; essential role in innate immunity; increased production 
linked to CD[31]PECAM1 3.15 CD31; implicated in transendothelial leukocyte migration in experimental colitis[32]CCL20 -2.33 -5.08 chemokine expressed by neutrophils, enterocytes, B‑cells and dendritic cell; IBD predilection gene[33]CXCL5 -38.89 -5.32 regulates neutrophil homeostasis and chemotaxis; increased serum levels in IBD patients reported[34]IL-24 -3.49 -4.82 Involved in host defence against bacteria and fungi; increased expression in patients with active IBD[35]TREM1 amplifier of antimicrobial immune responses and inflammation in experimental colitis and IBD[36]P < 0.05; Threshold: ≥ 2-fold change. Positive values refer to genes upregulated and negative values to genes downregulated in CD patients. LPS: 
Lipopolysaccharide; PGN: Peptidoglycan; PBMCs: Peripheral blood mononuclear cells. CD: Crohn’s disease; IBD: Inflammatory bowel diseases.
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ences between groups. Comparing controls to CD 
patients, no significant differences were detected when 
samples with and without vitamin D incubation were 
considered conjointly, due to the strong overlaying effect 
of vitamin D. However, focusing on the subgroup of 
vitamin D treated samples, disease­related differences 
were observed (no. 5­8 in Supplementary Table 2). Here, 
with age adjustment, three genes displayed a disease­
dependent expression pattern (Table 5): consistent 
with the microarray data, significantly higher CLEC5A 
and LYZ transcript levels were observed in PBMCs 
of patients with CD. The same finding was observed 
for TREM1, which was included due to its vitamin 
D­dependent expression pattern but not because of 
the microarray results. Together, these findings suggest 
that CD­associated changes in gene expression could be 
attributed to treatment protocols that include vitamin D, 
as analyses in the remaining subgroup (w/o vitamin D) 
did not show any differences (all P > 0.20). 
We also analyzed the influence of NOD2 mutations 
on the expression of the gene panel described above. 
Considering all treated and untreated samples (Supple­
mentary Table 2), a significant effect of the NOD2 status 
was observed for 5 of these genes, including CLEC5A 
and LYZ, and one additional gene from Table 2, integrin 
subunit beta 2 (ITGB2) (Table 6). With a P­value of 0.053, TREM1 just missed statistical significance. 
Unexpectedly, heterozygous CD patients displayed 
the highest expression levels for all of the genes, 
whereas no statistically significant differences between 
persons with WT­NOD2 (patients and controls) and 
homozygous NOD2 mutations were detected. The 
phenomenon is apparently unrelated to medication, 
which was very similar in the groups of patients with 
heterozygous and homozygous NOD2 mutations (Table 
4). This conclusion is also supported by statistical evalu­
ations, which did not show any significant association 
between treatment with prednisolone, azathioprine or 
anti­TNF­α and expression of CLEC5A, LYZ and TREM1 
in PBMCs of patients with CD.DISCUSSION
Many studies have shown that numerous risk genes of 
CD code for molecules involved in host defense against 
pathogens, such as nucleotide­binding oligomerization 
domain 2 (NOD2), ATG16L1, and those implicated 
in the T helper type 17 (Th17) pathway[38­43]. Here, 
we tested the hypothesis that PBMCs of patients with 
CD, even at the stage of clinical remission, exhibit an 
Table 4  Characteristics of the patients -nucleotide-binding oligomerization domain 2 status, classification and activity of the disease, C-reactive protein and vitamin D levels, and medication at the time of the studyNo. Sex Age NOD2 Montreal 
classification
CDAI CRP (mg/L) Vitamin D (nmol/L) Prednisolon (> 10 mg/d) Azathio-prine Anti-TNF-α1 M 24 WT1 A2 L3 L4 B1 121 2.58 104.0 Yes No Yes2 M 28 WT1 A2 L3 B3p   46 < 1.0 62.9 No No Yes3 M 64 WT1 A3 L3 B2p 111 4.58 27.0 Yes No Yes4 F 60 WT A2 L3 B2 100 2.27 72.5 No No Yes5 F 62 WT A3 L3 B3p   82 < 1.0 58.2 Yes Yes Yes6 M 46 WT A2 L3 L4 B2p 110 4.97 32.9 No No Yes7 M 38 HO A2 L3 B3p   92 13.30 40.2 No Yes No8 M 64 HO A3 L3 B1   34 < 1.0 53.0 No No Yes9 F 48 HO2 A2 L3 B2   54 < 1.0 67.6 No No Yes10 M 54 HO A2 L3 B2p 103 1.63 51.9 No Yes No11 M 26 HO A1 L3 B2p 120 7.86 31.0 No Yes Yes12 M 27 HT A2 L3 B1 106 1.41 47.2 No No Yes13 M 37 HT A2 L3 B2p 166 4.56 37.9 No Yes No14 F 48 HT A2 L1 B3p 115 1.01 55.2 No Yes Yes15 M 57 HT A1 L3 B2p 132 12.30 52.3 No No Yes16 M 47 HT A2 L3 B3   60 2.62 92.0 No Yes No1Patients who were also included into microarray analysis; 2SNP8 mutation. All other HO/HT mutations refer to SNP13. NOD2: Nucleotide-binding oligomerization domain 2; CDAI: Crohns disease activity index; CRP: C-reactive protein; TNF : Tumor necrosis factor; WT: Wild-type; HO: Homozygous mutation; HT: Heterozygous mutation.Table 5  differentially expressed transcripts in vitamin D-pretreated peripheral blood mononuclear cells from Crohns disease patients and controls (with and without additional stimulation with lipopolysaccharide and peptidoglycan, respectively, age adjusted)Gene P  value Upregulated inCLEC5A 0.030 CD patientsLYZ 0.047 CD patientsTREM1 0.023 CD patientsCD: Crohns disease.
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altered gene expression profile upon challenge with 
pathogen­associated molecular patterns (PAMPs) and/
or the immunomodulatory hormone vitamin D, which 
has previously been shown to exert differential effects 
on the expression of NOD2­ and TLR­induced cytokines 
in the context of CD[26]. 
Initial microarray experiments identified more than 
200 genes with different expression patterns among 
patients with CD and controls. Based on predefined 
expression criteria, genes with roles in inflammation and 
immunity were selected for in­depth analysis by real­
time PCR. A disease­associated expression pattern was 
identified for CLEC5A, lysozyme and TREM1. Six genes, 
including CLEC5A and lysozyme, displayed a NOD2­
dependent expression pattern. With respect to lysozyme 
and TREM1, our findings are consistent with previous 
reports, which found that increased levels of both 
proteins in serum were implicated in the pathophysiology 
of IBD[44,45]. To the best of our knowledge, however, this 
is the first report of an association between CLEC5A 
expression and CD. CLEC5A has most recently been 
identified as an important receptor in innate immunity 
by neutrophil trap formation and secretion of different 
proinflammatory cytokines after stimulation with Listeria monocytogenes[43]. This finding is especially interesting, 
as defective bacterial clearance was shown to play a 
crucial role in the pathogenesis of CD[46,47]. Of note, 
both CLEC5A and TREM1 proteins can be linked to the 
product of the best­established CD risk gene, NOD2, by 
the STRING database[48] (Figure 2).
In conclusion, we found that PBMCs of patients with 
CD display alterations in their response to vitamin D and 
PAMPs. Disease­associated and NOD2­dependent gene 
expression profiles are preserved even at the stage 
of clinical remission. Our data identify CLEC5A, LYZ 
and TREM1 as genes of particular interest for follow­
up studies. We hypothesize that these genes may act 
in a common network relevant to CD pathogenesis. 
Establishment of biomarkers to better predict the clinical 
course of the disease remains a long­term goal of our 
studies.ARTICLE HIGHLIGHTSResearch background In Crohns disease (CD), the interplay of genetic and environmental factors converges at the level of an altered antipathogenic immune response, which is incompletely understood. Peripheral blood mononuclear cells (PBMCs) provide a useful tool to study elements of the immunopathogenesis of the disease in vitro. Research motivation Currently, there is a lack of biomarkers to predict the clinical course of CD. Furthermore, the development of specific therapies would benefit from an improved mechanistic understanding of the pathogenesis of the disease.Research objectives 
The aim of this study was to identify disease-specific gene expression profiles of PBMCs from patients with CD in clinical remission. Specifically, we were 
interested in alterations of the gene expression profile after challenging PBMCs with pathogen-associated molecular patterns (PAMPs) and the immunomodulatory hormone vitamin D.Research methodsPBMCs from patients with CD and healthy donors were cultured with vitamin D, peptidoglycan (PGN) and lipopolysaccharide (LPS), before RNA was isolated and subjected to microarray analysis and quantitative real-time PCR. Disease-
specific gene expression profiles were evaluated by general linear model repeated measure analysis, paying particular attention to the well-established CD risk gene NOD2.Research results 
Microarray experiments yielded a total of 267 genes that were significantly up- or downregulated in PBMCs of patients with CD, compared to healthy donors, after challenge with vitamin D and/or a combination of LPS and PGN. For further analysis by real-time PCR, genes with roles in inflammation and immunity were selected. For three of these genes, CLEC5A, lysozyme and TREM1, a disease-associated expression pattern was validated. Six genes, including CLEC5A and lysozyme, were found to be expressed in a NOD2-dependent manner.Research conclusions PBMCs of patients with CD display alterations of their response to vitamin D and PAMPs that are preserved even at the stage of clinical remission. CLEC5A, TREM1 and NOD2 may act in a common network relevant to CD pathogenesis.
Table 6  Transcripts with a NOD2 -dependent expression patternGene P  value Highest levelsCD101 0.002 HeterozygotesCLEC5A 0.020 HeterozygotesCXCL5 0.009 HeterozygotesIL-24 0.044 HeterozygotesITGB2 0.041 HeterozygotesLYZ 0.042 Heterozygotes
TREML1
TREML2
TREM2
CLEC5ATYROBP
TREM1
TLR4NOD2TLR2FPR1
KIR2DL1
Figure 2  Network analysis using the STRING database[48]. The network was derived employing human TREM1 as the search term (https://string-db.org/cgi/
network.pl?taskId=PmXpOD7RMwaM).
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Research perspectivesFollow-up studies on alterations of the antipathogenic immune response may provide novel insights into the pathogenesis of CD and may also help to establish biomarkers to better predict the clinical course of the disease.ACKNOWLEDGMENTS
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